



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 9/00		A2	(11) International Publication Number: WO 00/52147 (43) International Publication Date: 8 September 2000 (08.09.00)
<p>(21) International Application Number: PCT/US00/05551</p> <p>(22) International Filing Date: 3 March 2000 (03.03.00)</p> <p>(30) Priority Data: 60/123,148 5 March 1999 (05.03.99) US</p> <p>(71) Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; 632 Boyd Graduate Studies, Athens, GA 30602-7411 (US).</p> <p>(71)(72) Applicants and Inventors: TRAVIS, James [US/US]; 825 Riverbend Parkway, Athens, GA 30605 (US). POTEMPA, Jan [US/US]; Apt. #102, 170 Barrington Drive, Athens, GA 30605 (US). BANBULA, Agnieszka [US/US]; Apt. #E13, 280 Picadilly Square, Athens, GA 30605 (US).</p> <p>(74) Agent: MUETING, Ann, M.; Muetting, Raasch, Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: PROLYL PEPTIDASES AND METHODS OF USE</p> <p>(57) Abstract</p> <p>The present invention provides isolated polypeptides, prolyl tripeptidyl-peptidases, and active analogs, active fragments or active modifications thereof, having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 30 amino acids. Isolated nucleic acid fragments encoding isolated prolyl tripeptidyl-peptidases are also provided, as are methods of reducing growth of a bacterium by inhibiting a prolyl tripeptidyl-peptidase.</p>			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

PROLYL PEPTIDASES AND METHODS OF USE

5

CONTINUING APPLICATION DATA

This patent application claims the benefit of U.S. provisional patent application No. 60/123,148, filed March 5, 1999, which is incorporated by reference herein.

10

GOVERNMENT FUNDING

The present invention was made with government support under Grant No. DE 09761, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

15

BACKGROUND OF THE INVENTION

Porphyromonas gingivalis (formerly *Bacteroides gingivalis*) is an obligately anaerobic bacterium which is implicated in periodontal disease. *P. gingivalis* produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors. A number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by *P. gingivalis* proteases. Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.

Progressive periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration. Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site. Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a. The complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases. The human plasma convertases

5 cleave the α -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e. C3a and C5a). The anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability. The larger products from C3 and C5 cleavage (i.e. C3b and C5b) participate in functions including complement cascade activation, opsonization, and lytic complex formation.

10 Recent studies have indicated that this periodontopathogen produces at least seven different enzymes belonging to the cysteine and serine catalytic 15 classes of peptidases, among which three cysteine proteinases (gingipains) are predominant (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458). The gingipains are the best characterized group of *P. gingivalis* enzymes as their structure, function, enzymatic properties and pathological significance are known. From *in vitro* studies it is apparent that two gingipains 20 R (also referred to generally as "Arg-gingipains" and more specifically as RgpA and RgpB), enzymes specific for cleavage at Arg-Xaa peptide bonds, have a significant potential to contribute to the development and/or maintenance of a pathological inflammatory state in infected periodontal pockets through: (i) activation of the kallikrein-kinin cascade, (ii) the release of neutrophil 25 chemotactic activity from native and oxidized C5 of the complement pathway, and (iii) activation of factor X. In addition, gingipain K (also referred to as "Lys-gingipain"), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis. Finally, the presence of a hemagglutinin/adhesion domain in the 25 non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of *P. gingivalis* to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.

30 In comparison to the gingipains, relatively little is known about other cysteine proteinases produced by *P. gingivalis*. Two genes, referred to as *tpr* and *prtT* have been cloned and sequenced and although they encode a putative papain-like and streptopain-like cysteine proteinases, respectively, neither has been purified and characterized.

The presence of serine proteinase activity in cultures of *P. gingivalis* has been known for several years; however, only limited information is available about such enzymes. Indeed, a serine endopeptidase has been isolated from culture media, although it was only superficially characterized (Hinode D., et al., 1993) *Infect. Immun.* **59**, 3060-3068). On the other hand, an enzyme referred to as glycylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested that, in collaboration with collagenase, glycylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) *J.Dent. Res.* **64**, 106-111). In addition to this potential pathological function, glycylprolyl peptidase may also play a vital role in providing *P. gingivalis* with dipeptides which can be transported inside the cell and serve as a source of carbon, nitrogen, and energy for this asaccharolytic organism. Recently, a gene encoding glycylprolyl peptidase in *P. gingivalis* has been cloned and sequenced, and it is now apparent that this enzyme is homologous to dipeptidyl-peptidase IV (DPP-IV) from other organisms (Kiyama, M., et al. (1998) 1396, 39-46). The nucleotide sequence of the genome of this bacterium is currently being determined by The Institute for Genomic Research, and is available at www.tigr.org.

SUMMARY OF THE INVENTION

The present invention is directed to an isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Alternatively, the isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof is isolated from *P. gingivalis*. Typically, amidolytic activity is determined with a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The peptide cleaved by the isolated prolyl tripeptidyl-peptidase can include the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID

NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, or SEQ ID NO:37. The amino acid sequence of the isolated prolyl tripeptidyl-peptidase can include the amino acid sequence GXSXXG (SEQ ID NO:39), the 5 amino acid sequence GXSXGG (SEQ ID NO:40), or the amino acid sequence of SEQ ID NO:30.

Another aspect of the invention is an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 10 amino acids. Typically, the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The invention is also directed to an isolated polypeptide comprising an 15 amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

An alternative aspect of the invention is an isolated nucleic acid fragment 20 encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no 25 greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The nucleic acid fragment can have a nucleotide sequence comprising SEQ ID NO:38. A complement of the nucleic acid fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by 30 three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.

Another aspect of the invention is an isolated nucleic acid fragment 35 encoding a polypeptide that includes an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

The invention is also directed at a method of identifying an inhibitor of a 40 prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, including identifying a molecule that inhibits the

amidolytic activity of the prolyl-tripeptidyl peptidase. The inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

An aspect of the invention is a method of reducing growth of a bacterium. This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof. The method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase. The method can be used to protect an animal from a periodontal disease caused by *P. gingivalis* including administering to the animal the inhibitor. The disease can be selected from the group consisting of gingivitis and periodontitis. The inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.

Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The immunogenic composition can include an adjuvant.

The invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.

Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ ID NO:44, or SEQ ID NO:45.

Definitions

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the 5 definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.

“Peptidase,” “proteinase,” and “protease” all refer to enzymes that 10 catalyze the hydrolysis of peptide bonds in a polypeptide. A “peptide bond” or “amide bond” is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid. “Peptidase inhibitor,” “proteinase inhibitor,” “protease inhibitor,” and “inhibitor” all refer to molecules 15 that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.

As used herein, the term “isolated” means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized. Preferably, the polypeptide or nucleic acid fragment is purified, i.e., essentially 20 free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.

“Amidolytic activity” refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide. The term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide. 25 “Prolyl-tripeptidyl peptidase” and “PTP” refer to a polypeptide having a particular “amidolytic activity”. A “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or 30 modified amino acid except proline, and the α -amino of the amino terminal residue is not blocked. A “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide. The term “natural amino acid” refers to the 20 amino acids typically produced by a cell. The term “modified amino acid”

refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A "target polypeptide" is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.

5 An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.

10 "Nucleic acid fragment" as used herein refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA. A nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques. A nucleic acid molecule may be 15 equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.

20 "Percentage amino acid identity" refers to a comparison of the amino acids of two polypeptides as described herein.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the *P. gingivalis* cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles). (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.

30 Fig. 2. SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme. Lane a, molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa; α -lactalbumin, 14

kDa); *lane b*, acetone precipitate from Triton X-100 extract of *P. gingivalis*, *lane c*: hydroxyapatite column eluate; *lane d*, Phenyl-Sepharose column eluate; *lane e*, MonoQ column eluate; *lane f*, purified PTP-A from MonoP column wash; *lane g*, autoradiograph of 3 H-DFP labeled enzyme exposed for 96 h to X-ray film. All 5 samples were reduced and boiled prior to PAGE analysis.

Fig. 3. Multiple sequence alignment of *P. gingivalis* PTP-A (PTP-A) and its bacterial and eukaryotic homologues. Pg-DPP, DPP from *P. gingivalis* (Kiyama, M., et al., (1998) *Bioch. Bioph. Acta* **1396**, 39-46) containing an 10 amino-terminal sequence corrected according to the *P. gingivalis* W83 genome data available from The Institute of Genomic Research at www.tigr.org); Fm-DPP, DPP from *Flavobacterium meningosepticum*; Hs-DPP, human DPP IV; and Mm-FAP, mouse fibroblast activation protein. Peptide sequences obtained 15 from PTP-A analysis described herein are indicated with arrows (note that the sequence of the peptide 81-97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal α -helix is double-underlined. Homologous regions (i.e., regions of identical amino acids and/or 20 conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background.

Fig. 4. Comparison of *P. gingivalis* PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3). Sequences of *P. gingivalis* PTP-A, DPP, DPP-H1, DPP-H2, and DPP-H3 were obtained from 25 conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished *P. gingivalis* genome database: gnl | TIGR | *P. gingivalis* contig 126 (positions 13 228 – 15 426), contig 87 (positions 6 424 – 4 399), contig 65 (positions 161 – 1 786), contig 101 (positions 30 8 895 – 6 845), and contig 9 (positions 4 216 – 2 162), respectively. Residues predicted as catalytic triads are marked with asterisks. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted.

Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

5 **Fig. 5. Influence of Pefabloc-serine proteinase inhibitor on *P. gingivalis* growth.**

10 **Fig. 6. Comparison of *P. gingivalis* PTP-A and DPP to sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P. gingivalis* PTP-A (126PP), DPP (87PP), DPP-H1 (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

15

Fig. 7. Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ ID NO:30) of PTP-A.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the 25 alpha-carboxyl group end of the proline.

When the prolyl peptidase is a prolyl tripeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or 30 modified amino acid except proline, and the α -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro-Yaa peptide bond. Preferably, isolated polypeptides do not cleave a target peptide having a blocked α -amino of the amino terminal residue.

Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond. In increasing order of preference, isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 amino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 5 amino acids or at least 3,000 Da. Preferably, the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.

When the prolyl peptidase is a prolyl dipeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide 10 of the general formula $\text{NH}_2\text{-Xaa-Zaa-Yaa-(Xaa)}_n$ (SEQ ID NO:12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the α -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target 15 polypeptide that is hydrolyzed is the Zaa-Yaa peptide bond. Preferably, isolated polypeptides does not cleave a target peptide having a blocked α -amino of the amino terminal residue. Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond.

Due to their cyclic aliphatic character proline residues bestow unique 20 conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the amino-termini of many biologically active peptides, may protect them against proteolytic degradation by peptidases with general specificity. A specialized group of proteolytic enzymes, typically referred 25 to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide. The peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline. The bacterial prolyl peptidases can cleave a polypeptide to liberate a 30 tripeptide or a dipeptide. Prolyl peptidases that do not cleave a target peptide if the α -amino of the amino terminal residue is blocked can be referred to as exopeptidases. The *in vivo* activity of these specialized proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other

biologically active peptides. In addition, hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re-utilization of amino acids by living organisms, including bacteria. However, prolyl peptidases from bacterial pathogens, if released into the host environment, may 5 interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.

The external (i.e., cell surface) localization and uncontrolled activity of bacterial peptidases, including prolyl peptidases, likely contributes significantly to 10 run-away inflammation in the human host and the pathological degradation of connective tissue during periodontitis. For instance, working in concert bacterial prolyl peptidases (e.g., prolyl tripeptidyl peptidases and DPP IV) have the ability to 15 completely degrade collagen fragments locally generated by endogenous or bacterial collagenases. Because type I collagen is the major component of periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation. Thus, 20 there is a need in the art to characterize bacterial peptidases to facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

The polypeptides of the present invention, preferably prolyl peptidases, can 25 be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation. Antibodies to prolyl peptidases can also be used to identify and/or isolate additional prolyl peptidases. Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.

An example of a prolyl-tripeptidyl peptidase is prolyl-tripeptidyl peptidase A (SEQ ID NO:30) (also referred to as PTP-A) from *P. gingivalis*. Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass 30 peptidase may be due to the proteolytic cleavage of the peptidase from the surface of *P. gingivalis*. PTP-A is a new member of clan SC, family S9 of serine peptidases. Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which

plays a pivotal role peptidase activity. The members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine. Members of the clan SC are also characterized by a tertiary structure including $\beta/\alpha/\beta$ units, and an α/β hydrolase fold. In addition to the 5 catalytic triad order, the amino acid sequence GXSXXG (SEQ ID NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family. Family S9 has the consensus sequence GXSXGG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies 10 peptidases to this family. For instance, peptidases of this family generally have two domains, an amino-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad. Some members of the S9 family have only the catalytic domain.

15 The S9 family is diverged and divided in three subfamilies: S9A, cytosolic oligopeptidases from archae and eukaryotes; S9B, eukaryotic acylaminoacylpeptidases; and S9C, dipeptidyl peptidase IV from bacteria and eukaryotes. The catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ ID NO:30 and include the remaining carboxy-terminal 20 amino acids (see, e.g., Fulop, et al., (1998) *Cell* **94**, 161-170). Despite structural similarities to peptidases from the S9 family, the tripeptidyl-peptidase activity of PTP-A is unusual for this family of enzymes, and no other known similar activity has so far been attributed to any other member of the S9 family. In fact, all strict 25 tripeptidyl-peptidases belong only to the subtilisin family (S8) and S33 family of serine peptidases; however, they neither share a structural relationship with PTP-A nor have activity limited to cleavage after proline residues. In particular, there are no other known prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Iodoacetamide is a compound that is 30 traditionally a peptidase inhibitor. Typically, the activity of a prolyl tripeptidyl peptidase is increased about two-fold. Furthermore, unlike oligopeptidases, the prolyl tripeptidyl-peptidases of the present invention can cleave target peptidases having as few as 4 amino acids but also target peptides having at least 30 amino

acids or a molecular weight of at least 3,000 Da. In these respects, the *P. gingivalis* tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

5 Examples of putative prolyl-dipeptidyl peptidases are DPP-H1 (SEQ ID NO:43), DPP-H2 (SEQ ID NO:44), and DPP-H3 (SEQ ID NO:45). These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6). Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4). DPP IV has been
10 characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized. DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24. DPP IV has been purified in two forms. One of the forms is a full length gene translation product containing a blocked
15 amino-terminal residue. The second form had the amino-terminal amino acid sequence HSYRAAVYDYDVRRLNVKPLSEHVG (SEQ ID NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39-46), indicating that it was proteolytically truncated on the amino-terminus.

In *P. gingivalis*, PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane
20 anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N-terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure. Nevertheless,
25 membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media. The cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the
30 bacterium entirely dependant on an external peptide supply. In this regard, PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl-peptidases may inhibit the *in vivo* growth of organisms, including *P. gingivalis*.

For instance, treatment of *P. gingivalis* cultures in lagphase (i.e., the period after inoculation of a culture and before the organism begins to divide) and early logarithmic growth with the inhibitors PEFABLOCK and 3,4-dichloroisocoumarin inhibits growth of *P. gingivalis*.

5 Preferably, a polypeptide of the invention, preferably a prolyl peptidase, contains the amino acid sequence GXSXXG (SEQ ID NO:39), most preferably, GXSXGG (SEQ ID NO:40), where G is glycine, X is any amino acid, and S is the active site serine. The active site serine can be identified by, for instance, labeling with diisopropylfluorophosphate as described herein. Preferably, the catalytic
10 domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID
15 NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).

The invention further includes a polypeptide, preferably a prolyl tripeptidyl-peptidase, that shares a significant level of primary structure with SEQ ID NO:30.
20 The two amino acid sequences (i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO:30) are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted
25 in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the number of amino acids that the two sequences have in common within the
30 alignment, divided by the number of amino acids in SEQ ID NO:30, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100. Preferably, a prolyl tripeptidyl peptidase has

greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30. Preferably, amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ ID NO:30 are used. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

In general, the amidolytic activity of the polypeptides of the invention, preferably prolyl peptidases, can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer. Preferably, the lower ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1:100, even more preferably at least about 1:1,000, most preferably at least about 1:10,000. Preferably, the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1:1,000,000 and most preferably no greater than about 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay. Preferably, the buffer is about 200 mM HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES. Preferably, the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5. Preferably, the temperature of the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours. Preferably, the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1:100 to no greater than 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours. In general, the time of the assay can vary depending on the substrate and enzyme:substrate ratio. Typically, target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase. Preferably, the assay is allowed to continue until at least 1 % of the target peptide is hydrolyzed.

Prolyl-tripeptidyl peptidases of the present invention preferably are inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2-aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfluorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and diisopropylfluorophosphate, and most preferably diisopropylfluorophosphate. The

peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin, α_1 -proteinase inhibitor, α_1 -antichymotrypsin and α_2 -macroglobulin, most preferably. Significantly and unexpectedly, the amidolytic activity of a prolyl-tripeptidyl peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Preferably, the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.

The polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID NO:30. An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro-Yaa peptide bond present in a target polypeptide of the general formula NH₂-Xaa-Xaa-Pro-Yaa-(Xaa)_n (SEQ ID NO:25). Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro-Yaa peptide bond. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free NH₂.

Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will

hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond. An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain. Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond.

10 Prolyl peptidases can be obtained by several methods. Isolation of a prolyl-tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art. Alternatively, cells can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface. The following are 15 nonlimiting examples of suitable protein purification procedures: fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration 20 using, for example, Sephadex G-75. Preferably, isolation of a prolyl-tripeptidyl peptidase from *P. gingivalis* is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.

25 Prolyl peptidases can also be isolated from organisms other than *P. gingivalis*. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region. A “coding region” is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The 30 boundaries of a coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end. “Regulatory region” refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked. Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation

stop sites, and terminators. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved 5 under conditions compatible with the regulatory region. Alternatively, other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein. A prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art. 10 Alternatively, the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.

The expression of a prolyl-tripeptidyl peptidase by an organism other than *P. gingivalis* can be detected using specific substrates of the general formula NH₂- 15 Xaa-Xaa-Pro-LG or NH₂-Xaa-Xaa-Pro-Yaa (SEQ ID NO:41), where LG is a leaving group. The leaving group can be a chromogenic or fluorogenic group known to the art. The expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free 20 leaving group, each of which can be assayed using techniques known to those of skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.

As described in the Examples, the amino acid sequence of the amino-terminal end of a PTP-A fragment was used to identify the nucleotide sequence of 25 the PTP coding region. The nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished *P. gingivalis* W83 genome. However, even though the nucleotides that encode the *P. gingivalis* PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated. The data obtained from the database only contained 30 the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame. Moreover, there is little data known to the art regarding regulatory regions required for either the transcription or the translation of a nucleotide sequence in *P. gingivalis*.

Thus, a person of ordinary skill, having the nucleotide sequence of the genomic clone, would not be able to predict that the open reading frame encoding PTP-A was transcribed or translated. Moreover, even if there was a suggestion that the open reading frame was both transcribed and translated, there is no suggestion 5 that the polypeptide encoded by the open reading frame would have the novel activity of PTP-A.

Accordingly, the present invention is directed to a nucleic acid fragment 10 encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof. The nucleic acid fragment can have a nucleotide sequence as shown in SEQ ID NO:38. Alternatively, nucleic acid fragments of the invention include those whose complement hybridize to SEQ 15 ID NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38. Preferably, at least about 20 nucleotides of the complement hybridize with SEQ ID NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.

Alternatively, the nucleic acid fragment can have a nucleotide sequence 20 encoding a polypeptide having the amino acid sequence shown in SEQ ID NO:30. An example of the class of nucleotide sequences encoding such a polypeptide is SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.

The identification of similar coding regions in other organisms can be 25 accomplished by screening individual wild-type microorganisms for the presence of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.

Standard hybridizing conditions are a modification of the conditions used 30 by Church et al. ((1984) *Proc. Natl. Acad. Sci. USA* **81**, 1991): 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C. Preferably, a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the

nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.

“Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment. Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'-ATGC and 5'-GCAT are complementary. The term complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment. For instance the third nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT will not base pair, but these two nucleic acid fragments are complementary as defined herein. Typically two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.

Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase. For instance, a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38. Preferably a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length. Particularly preferred probes are

20 TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTACGGAGGAC
25 CT (SEQ ID NO:36,
GTGGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTT
(SEQ ID NO:37, and SEQ ID NO:38. Methods of detectably labeling a probe are well known to the art.

30 The nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro-Yaa

peptide bond on a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25). Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).

5 Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody. Preferably the antibody is directed to PTP-A. The production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.

10 The use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ ID NO:38. The coding region can then be isolated and ligated into a vector as described below. Two nucleic acid sequences are "similar" if the two nucleic acid sequences can be aligned so that the 15 number of identical amino acids along the lengths of their sequences are optimized. Preferably, two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.

As mentioned above, a nucleic acid fragment of the invention can be 20 inserted in a vector. Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the 25 nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid.

30 Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK233-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which

numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used 25 terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

The nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth 30 medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein. Alternatively, antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45. An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal. Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal.

5 Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein. Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal. An example of a

10 fragments of a prolylpeptidase is a catalytic domain. Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid

15 moieties, cofactors, and the like.

20

Accordingly, an aspect of the invention is an immunogenic composition comprising an isolated prolyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, preferably a prolyl tripeptidyl-peptidase. The prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the

25 Pro-Yaa peptide bond present in a target polypeptide with the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), wherein the amidolytic activity is measured at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:100 to no greater than about 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

30 The immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other

5 ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

10 The immunogenic composition can be used in a method for protecting an animal from a disease caused by *P. gingivalis*. This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification. The diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include lose of tooth attachment and periodontal pocket formation.

15 Alternatively and preferably, periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase. An inhibitor of a prolyl peptidase, preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier. For instance, inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well known to the art (see, e.g., Kornman, K., (1993) *J. Periodontol.* **64**, 782-791). Preferably, an inhibitor is applied subgingivally or by controlled release delivery.

20 The prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria *in vitro* or *in vivo*. Preferably, the bacteria is a periodontal pathogen, i.e, a bacterial pathogen that causes periodontal disease, more preferably the bacteria is *P. gingivalis*. The 25 inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply. The action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the *in vivo* growth of organisms, including *P. gingivalis*. The method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl-tripeptidyl peptidase) and the amount of free amino acids that result from further 30 cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl-

peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased. The amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.

5 Preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor. Preferably, an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase,

10 by blocking the active site of the polypeptide. The polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.

The present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active modification thereof, preferably a prolyl-tripeptidyl peptidase. The method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule. The amidolytic activity can be measured by cleavage of the Pro-Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein.

15 One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected that some modified amino acids will cause the target peptide to act as an inhibitor.

20

25

EXAMPLES

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

30

Example 1Materials

Diisopropylfluorophosphate (DFP), leupeptin and 3,4-dichloroisocoumarin, were purchased from Calbiochem (La Jolla, CA). Antipain, iodoacetamide, 5 substance P, bradykinin and bradykinin related peptides, were obtained from Sigma. Other peptides used in this study were synthesized at the Molecular Genetic Instrumental Facility (University of Georgia, Athens, GA) using Fmoc protocol with an advanced ChemTech MPS350 automated synthesizer. H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA 10 (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked amino-terminal group) were obtained from Bachem (King of Prussia, PA). Prolinal was kindly provided by Dr. James Powers (Georgia Institute of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).

15

Methods

Source and Cultivation of Bacteria— *P. gingivalis* HG66 was obtained from Dr. Roland Arnold (University of North Carolina, Chapel Hill), while the strains W50 (ATCC 53978) and ATCC 33277 were obtained from the ATCC. All 20 cells were grown as described previously (Chen, Z., et al., (1992) *J. Biol. Chem.* 267, 18896-18901).

Enzyme Activity Assays— Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (1mM) in 0.2 M HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The 25 concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA). In inhibition studies, the enzyme was first preincubated with inhibitor for 15 min at 37°C, substrate added, and residual activity recorded after 5 minutes to 30 minutes. 30 H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.

Protein Determination—Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.

Localization of Tripeptidyl-Peptidase Activity—Cultures of *P. gingivalis*

5 HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake). Unbroken
10 cells and large debris were removed by centrifugation (10,000 x g, 30 minutes) and the opalescent supernatant subjected to ultracentrifugation (150,000 x g, 120 minutes), yielding a pellet containing bacterial membranes and a supernatant which was considered as membrane-free cell extract. All fractions, as well as the full culture, culture medium, and full culture after sonication, were assayed for
15 amidolytic activity against H-Ala-Phe-Pro-pNA.

Enzyme Purification—All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram
20 of cells wet weight). Triton X-100 (10% volume/volume in H₂O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes). Proteins in the supernatant were precipitated with cold acetone (-20°C) added to a final concentration of 60% and collected by centrifugation. The
25 pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide. The dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml/hour.
30 After equilibration, the column was washed until the A₂₈₀ fell to zero. Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H-Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively. The activity against the latter

substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate. The column was washed with two volumes of 5 equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml/minute, 10 following which bound proteins were eluted with a gradient of 0- 300 mM NaCl. The active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis-Tris buffer, using a pH gradient developed with 50 ml of 10x diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0.

15 *Electrophoretic Techniques*—The SDS-PAGE system of Schagger and von Jagow (Schagger, H., and von Jagow, G. (1987) *Anal. Biochem.* 166, 368-379), was used to monitor enzyme purification and estimate the enzyme molecular mass. For amino-terminal sequence analysis, proteins resolved in SDS-PAGE were electroblotted to polyvinylidene difluoride membranes using 10 mM CAPS, pH 11, 20 10% methanol (Matsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038). The membrane was washed thoroughly with water and stained with Coomassie Blue G250. The blot was air dried, and protein bands cut out and subjected to NH₂-terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.

25 *Enzyme Fragmentation*—The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes. Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458) from *P. gingivalis* was then added to make an enzyme:substrate molar ratio of 1:100. The reaction mixture was 30 made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a μBondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a

gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.

For determination of the active site serine residue and to confirm that the purified enzyme was a serine peptidase, 100 µg of purified PTP-A was first 5 incubated with 170 µCi of [1,3-³H]DFP (Amersham, Arlington Heights, IL) for 30 minutes at 25°C in 20 mM HEPES, pH 7.5. The reaction was quenched by addition of cold DFP to a final concentration of 10 mM and the radiolabelled material analyzed by SDS-PAGE, followed by autoradiographic analysis. The gel was dehydrated, soaked in PPO solution for 2 hours, dried, and the DFP-binding 10 proteins detected by fluorography after an exposure time of 96 hours on X-ray film (XAR; Kodak, Rochester, NY). The bulk of radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse-phase HPLC as described above. Radioactivity in each peptide fraction was measured using a β liquid scintillation counter, and the labeled peptide, as well as 15 other selected peptides were subjected to sequence analysis.

Identification of the PTP-A Gene— The database containing the unfinished *P. gingivalis* W83 genome, available from The Institute for Genomic Research, was searched for the presence of nucleotide sequences corresponding to the NH₂-terminal and the internal PTP-A amino acid sequences using the TBLASTN 20 algorithm, BLAST version 2.0.8, and the default values for all parameters (Altschul, S.F., et al.,(1997) *Nucleic Acid Res.* 25, 3389-3402). An identified clone gnl | TIGR | *P. gingivalis*_126 was retrieved from The Institute for Genomic Research data base (<http://www.tigr.org>). The position of the PTP-A gene was localized using the NCBI open reading frame (ORF) finder (available from the 25 National Center for Biotechnology Information, at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>). The amino acid sequence, obtained by conceptual translation of the entire ORF, was further used for homology screening by use of the NCBI BLAST search tool.

Enzyme Specificity— Peptides were incubated with 1 µg PTP-A at an 30 enzyme:substrate molar ratio of 1:100 for 3 hours or 24 hours in 50 µl of 200 mM HEPES, pH 7.5, at 37°C, and the reaction stopped by acidification with trifluoroacetic acid. The samples were then subjected to reverse-phase high

pressure liquid chromatography using a μ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA) and an acetonitrile gradient (0-80 % in 0.075% trifluoroacetic acid in 50 min). Each peak, detected at 220 nm, was collected, lyophilized, re-dissolved in 50% (volume/volume) methanol, 0.1% acetic acid and subjected to analysis by mass spectrometry.

5 *Mass Spectrometry*—A Finnigan MAT 95S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C., et al., (1997) *J. Biol. Chem.* **272**, 5747-5751). Peptides were identified by fitting of the obtained 10 spectra to specific sequences using an Internet application program MsFit available at <http://falcon.ludwig.ucl.ac.uk/msfit.html>.

Example 2

Enzyme Localization, Purification and Initial Characterization

15 Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of *P. gingivalis* HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated 20 enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form. Subsequent acetone precipitation of proteins in the Triton X-100 fraction successfully separated the activity from pigment which remained in solution. The redissolved protein fraction, after dialysis, was applied 25 to hydroxyapatite (100 ml) equilibrated with 20 mM potassium phosphate buffer pH 7.0. The elution was carried out with 20 mM potassium phosphate buffer pH 7.0, using a phosphate gradient from 20 mM to 300 mM at flow rate 20 ml/h. At this step substantial separation of the PTP-A activity from both the DPP IV and bulk protein was achieved (Fig. 1a). Further purification performed by subsequent 30 chromatography steps including Phenyl-Sepharose (Fig. 1b), MonoQ (Fig. 1c) and MonoP columns (Fig. 1d), resulted in the isolation of purified enzyme.

Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h. The column was

washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied. The PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by 5 ultrafiltration. The concentrated PTP-A containing fractions were applied to a MonoQ column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl. The concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP 10 column equilibrated with the same buffer. A pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.

Significantly, the chromatography step on the MonoP column yielded the A₂₈₀ profile much sharper than the activity peak. Although this imperfect overlap of protein and activity may suggest that the protein component does not represent 15 the active enzyme, the rest of data argues with such a contention. This apparent contradiction may be likely explained by the enzyme inhibition by the reaction product of H-Ala-Phe-Pro-pNA hydrolysis but this possibility has not been explored. The yield of protein and activity recovery in a typical purification procedure is summarized in Table 1.

Table 1. Purification of the PTP- A from *P. gingivalis*

Step		Volume (ml)	Protein (mg)	Total activity*	Specific activity (units/mg)	Purification fold	Yield (%)
	Triton X-100 extract after centrifugation	200	1200	757 673	642	1	100
5	Acetone precipitate	50	600	537 622	896	1.4	71
10	Hydroxyapatite chromatography	50	22	400 039	18 183	28	53
	Phenyl-Sepharose	48	10	312 505	31 250	48	41
		3	1.5	244 828	163 218	254	32
15	MonoQ						
	Monop	4	0.7	188 400	269 142	420	25

* Based on the enzymatic activity using H-Ala-Phe-Pro-pNA where one unit = mOD/min/1ml

SDS-PAGE analysis of the purified enzyme revealed the presence of two protein bands with apparent molecular masses of 81.8 and 75.8 kDa, respectively (Fig. 2, lane f). Autoradiography of the enzyme sample radiolabeled with [1,3-³H]DFP (Fig. 2, lane g) clearly indicated that the bands represented either two distinct serine peptidases or different molecular mass forms of the same enzyme. In an attempt to distinguish between these two options, the electrophoretically resolved proteins were subjected to amino terminal sequence analysis. Unfortunately, it was found that the 81.8 kDa form of PTP-A had a blocked N-terminus. In contrast, the sequence NH₂-SAQTTRFSAAADLNALMP (SEQ ID NO:23) was found at the N-terminus of the lower molecular mass form of the enzyme. This result led us to the possibility that the 75.8 kDa form of PTP-A was derived from the 81.8 kDa form through proteolytic cleavage of a 6 kDa amino-terminal peptide. To confirm this hypothesis and, in addition, to localize the active site residue within *P. gingivalis* PTP-A, the mixture containing both radiolabeled enzymes was proteolytically fragmented and peptides resolved by reverse-phase HPLC. This procedure yielded only one major radioactive peptide peak, and the purified peptide was found to have a single amino acid sequence: IGVHGWXYGGFMTTNL (SEQ ID NO:24), where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP. These data convincingly indicate that the two protein bands of purified PTP-A represents different forms of the same enzyme. The portion of the purified PTP-A having a truncated N-terminus may be due to cleavage by Lys-specific peptidase and is likely to be an artifact which occurred during the purification procedure. Nevertheless, the proteolytic shedding of membrane bound PTP-A also occurs during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.

Example 3

pH Optimum, Stability and Inhibition Profile

Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases

(Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase. Surprisingly, however, 3,4-dichloroisocumarin was only a poor inhibitor, and PMSF, leupeptin, antipain and prolinal had no effect at all. Interestingly, 5 preincubation of PTP-A with iodoacetamide, but not with N-ethylmaleimide, stimulated enzyme amidolytic activity about two-fold. Human plasma inhibitors, such as α_1 -proteinase inhibitor, α_1 -antichymotrypsin and α_2 -macroglobulin did not affect the enzyme activity, nor were they cleaved by PTP-A.

The effect of inhibitors on amidolytic activity of DPP IV was also 10 determined using the same conditions as those used for PTP-A, but using H-Gly-Pro-pNA as a substrate.

Table 2. Effect of inhibitors on the amidolytic activity of PTP-A and DPP IV.
 Results are for a 15-min incubation at 37 C in 0.2 HEPES pH 7.6,
 with 1 mM H-Ala-Phe-Pro-pNA as substrate.

	Inhibitor	Concentration	Residual activity of PTP-A, %	Residual activity of DPP IV, %
5	Diisopropyl fluorophosphate	10 mM	0	0
10	Phenylmethanesulfonyl fluoride	10 mM	96	20
15	PEFABLOC SC	1mg/ml	20	15
20		10mg/ml	0	0
25	3,4-dichloroisocoumarin	1 mM	56	100
30	Iodoacetamide	5 mM	200	100
35	N-Ethylmaleimide	5 mM	100	100
	1,10- orthophenanthroline	0.1 mM	93	100
	EDTA	0.1 mM	100	100
	Leupeptin	0.1 mM	100	100
	Antipain	10 mM	100	20
	Prolinal	10 mM	100	0
	Val-Pro	10 mM	100	30
	Ala-Pro	10 mM	100	1
	Ala-Gly-Pro			

Example 4
Substrate Specificity

Among several chromogenic substrates tested, including H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, H-Pro-pNA, only H-Ala-
5 Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl-peptidase activity. To further confirm this specificity several synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A. Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved
10 (Table 3), with the significant exception of peptides with adjacent proline residues (peptides 3, 4 and 16). In addition, a free α -amino group was absolutely required for cleavage after the third proline residue as exemplified by resistance to enzymatic hydrolysis of peptide 9, which differs from the peptide 8 only in acylation of the α -amino group of the N-terminal valine residue. Except for these
15 two limitations, the peptide bond -Pro- \downarrow -Yaa- was cleaved at the same rate in all peptides with the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the amino acids and the length of the peptide. In all cases the reaction was completed within 3 hours and
20 prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus. In addition, these data indicate that the preparation of PTP-A was free of any contamination with either aminopeptidase, dipeptidyl peptidase, or endopeptidase activities.
25 The cleavage specificity of DPP IV was also determined using the same conditions as those used for PTP-A. The results (Table 3) demonstrate that DPP IV does not cleave between two proline residues.

Table 3. Cleavage specificity of PTP-A and DPP IV on synthetic peptides.

Substrate	Cleavage site	SEQ ID NO:
Peptide 1	H-Arg-Pro-Pro- \downarrow -Gly-Phe-Ser-Pro-Phe-Arg	1
Peptide 2	H-Arg-Pro-Pro- \downarrow -Gly-Phe	2
Peptide 3	H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	3
Peptide 4	H-Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	4
Peptide 5	H-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg	5
Peptide 6	H-Arg-Pro- \downarrow -Lys-Pro- \downarrow -Gly-Gln-Phe-Phe-Gly-Leu-Met-NH ₂	6
Peptide 7	H-Val-Pro-Pro- \downarrow -Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Pro-His-Arg-Gln	7
Peptide 8	H-Val-Pro-Pro- \downarrow -Gly-Glu-Asp-Ser-Lys	8
Peptide 9	Ac-Val-Pro-Pro-Gly-Glu-Asp-Ser-Lys	9
Peptide 10	H-Val-Glu-Pro- \downarrow -Ile-Pro-Tyr	10
Peptide 11	H-Arg-Gly-Pro- \downarrow -Ile-Pro-Ile	11
Peptide 12	H-Ala-Arg-Pro- \downarrow -Ala-D-Lys-amide	
Peptide 13	H-Pro-Asn-Pro- \downarrow -Asn-Gln-Gly-Asn-Phe-Ile	13
Peptide 14	H-Arg-His-Pro- \downarrow -Lys-Tyr-Lys-Thr-Glu-Leu	14
Peptide 15	H-Gly-Yal-Pro- \downarrow -Lys-Thr-His-Leu-Glu-Leu	15
Peptide 16	H-Lys-Gly-Pro-Pro-Ala-Ala-Leu-Thr-Leu	16
Peptide 17	H-Gln-Lys-Gln-Met-Ser-Asp-Arg-Arg-Glu-Asn-Asp-Met-Ser-Pro-Ser-Asn-Asn-Val-Pro-Ile-His-Val-Pro-Pro- \downarrow Thr-Thr-Glu-Asn-Lys-Pro-Lys-Val-Gln	17
Peptide 18	H-Phe-Ile-Arg-Glu-Pro-Val-Ile-Phe-Leu	18
Peptide 19	H-Gly-Ile-Arg-Pro-Tyr-Glu-Ile-Leu-Ala	19
Peptide 20	H-Leu-Pro- \downarrow -Asp-Leu-Asp-Ser-Ser-Ile-Gln-Glu-Leu-Ser-Pro-Gln-Glu-Pro-Pro-Arg-Pro-Pro-Glu-Ala	20
Peptide 21	H-Cys-Leu-Ser-Ser-Gly-Thr-Leu-Pro-Gly-Pro-Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser	21
Peptide 22	H-Lys-Ile-Ala-Gly-Tyr-His-Leu-Glu-Leu	22
Peptide 23	H-Ser-Pro- \downarrow -Tyr-Ser-Ser-Asp-Thr-Thr	46
Peptide 24	H-Ala-Pro- \downarrow -Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys	47

[†] indicates cleavage site mediated by PTP-A[†] indicates cleavage site mediated by DPP IV

The lack of cleavage after internal proline residues in the synthetic peptides corresponds well with the absence of any proteolytic activity on several protein substrates including IgA, IgG, albumin, azocasein, carboxymethylated 5 ribonuclease and gelatin. However, the size of substrate, which is a limiting factor in the activity of oligopeptidases (Walter, R., et al., (1980) *Mol. Cell. Biochem.* 30, 111-126), is not restricting in the case of PTP-A, because the enzyme is able to cleave a tripeptide (NH₂-Xaa-Xaa-Pro) from the N-terminus of both human cystatin C and interleukin 6.

10

Example 5

PTP-A Sequence Analysis

Partial PTP-A amino acid sequence data allowed us to identify the *P. gingivalis* genomic clone gnl | TIGR | *P. gingivalis*_126 in the Unfinished 15 Microbial Genomes data base, TIGR. An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB were present in the protein primary structure inferred from the nucleotide sequence of the ORF. The 732 amino acid polypeptide with a calculated mass of 82,266 Da 20 was encoded in this ORF. The homology search performed using the NCBI TBLASTN tool against GenBank+EMBL+DDBJ+PDB databases and subsequent multiple sequence alignments using the ClustalW Multiple Sequence Alignment tool (Fig. 3) indicated that PTP-A is a new member of the prolyl oligopeptidase (S9) family of serine peptidases (Rawlings, N.D., et al., (1991) *Biochem. J.* 279, 907-908).

25

The sequence GXSXGG (SEQ ID NO:40) is a signature feature for the S9 family of serine peptidases. Within this large and diverse S9 family of evolutionary and functionally related enzymes both from prokaryotes and eukaryotes, PTP-A was most closely related to bacterial dipeptidyl peptidase IV (DPP IV) from *Flavobacterium meningosepticum*, *Xantomonas maltophilus*, and *P. gingivalis*, 30 sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively. Remarkably, the COOH-terminal region of the PTP-A molecule (residues 502 - 732) shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3). This part of the molecule contains the amino acid

residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima,T., et al., (1995) *Arch. Biochem. Biophys.* 320, 123-128) it is apparent that Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP-A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP. In addition, the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic α -helix responsible for membrane anchoring of this enzyme.

In *P. gingivalis* PTP-A, as well as in DPP IV, all activities are cell surface associated, and it is conceivable that the enzymes are membrane anchored through putative signal sequences which are not cleaved but remain as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. The cell surface localization of di- and tripeptidyl-peptidases suggests a putative physiological function in providing nutrients for growing bacterial cells. Here, the inability of asaccharolytic *P. gingivalis* to utilize free amino acids (Dashper, S.G., et al., *J. Dent Res.* 77, 1133 (Abstract) (1988)) makes the bacterium entirely dependant on an external peptide supply. In this regard, DPP-IV and PTP-A activities are probably very important, if not indispensable, for bacterial growth.

This suggestion is strongly corroborated by the fact that the *P. gingivalis* genome contains three additional genes encoding peptidases homologous with DPP-IV and PTP-A and one related to aminopeptidase B. The peptidases homologous with DPP-IV and PTP-A are referred to as homologs H1 (SEQ ID NO:43), H2 (SEQ ID NO:44), and H3 (SEQ ID NO:45) (Fig. 6). If expressed, each gene product would probably have enzymatic activity because each has a well preserved catalytic triad (Fig. 4). In addition, all of these genes encode a putative signal peptide which may act in providing membrane-anchorage motifs.

Example 6**Influence of Proteinase Inhibitor on *P. gingivalis* Growth**

To evaluate whether *P. gingivalis* growth was influenced by the presence of a peptidase inhibitor, *P. gingivalis* in logphase growth was diluted 1:5 into liquid media and incubated at 37°C. The cell density was monitored by measuring the optical density at 600 nm (OD₆₀₀). When the optical density began to increase, Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml. The control culture received no Pefabloc. The cultures receiving Pefabloc exhibited decreased growth (Figure 5). The peptidase inhibitor had to be added before the culture reached an OD₆₀₀ of about 0.3 for the peptidase inhibitor to have an effect on growth.

The complete disclosures of all patents, patent applications, publications, and nucleic acid and protein database entries, including for example GenBank accession numbers and EMBL accession numbers, that are cited herein are hereby incorporated by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

20

Sequence Listing Free Text

SEQ ID NOS:1-11: Synthetic peptides

SEQ ID NO:12: Target peptide

SEQ ID NOS:13-22: Synthetic peptides

25 SEQ ID NO:23: Amino-terminus of the lower molecular mass form of PTP-A.

SEQ ID NO:24: Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.

30 SEQ ID NO:25: Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.

SEQ ID NO:26: Mouse fibroblast activation protein

SEQ ID NO:27: Human DPP IV

SEQ ID NO:28: DPP from *Flavobacterium meningosepticum*

SEQ ID NO:29: DPP from *P. gingivalis*

SEQ ID NO:30: *P. gingivalis* PTP-A

5 SEQ ID NO:31: Portion of PTP-A

SEQ ID NO:32: Portion of DPP from *P. gingivalis*

SEQ ID NO:33: Portion of H1 homolog of *P. gingivalis* DPP

SEQ ID NO:34: Portion of H2 homolog of *P. gingivalis* DPP

SEQ ID NO:35: Portion of H3 homolog of *P. gingivalis* DPP

10 SEQ ID NOS:36-37: Probes

SEQ ID NO:38: Nucleotide sequence of coding region encoding PTP-A.

SEQ ID NO:39: Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSXXG.

SEQ ID NO:40: Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSXGG.

15 SEQ ID NO:41: A specific substrate for a prolyl-tripeptidyl peptidase, where Xaa represents a natural or modified amino acid residue, and Yaa represents a natural or modified amino acid residue except proline.

20 SEQ ID NO:42: DPP from *P. gingivalis*

SEQ ID NO:43: H1 homolog of *P. gingivalis* DPP

SEQ ID NO:44: H2 homolog of *P. gingivalis* DPP

SEQ ID NO:45: H3 homolog of *P. gingivalis* DPP

SEQ ID NO:46: Synthetic peptides

25 SEQ ID NO:47: Synthetic peptides

SEQ ID NO:48: Amino terminal sequence of DPP IV

What is claimed is:

1. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
2. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours, and wherein the prolyl tripeptidyl-peptidase is isolated from *P. gingivalis*.
3. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the peptide cleaved by the isolated prolyl tripeptidyl-peptidase comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, and SEQ ID NO:37.
4. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSXXG (SEQ ID NO:39).
5. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSXGG (SEQ ID NO:40).
6. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises SEQ ID NO:30.

7. An isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
8. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
9. An isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
10. The nucleic acid fragment of claim 9 wherein the nucleic acid fragment has a nucleotide sequence comprising SEQ ID NO:38.
11. The nucleic acid fragment of claim 9 wherein a complement of the nucleic acid fragment hybridizes to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
12. An isolated nucleic acid fragment encoding a polypeptide wherein the polypeptide comprises an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
13. A method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, comprising identifying a molecule that inhibits the amidolytic activity of the prolyl-

tripeptidyl peptidase by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

14. A method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
15. A method for protecting an animal from a periodontal disease caused by *P. gingivalis* comprising administering to the animal the inhibitor of claim 14 wherein the disease is selected from the group consisting of gingivitis and periodontitis.
16. The method of claim 15 wherein the inhibitor is administered by a method selected from the group consisting of subgingival application and controlled release delivery.
17. A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl dipeptidyl-peptidase with an inhibitor of the prolyl dipeptidyl-peptidase.
18. An immunogenic composition comprising an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
19. The immunogenic composition of claim 18 further comprising an adjuvant.

20. A composition comprising an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
21. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:43.
22. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:44.
23. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:45.

Fig 1




Fig. 2




Fig. 3

2010 NO:

26	1 fm-FAP	1 MKTWIKRTPEGMTTAAIAVVICIVLRLPS - YKPEGNT - RALT - LNGT - SYKTYF
27	Hs-DPP	1 MKTPWVVLGLLIGAAAIVTITVPPVV LN GTDD TADS - KTYT - T YLKNT - RLKLYS
28	Fm-DPP	1 ---MKKKIESLSSHAIAVAFHGLSAQEITLDK YS Q RA - GISGRASND ---
29	Pg-DPP	1 -MKRPVIRILLIGITCAAAQTGNKP DL E TS M YA SAGSGRS PD ---
30	PTP-A	1 ---MKKTIIEOOLFISCAATVALPCSAQS PETSGKE TLEQLMPGG FYN -- YPEYVV
Mm-FAP	59 PNWISEQEYHQD - EDDNIEFVYNE - RE -- SY I SNS MKSVN -- ATDYG SPDRQF Y	
Hs-DPP	60 LWRWSDHEVYK -- DEENI VENAEYCN -- S F ENS FDEFGHSINDYS SPDGQF L	
Fm-DPP	48 ---G E NYAT -- EPTGIAKRSYK SQ -- KEKN VDG FQGYT --- SNDESK -- H	
Pg-DPP	51 ---G E NYTE VNRERTA I ERYN YASCKAVD FSVERARECPFKQIQNYE SSTGHKL	
	56 GLOWMG NY DME -- GDD VENKANGKSAQ TRFSAADLNALMPEGCK QT DAFPSFR	
	→	
Mm-FAP	114 LESDYSK RYSYTAT YVYD LQNGE F RGY LPRPIQY C SPVGSKIAYVY NNLYK	
Hs-DPP	116 LEYNYVKQ RRSYTAS D YD LNK RQ TEERIPNNTQW T SPVGHKIAYVWAN IYK	
Fm-DPP	92 LOKSSQS RRS E LK E Y KDLKSRIV S LNNANWIQE PRFSPDGSKVAEADNNI YQ	
Pg-DPP	106 LFTDMES RRSYRAAVYD YD VRNIAVKPLS HVGKVMIPFSPDGMRVAFVRDNNTI K	
	113 TLDAGR G VVLFTQ GLVG D LARKVTLF TNEETAS DFSPVGDFVAYVR E NY EFA	
	→	
Mm-FAP	174 QRP -- G PPEQITYTG I NRIENG PDWVYEEMLATKYA I WSPDGKFLA VEEF S D	
Hs-DPP	176 IEP -- NLPSYRITWTG E I YNCE TDWVYEEVF SAYSAL WSPNGT E LA EAEV E	
Fm-DPP	151 DLN - TGK I TO ITDG KNEI I NC GDWVYEEFGHADYYQAN KAGDAV E VRED E RKV	
Pg-DPP	166 KFD - F TEV O V TTDGOINSI I NC ATD WVYEEFGVTLMSWS ADNAELAFVRSD E SAV	
	173 RGGKLG GMSRAIAVTI G T E TLVYQOAVH REEGIEKGTEWS PKGSCLAEYRMDOSMV	
Mm-FAP	232 PI I AYSYVGDG -- QYPRE I N E YPKACAKNPVVR VDT TYP HVG -- P E FVPEMI	
Hs-DPP	234 PLIEYSFYSDESLOYPK RY P YPKACAVNPVTKF VMTD LS VTNATS TAPASM	
Fm-DPP	208 PEIN PI MYQN -- LYPKL TYKYPKAGEE NSAV A Y S G A Q -- FGSSEKY	
Pg-DPP	223 PEYR PMMEDK L YPEDTYKYPKAGEKNSTV H Y ADRN KS S PIDADG	
	232 KPTP VDMHP -- LEAEISPK Y Y VAGTPSHHV G YH A G VY -- TGEPEKEK	
Mm-FAP	287 ASSDY I WLTWVSSER C QOWL V N V S V S CDFREDWHAWECPKNQEH E E RT W	
Hs-DPP	294 LIGDH LCDVTWATOER S QOWL I N Y S V D CDYDESSGRWNCLVARQH E M T T W	
Fm-DPP	262 I P Q N -- AND E V ATAN R Q N KVD K NTK AAVS -- K FTE IDN W	
Pg-DPP	277 I P R A S D -- NAD E PAV T L N R I Q N D F K YY HPK L VPK L Q MNKR	
	285 T N S I P -- DENI Y VAEVNRAQNECKV NAYDAE GRFVR T FVE D KH	
Mm-FAP	347 AGGFF TPAF SODATSY K I S E D G H I H I K D T V E N A I Q I T S C K W B A T Y R R T Q D	
Hs-DPP	354 VGRFRP EPHF I LD C N S F K I S N E E G H I C Q IDK D C T F I T K G T W E V I C T E T S D	
Fm-DPP	311 E T D N -- E F L D D N S -- E L A S E D G H H I Y P Y D A A C K K O V S K G D W H I N Y C Y N P K	
Pg-DPP	326 V I S D W Q T K F I T G G E A V S E D G H A H I Y L Y D N K G V H R I T S G N W D V R K L G D A S	
	335 V E P L H P -- T E L P G S N N Q E I I O S R I D G N H I Y L Y D T T C I Q T K G E W E V T N F A G D P K	
Mm-FAP	407 S L F Y S N E E G Y P G R R N I Y R S I G N S P P S K K C V T C I R K E R C Q Y Y I A S E S Y K K Y V A L V C	
Hs-DPP	414 Y L Y Y I N E Y K G M P G G R N Y Q L Q L S D Y T K V T C L S C B I N P E R C Q Y Y I V S E S K E K Y Y Q L R C	
Fm-DPP	368 --- T K E V I Q A T E K G S I N V S K N I N T G -- K T Q I L S N A E G N N S A A E S K T F N Y E I N T S	
Pg-DPP	384 --- G T V Y Q A E E S P I R A V V A D A K G R -- K T B I S L N V G T N D A L F S G N Y A Y Y I N T Y	
	393 --- G R Y F E T E A S P I E R H F Y C D I K G G -- K T D L T P E S G M H R T Q I S P D S A I H D F	
Mm-FAP	467 Y E B G I P S I H D G R T D Q E Q V I L E P N K E L P N S L N I P K V E K K K K D G C L T F D Y K M I	
Hs-DPP	473 S E B G I P Y E H H S S V N D K G I V L E D N S A L I K M L Q N V P S K K D F I I L N E T K F Y O M I	
Fm-DPP	421 S T A K I P T K Y I L K D A N G K I E L O N N D D L L N K L S D F I A K E F I T I P N A G D Q V N A W M I K	
Pg-DPP	435 S S I A T P A V S I F R S K G A K E T L E D N V A L R E R L A Y R Y N P K E F T T I K T Q S C L E V N A W M K	
	446 Q S P T I P R K V T V T N I G K G S T I L C A K N P T G Y A M P E R T G T M A A D -- Q T P M K I T	
Mm-FAP	525 P P Q E D R S K K Y P B L I K Q V Y G P C S Q S V K S V A V N -- W I T Y L A S K E G I V A I V D G R G T E R O G	
Hs-DPP	531 P P H F D K S K K Y P B L I D V Y G P C S Q S O K A D I V S R L N -- W A T Y L A S T E N I V A S E D G R G C S G K O G	
Fm-DPP	480 P K N E D P S E K K Y P V E F O Y S G P G S Q V D A V S D G G N G I W F D M L A Q K G Y V V C V D G R G T G E R G	
Pg-DPP	495 P I D E D P S E K K Y P V E F V Y V Y E G E H D O V V T K T R S S V G G W D I Y A Q K G Y A V F I V D S R G C A N R G	
	502 P L H E D P S E K K Y P V E F V Y V Y E G E H D O V V T K T R S S V G G W D I Y A Q K G Y A V F I V D S R G C A N R G	

Mm-FAP	582	DKELHAYRKLGVYEVEDQITAVPKFIEGRIIDEERIAIWGWSYGGYVSSEALASGTGIF	* →	Fig. 3
Hs-DPP	588	DKIMHAIINRRLGTEFVEDQIPIAARQFSKYGFDNKRIATIWGWSYGGYVTSMVLGSGSGVF		
Fm-DPP	539	TKYKKVTVYKNLCKYEDQITAAKWEQGNQSYVDKSRIGIEGWSYGGYMASTIAMTKGADVF		
Pg-DPP	551	EEPRKCTYMLGVEESDDQIPIATAIGQIPVDAARIGIWGWSYGGYTTIMSLCRGNCIF		
	561	AAPEQVHRRILGOTEMADOMCGVDFIKSQSWVDADRGVHGWGWSYGGEMTINLYLTHGDVF		
Mm-FAP	642	KCGIAVAPVSSWCVVAVSITYSERFMGLPTKDDNLEHYKNSTVRAEYFRNVDYLLIHGTA		
Hs-DPP	648	KCGIAVAPVSPWEMYESVYTERYMGILPTPEDNLEHYENSNVMSRAENEKQVEYLLIHGTA		
Fm-DPP	599	KMGIAVAPVIAHREYDSLYTERFLQTPQENK--DGYDINSPITTYAKILLKG-KELLIHGTA		
Pg-DPP	611	KAGIAVAPVADWREYDSMYTERFMRTPKENA--SGYKMSAEDVASOLOG-NLLIVSCSA		
	621	KVGVAGGPVIDWNRVETMYGERYFDAPQENP--EGYDAANEEKRAQDLKG-RIMLIHGAI		
Mm-FAP	702	DDNVHFQNSAQIAKALVNAQWDFQAMWYSDOHCGISSCRSONHLYTHEMTHFLIKQCFSLSD		
Hs-DPP	708	DDNVHFQSSAQISKALVDVGWDFQAMWYTDEDHGIASSTAHOHLYTHEMSHEHJKOCFSLP-		
Fm-DPP	656	DDNVHFQNSMEEFSEALIIONKKOFLDFMAYPDKNHSIIGGANIRPOLYEKMTNEGLEN---		
Pg-DPP	668	DDNVHLQNEMLFTHAALVQANIPEDMAIYMDKNHSIIGGANIRYHLYTRKAKELFEDNL---		
	578	DPVVVWQHSIIFIBACVKARTYPDYYVYPSHEHNWMCVD-RVHLYETITTRYFTDHL---		

*

*


Fig.4

SEQ ID NO:

PTP-A	556	VDADRIGNEWSYGGFV	...RIMETHGA	DPVWWOBSEFTLISACVKARTYPD	YPSHEHNIVCGF-R	717
DPP	499	VDADRIGIWSYGGFV	...NILEYSCADDNVHON	LTFTLAVQANIPPE	ALDKNHSNIGGNT	661
DPP-H1	350	VDPDRIGIWSYGGFV	...PELEVQANDP	QIVTALLRGEVFTAVKINECHG	GREENS	524
DPP-H2	640	VNGKRVGGC	...PELTHGSYD	TEODHTEPEPERR	810	
DPP-H3	495	VDGDRIGAVGASYGGFV	...EFLINHGEID	TEODHTEPEPERR	667	

*

Fig 5

Influence of Pefablock- serine proteinase inhibitor on *P. gingivalis* growth.

SEQ 10 NO:

Fig. 6

30 126PP 1 **MKKT**IFQOLF---LSVCALTVALPCSAQSPETSGKEETLEQLWPGCKEF--YNFYPEYV
 41 87PP 1 -----XPDGEHY--TEMNBERT
 43 65PP 1 -----VDKGG--NEYHLFA
 44 101PP 1 **MKK**SLLMILLSAATISSIEAQTIQQMKAGGPWPVRAAFKTDTCGMNGSKNPADLHQAY
 45 9PP 1 **MNK**KIFSMVAAS--LIGSAMTPSAGTNTGEHLPPELMTLSRVSEMAKS--PDGKTA
 126PP 55 VGLQWMGDNYVF---IEGDDLVHNKANG-----KSAQTRFSAAIDLALMPEGCKQ
 87PP 16 AIIRY---NYAS---GKAVDTLISVER-----ARECPFKQIQ-N-----YE
 65PP 14 SNIDG---S-----NTRDLTPFDGVK-----ASILNMLKEQK-D-----YM
 101PP 61 DATDKDLRNVSAKDGRIGRKAGSKAEDSEMAVSYFALTAEHFAKADI EVFGQGRMSLW
 9PP 57 AVSFP--DVKT-----NKATRELFVNL-----GSGRKQITDTESN-----EYAPAW

126PP 104 **TTE**AFPSFRTLADGRS--LWVLFQGGLWGFDMILARKVTYL--FDTNEETASLDFSF---
 87PP 50 VSSTGHHILLFTDMES--IYRHSYRAAVYDYDVRRIIVKPL--SEHVCKVMIPTFSP---
 65PP 46 **I**ISMNNK---NNPQ---IFEPYKLNVVTETLQLYEN--KDAANPIQGYEFDK---
 101PP 121 LDEKQIGEADSPNSKEDDTLRFASLSSLVPETHILLIKSILLEGDTTATDVRVVLKPKTA
 9PP 98 **M**AGKKE-DAFMSNEGG---SMQLWVMNADGTERQDSN-----IEGGITGFLFSP---

126PP 157 -V-----S-DRVAYVENHN-LYIARG--GKLGEGMSRAIAV**TIDGTETL**YQGA---
 87PP 103 -D-----G-RM-AEVDRDNN-**I**FIK-----KFDFDTE--VQVTTDQINSI**LNGATD**
 65PP 90 -D-----S-ELRGYSH-----LNGIESELYKD--
 101PP 181 **R**OSALALYPNTSKERISLKHMMGTFLSGGSLSPGKYVLTSYR**V**SRDNKPAVTVNQLRD
 9PP 144 -D-----E-KQVLFSTD-----KFGKRTKD**E**YPDLDK

126PP 201 -VHQREFGIEKG--TFSPKGSCLAFYRM-----DQS-MVKPTPIVDYH---PL
 87PP 144 WVYEEEEFGVTNL--MS-SADNAFLAIVVS-----DES-AVPEYRMPMYED---KL
 65PP 112 -LATGEFRALKK--THDDDFGVIATNYA-----SKN-KDEAYVLTNL-----S
 101PP 241 AKGNILLNLNEKEALGRMPHEDMUMVIRKEGNAKRLVAF**E**PMGKGKETLVSNLPEQFRM
 9PP 170 AT**R**IITDLMYK---HDEWWVETI**PHP**FI-----AN-ATDGMITTGKD---I

126PP 243 EAESKPLYYPNAGT---PSHHVTVGIVYHLA---TG-KTVYIQTGEPE**E**KEKFLTNSLWSWPDE
 87PP 188 YPDYTKYTKAGE---KINSTVSLHLYNVA---DR-NTKSVS**E**PIDADGYIPRIAFTDNA
 65PP 153 DK-TRIVLVDLKQN--K---TIREIFANE---DY-DVSGEHLSS-RK-----
 101PP 301 SP**A**RYIIFYKQEKGPQNDPLFURHLDPPDRQSDWWRDRSQTIVLNAESGVYGPLTEGYST
 9PP 210 ME-GEPIYEALMKPW---S-GIEDFSWSP---DG--QNIAYASRKNTG-----

126PP 296 NI**Y**VAE--VNRAQNECKVNAIDAETGRFVRTLFVETDKHVEP--LH-P---LTFEP-
 87PP 241 DEHAYAT--LNRQLQNLFKM-YVHPKSLVPKLI**L**QD**N**KEYVDSWIO-T---LKSTT-
 65PP 188 -R-----N-YEIDLMA--VEGEKSVVVPVSATYKELHKLME-----KEFK--
 101PP 361 TYTYDIA**P**DSKRALIGTLSTDTRRRPFTATIMEYNETGKADTLITRDPSIDA**Q**YTFD
 9PP 247 -MA**S**LS--TN---SDIYE--**I**NLASGRTHNISEGMWGYDTPK-----FSPD

126PP 346 **G**SNNO**H**IQOSR-RDGW**N**HLY-----**I**DTTGRLI**Q**VTKGEWEV**I**NFA-----G
 87PP 292 **GG**G--**H**AYVSE-KDG**A**HTY-----YDNKGV**W**HRRI**T**SGNW**D**V**T**KLY-----G
 65PP 224 **G**KE--**H**SVV-----D-----YDD-----
 101PP 421 **G**KH--LIVMGS-ADA**F**GNIG**G**NLKSGVTPNSYDKQF**F**FLFDLSTRKATA**T**TKN**N**NPSVSAG
 9PP 287 **G**K**S**--IAW**I**S**M**ERDGYES-----DLKRLF**V**ADLA**I**GKRTH**V**NPT**D**YNVDMI

126PP 389 -FPKGTRLYFESTEASPLERHFCIDINGKTKDL**T**P-ESGMHRTOLSP--GSA**I**DIF
 87PP 333 -V**A**SGT-VEYQS**A**ESPIRRAV**V**AA**M**GRK**T**K-L**SL**-NVGTND**AL**FS**GN**-YAYYINTY
 65PP 235 --**E**--**I**LLIAV**C**SDKLYGTY**T**Q**R****T**--**T**K-----KFT-----L**YD**-L
 101PP 478 RE**C**RKNN-Y**Y**YFRA**I**NG-S**R**Q**Y**RL**E**LT**L**LE**I**SQ**I**QT**G**ED**V**V**Q**W**F**G**W**AD**N**GA**W**Y**S**Q
 9PP 332 Q**W**AP**D**SK**G**LY**E**L**A**CKEA--ETNL**W**E**I**T**L****T**GN**I**RO**I**IT**Q**Q**H**DY**A**DF**S**VR**N**D---V**M**LA**K**R

Fig. 6

126PP	446	QSPTVIRKVTVTNIGKESHTLEEKNPDTGYAAMPETGT-----T	IMAADGQTPLYYKLT
87PP	388	SSAATPAVSVFRSGAKELRTLEDVALRERLKAYPYNPKEFTT	IKTQSGL-LELNAIV
65PP	269	-----M1QK-----EED-----VAEMRPI-----KEKSRDG-LTIHGFIT	
101PP	536	SENNADRLYRLDGTRGKLWDLISAEKLANIDFTPARDWN-----YTAPDG-TVVEGMYY	
9PP	387	HSFELPDDLYRVNLXNEAAQAVT	ENKVILDRLPTCEKR---WAKTTDG-GNMLTRVV
126PP	501	MELHFDEAKKYFVIVVYVYGG-----PHAWLVTKTWRSSVGGWDIYMAOKGYA	WFTVDSRGSAN
87PP	447	KPIDEFDIUSRHYFVLMVQYSG-----PNSDQVLD--RYSFD-WEHYLASKGYV	VACVIGRGTGA
65PP	299	LEKAALECKKKVFLIVNPHGG-----AGIRD--SWGPNPETQDFASRGY	ATLQVNFRISGG
101PP	589	LEPQFDHSSKKYFMLVYYVYGGTSEINRTLEG--HYSLA-----MVBAGSYVVYTLNPS	GTTS
9PP	443	LEPNFDKNNKKYPAIILYQSG-----P-----NTVS-QFWSFRWNRLMAEQGYIVIA	PNRHGVPG
126PP	559	RCAABFEQVIHRRLGQTEPAOMCGVD-ELKSOSWVIAADRIGVHWSYGGHMITN	MLMLTHG
87PP	502	RGEERWRKCTYMQLCVFESEDDQIAAT-AIGQLPYVDAARIGIWCSYGGYT	PLMSICRGN
65PP	353	YCKEELRAGFKQIGRKAMDVEDGVR-YAISQGNVDEDRIAIYGAS	EGYAHLMGLVNTP
101PP	643	YQQEYAAARHVNAWGDRTADEIIIGSTKEFIRTHSEVNGKKVGCFGASYGGFMQY	YOTKNT
9PP	498	FGQKNEQISGDDYCGQNRCYLTAVD-EMKKEPYVLDGDRIGAVGASYGGRSVY	WLAGHHHD
126PP	618	DVFKVSGVACGPVI-----D-----AN--RYEIMYGRYFDA--PQENPEGYD-AANLLK	
87PP	561	GT-----KACTAVHFA-----D-----R-----FYDSVYTEREMRT--EKENASGYK-MESALD	
65PP	412	DLYACGVDYVGWSNIYTFFESFPEY	SK--PKEMVKELIYLDNPEAAIAKE-VSHFFQ
101PP	702	QIFAAAVSHAGISSIS---N-----YIGSGYAGMIGISTVASTDSYPWN	PDL-YAGHSHLFR
9PP	557	KRFAAFTAHAGIFNEMQYATTEEM	FA-NWDIGGPWEKLN---VVAQRTWA-TSPHKF
126PP	662	RACDEKGRKELIHCATEPVVWHSILFLDACVKARTYPDIYVAPSHE	NVGGPF--VHL
87PP	605	VASQLQGNLIVS	SANDNWLHONTMLFTEALVQANIPFDMAEYMDKNHSIYGGNTYHIL
65PP	469	ID-KINKPLEVVOGANDPRNNIHESDQIVTALRARGFEV	PYMVKYNEGHGFHREENSMEI
101PP	755	AD-KDHTPLLLHGSVETNWPTAEGVNLYNAIKILGREVEFIEFTEQDHF	FILEBERRIEW
9PP	612	VQ-NWDT	TIIMIHGELEFRILASQAMAAFDAALQLRGVPSEMLIYPDENJWVLOQONALLF
126PP	721	YETITTRYKTDH-----	
87PP	665	YTRKAKHGLFDNL-----	
65PP	528	TRAVLSEPAKHKKK-----	
101PP	814	TNSICAWFAEW	QDDPTWWNELYPPVNL
9PP	671	HRTFFGRGLDEW	KK-----

Fig 7

P. gingivalis W 83 PTP sequence

EQ 1A NO: 38 13228 atgaagaagacaatcttccaacaactattctgtctgtttgtgcc
 EQ 1A NO: 30 M K K T I F Q Q L F L S V C A
 13273 cttacagtggccttgccttgcggctcagtcctgaaacgagt
 L T V A L P C S A Q S P E T S
 13318 ggttaaggagttactcttgcggactgatgcccggagaaagag
 G K E F T L E Q L M P G G K E
 13363 tttataactttaccggcaatacgtggcggtttgcaatggatg
 F Y N F Y P E Y V V G L Q W M
 13408 ggagacaattatgtcttgcgggtatgatttagtttaat
 G D N Y V F I E G D D L V F N
 13453 aaggcgaatggcaatcggtcagacgaccagatttgcgtgcc
 K A N G K S A Q T T R F S A A
 13498 gatctcaatgcactcatgcggaggatgcataattcagacgact
 D L N A L M P E G C K F Q T T
 13543 gatgtttcccttcattccgcacactcgatgcggacggggactg
 D A F P S F R T L D A G R G L
 13588 gtcgttctatttacccaaggaggattatcgatgcgtatgcctt
 V V L F T Q G G L V G F D M L
 13633 gctcgaaagggtgacttatcttcgataccaatgaggagacggct
 A R K V T Y L F D T N E E T A
 13678 tctttggattttctccgtggagaccgtgtgcctatgtcaga
 S L D F S P V G D R V A Y V R
 13723 aaccataacccttacattgcgtggaggtaaattgggagaaggt
 N H N L Y I A R G G K L G E G
 13768 atgtcacgagctatcgctgtgactatcgatgaaactgagactctc
 M S R A I A V T I D G T E T L
 13813 gtatatggccaggccgtacaccacggtatcgatcgaaaaaa
 V Y G Q A V H Q R E F G I E K
 13858 ggtacattctggctccaaaaggagctgccttgcattatcga
 G T F W S P K G S C L A F Y R
 13903 atggatcagagtatggtaagcctacccgatagtggattatcat
 M D Q S M V K P T P I V D Y H
 13948 ccgctcgaagccgagtcacccgcatttacccatggcaggat
 P L E A E S K P L Y Y P M A G
 13993 actccgtcacaccacgttacgggtggatctatcatctggccaca
 T P S H H V T V G I Y H L A T
 14038 ggttaagaccgtctatctacaaacgggtgaaccaaggaaaaattt
 G K T V Y L Q T G E P K E K F
 14083 ctgacgaatttggatgtggatccggacgaaaatatcttgcgtatgta
 L T N L S W S P D E N I L Y V
 14128 gctgaggtgaatcgtgcataaaacaaatgtaaatgcctat
 A E V N R A Q N E C K V N A Y
 14173 gacgctgagaccggtagattcgtccgtacgcctttgttggaaacc
 D A E T G R F V R T L F V E T

Fig. 7

14218 gataaacattatgttagagccgttacatccctgacattcctccg
D K H Y V E P L H P L T F L P
14263 ggaagtaacaatcaagttcattggcagagccgtcgacggatgg
G S N N Q F I W Q S R R D G W
14308 aaccatctctatctgtatgatactacaggtcgatccgtcag
N H L Y L Y D T T G R L I R Q
14353 gtgacaaaaggggagtgggagggtacaaacttgcaggcttcgt
V T K G E W E V T N F A G F D
14398 cccaaaggaaacacggctctatttcgaaaagtaccgaagccagccct
P K G T R L Y F E S T E A S P
14443 ctcgaacgccattttactgtattgatataaaggagggaaagaca
L E R H F Y C I D I K G G K T
14488 aaagatctgactccggagtcggaaatgcaccgcactcagctatct
K D L T P E S G M H R T Q L S
14533 cctgatggttctgccataatcgatatttcagtcacctaactgtc
P D G S A I I D I F Q S P T V
14578 ccgcgtaaaggttacagtgacaaatatcgcaaagggtctcacaca
P R K V T V T N I G K G S H T
14623 ctcttgaggctaaagaacccgatacgggctatgccatgcccggag
L L E A K N P D T G Y A M P E
14668 atcagaacgggtaccatcatggccggatggcagacacccctt
I R T G T I M A A D G Q T P L
14713 tattacaagctcacatgcgttcattcgatccggcaaagaaaa
Y Y K L T M P L H F D P A K K
14758 tattcctgttattgtctatgtttacggaggacctcatgccaactc
Y P V I V Y V Y G G P H A Q L
14803 gtaaccaagacatggcgagctctgtcggtggatggatattat
V T K T W R S S V G G W D I Y
14848 atggcacagaaaaggctatgcgtcttacggatagtcgcgga
M A Q K G Y A V F T V D S R G
14893 tctgccaatagagggctgcgttcgaggatccatcgatcgt
S A N R G A A F E Q V I H R R
14938 ttggggcagaccgagatggccgatcagatgtgcgggtggatttc
L G Q T E M A D Q M C G V D F
14983 ctcaagagccaatcatgggtggatggcataataggatcat
L K S Q S W V D A D R I G V H
15028 ggctggagctatgggtttatgactacgaatctgatgcttacg
G W S Y G G F M T T N L M L T
15073 cacggcgatgtctcaaagtccggatgcggcggggctgtcata
H G D V F K V G V A G G P V I
15118 gactggaatcgatgatgagattatgtacggtgagcgttatttcgat
D W N R Y E I M Y G E R Y F D
15163 gcgccacaggaaaatcccgaaggatacgatgtgcacccatgc
A P Q E N P E G Y D A A N L L
15208 aaacgagccgtgatctgaaaggacgacttatgtgattcatgga
K R A G D L K G R L M L I H G
15253 gcgatcgatccggcgtggatggcagcattcactcctttcctt

Fig 7

	A	I	D	P	V	V	V	W	Q	H	S	L	L	F	L				
15298	gat	gct	tgc	gtg	aa	agg	cac	gc	ac	c	ct	tat	cct	gact	att	acgt	ctat		
	D	A	C	V	K	A	R	T	Y	P	D	Y	Y	V	Y				
15343	ccg	ag	gc	ca	cg	aa	ca	ta	at	gt	gat	gggg	cc	gg	ac	ag	gt	acat	ttg
	P	S	H	E	H	N	V	M	G	P	D	R	V	H	L				
15388	tat	gaa	aca	ata	acc	cg	tat	ttc	aca	ga	tat	ca	tt	at	ga	15426			
	Y	E	T	I	T	R	Y	F	T	D	H	L	*						

SEQ NO:38 ATGAAGAAGACAATCTCCAACA ACTATTTCTGTCTGTTGTGCCCTTACAGTGGCCTTGCCCTGTTGGC
 TCAGTCTCCTGAAACGAGTGGTAAGGAGTTACTCTGTGAGCAACTGATGCCGGAGGAAAAGAGTTTATA
 ACTTTACCCCGAATACGGTGTGGCTGGTTGCAATGGATGGAGACAATTATGTCTTATCGAGGGTGTATGAT
 TTAGTTTTAATTAAGCGGATGGCAAATTCGGCTCAGACGACAGGAGATTTCTGTGCGATCTCAATGCACT
 CATGCCGGAGGGATGCAAATTTCAGACGACTGATGCTTCCCTCATTCGCACACTCGATGCCGGACGGG
 GACTGGTCGTTCTATTACCAAGGAGGATTAGTCGGAATTGATATGCTTGCTCGAAAGGTGACTTATCTT
 TTCGATACCAATGAGGAGACGGCTTTGGATTTCTCTGTGGAGACCGTGTGCTATGTCAGAAA
 CCATAACCTTACATTGCTGTGGAGGTAAATTGGAGAAAGGTATGTCAGAGCTATCGCTGTGACTATCG
 ATGGAACGTGAGACTCTCGTATATGCCAGGCCAACCGCGTGAATTGGTATCGAAAAGGTACATTC
 TGGTCTCCAAAAGGGAGCTGCCCTGTTCTATCGAATGGATCAGAGTATGGTGAAGCCTACCCGATAGT
 GGATTATCATCCGCTCGAAGCGAGTCACAAACCGCTTATACCCCATGGCAGGTACTCCGTACACCCACG
 TTACGGTGGGATCTATCATCTGGCCACAGGTAAAGCGTCTATCTACAAACGGGTGAACCCAAGGAAAAA
 TTCTGACGAATTGAGTGGAGTCCGGACGAAAATATCTGTATGTTAGCTGAGGTAAATCGTCTGCTCAAAA
 CGAATGTAAGGTAAATGCCATGACGCTGAGACGGTAGATTCGTCGTA CGCTTGTGAAACCGATA
 AACATTATGTAAGCCGTTACATCCCTGACATCCTCCGGGAAGTAACAATCAGTCATTGGCAGAGC
 CGTCGGGACGGATGGAACCATCTCTATCTGTATGATACTACAGGTGCTGATCCGTCAAGGTGACAAAAGG
 GGAGTGGGAGGTTACAAAATTCGAGGCTCGATCCAAGGGAACACGGCTCTATTCGAAAGTACCGAAG
 CCAGCCCTCTCGAACGCCATTTCAGTGTATTGATATCAAAGGGAAAAGACAAAAGATCTGACTCCGGAG
 TCGGGAAATGCAACCGCACTCAGCTATCTGTGATGTTCTGCCATAATCGATATTTCAGTCACCTACTGT
 CCCCGTAAGGTTACAGTGACAAATATCGGCAAGGGTCTCACACACTCTGGAGGCTAAGAACCCGATA
 CGGGCTATGCCATGCCGGAGATCAGAACGGGTACCATCATGGCGGCCGATGGCAGACACCTCTTATTAC
 AACCTCACGATGCCGTTCATTCGATCCGCAAGAAAATATCTGTATTGCTATGTTACGGAGGACC
 TCATGCCCAACTCGTAACCAAGACATGGCGCAGCTGTGCGTGGATGGGATATCTATATGCCACAGAAAG
 GCTATGCCGCTTTACGGTGGATAGTCGCGGATCTGCAATAGAGGGGCTGCTTCGAGCAGGTATTCTAT
 CGTCGTTGGGGCAGACCGAGATGGCCGATCAGATGTCGGTGGATTCTCAAGAGCCATCATGGGT
 GGATGCCGATAGAATAGGAGTACATGGCTGGACTATGGTGGTTATGACTACGAATCTGATGCTTACGC
 ACGGGATGTCCTCAAAGTCGGAGTAGCCGGGGGCTGTCATAGACTGGAATCGATATGAGATTATGTAC
 GGTGAGCCTTTGATGCTTGCCTGAGGACGACTTATGCTGATTGATGGAGCGATCGATCCGGTGTGGTATGCCAGCATTAC
 TCCCTTCCCTGATGCTTGCCTGAGGACGACGACTATCTGACTATTACGTTATCCGAGGCCACGAACAT
 AATGTGATGGGGCCGGACAGAGTACATTGATGAAACAATAACCGTTATTTCACAGATCACTTATGAA

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52147 A3

(51) International Patent Classification⁷: C12N 15/57, 9/48, A61K 39/02

(21) International Application Number: PCT/US00/05551

(22) International Filing Date: 3 March 2000 (03.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/123,148 5 March 1999 (05.03.1999) US

(71) Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; 632 Boyd Graduate Studies, Athens, GA 30602-7411 (US).

(71) Applicants and
(72) Inventors: TRAVIS, James [US/US]; 825 Riverbend Parkway, Athens, GA 30605 (US). POTEPPA, Jan [US/US]; Apt. #102, 170 Barrington Drive, Athens, GA 30605 (US). BANBULA, Agnieszka [US/US]; Apt. #E13, 280 Picadilly Square, Athens, GA 30605 (US).

(74) Agent: MUETING, Ann, M.; Mueting, Raasch, Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,

[Continued on next page]

(54) Title: BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

| SEQ ID NO: | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | 353 | 354 | 355 | 356 | 357 | 358 | 359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | 433 | 434 | 435 | 436 | 437 | 438 | 439 | 440 | 441 | 442 | 443 | 444 | 445 | 446 | 447 | 448 | 449 | 450 | 451 | 452 | 453 | 454 | 455 | 456 | 457 | 458 | 459 | 460 | 461 | 462 | 463 | 464 | 465 | 466 | 467 | 468 | 469 | 470 | 471 | 472 | 473 | 474 | 475 | 476 | 477 | 478 | 479 | 480 | 481 | 482 | 483 | 484 | 485 | 486 | 487 | 488 | 489 | 490 | 491 | 492 | 493 | 494 | 495 | 496 | 497 | 498 | 499 | 500 | 501 | 502 | 503 | 504 | 505 | 506 | 507 | 508 | 509 | 510 | 511 | 512 | 513 | 514 | 515 | 516 | 517 | 518 | 519 | 520 | 521 | 522 | 523 | 524 | 525 | 526 | 527 | 528 | 529 | 530 | 531 | 532 | 533 | 534 | 535 | 536 | 537 | 538 | 539 | 540 | 541 | 542 | 543 | 544 | 545 | 546 | 547 | 548 | 549 | 550 | 551 | 552 | 553 | 554 | 555 | 556 | 557 | 558 | 559 | 560 | 561 | 562 | 563 | 564 | 565 | 566 | 567 | 568 | 569 | 570 | 571 | 572 | 573 | 574 | 575 | 576 | 577 | 578 | 579 | 580 | 581 | 582 | 583 | 584 | 585 | 586 | 587 | 588 | 589 | 590 | 591 | 592 | 593 | 594 | 595 | 596 | 597 | 598 | 599 | 600 | 601 | 602 | 603 | 604 | 605 | 606 | 607 | 608 | 609 | 610 | 611 | 612 | 613 | 614 | 615 | 616 | 617 | 618 | 619 | 620 | 621 | 622 | 623 | 624 | 625 | 626 | 627 | 628 | 629 | 630 | 631 | 632 | 633 | 634 | 635 | 636 | 637 | 638 | 639 | 640 | 641 | 642 | 643 | 644 | 645 | 646 | 647 | 648 | 649 | 650 | 651 | 652 | 653 | 654 | 655 | 656 | 657 | 658 | 659 | 660 | 661 | 662 | 663 | 664 | 665 | 666 | 667 | 668 | 669 | 670 | 671 | 672 | 673 | 674 | 675 | 676 | 677 | 678 | 679 | 680 | 681 | 682 | 683 | 684 | 685 | 686 | 687 | 688 | 689 | 690 | 691 | 692 | 693 | 694 | 695 | 696 | 697 | 698 | 699 | 700 | 701 | 702 | 703 | 704 | 705 | 706 | 707 | 708 | 709 | 710 | 711 | 712 | 713 | 714 | 715 | 716 | 717 | 718 | 719 | 720 | 721 | 722 | 723 | 724 | 725 | 726 | 727 | 728 | 729 | 730 | 731 | 732 | 733 | 734 | 735 | 736 | 737 | 738 | 739 | 740 | 741 | 742 | 743 | 744 | 745 | 746 | 747 | 748 | 749 | 750 | 751 | 752 | 753 | 754 | 755 | 756 | 757 | 758 | 759 | 760 | 761 | 762 | 763 | 764 | 765 | 766 | 767 | 768 | 769 | 770 | 771 | 772 | 773 | 774 | 775 | 776 | 777 | 778 | 779 | 780 | 781 | 782 | 783 | 784 | 785 | 786 | 787 | 788 | 789 | 790 | 791 | 792 | 793 | 794 | 795 | 796 | 797 | 798 | 799 | 800 | 801 | 802 | 803 | 804 | 805 | 806 | 807 | 808 | 809 | 810 | 811 | 812 | 813 | 814 | 815 | 816 | 817 | 818 | 819 | 820 | 821 | 822 | 823 | 824 | 825 | 826 | 827 | 828 | 829 | 830 | 831 | 832 | 833 | 834 | 835 | 836 | 837 | 838 | 839 | 840 | 841 | 842 | 843 | 844 | 845 | 846 | 847 | 848 | 849 | 850 | 851 | 852 | 853 | 854 | 855 | 856 | 857 | 858 | 859 | 860 | 861 | 862 | 863 | 864 | 865 | 866 | 867 | 868 | 869 | 870 | 871 | 872 | 873 | 874 | 875 | 876 | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | 887 | 888 | 889 | 890 | 891 | 892 | 893 | 894 | 895 | 896 | 897 | 898 | 899 | 900 | 901 | 902 | 903 | 904 | 905 | 906 | 907 | 908 | 909 | 910 | 911 | 912 | 913 | 914 | 915 | 916 | 917 | 918 | 919 | 920 | 921 | 922 | 923 | 924 | 925 | 926 | 927 | 928 | 929 | 930 | 931 | 932 | 933 | 934 | 935 | 936 | 937 | 938 | 939 | 940 | 941 | 942 | 943 | 944 | 945 | 946 | 947 | 948 | 949 | 950 | 951 | 952 | 953 | 954 | 955 | 956 | 957 | 958 | 959 | 960 | 961 | 962 | 963 | 964 | 965 | 966 | 967 | 968 | 969 | 970 | 971 | 972 | 973 | 974 | 975 | 976 | 977 | 978 | 979 | 980 | 981 | 982 | 983 | 984 | 985 | 986 | 987 | 988 | 989 | 990 | 991 | 992 | 993 | 994 | 995 | 996 | 997 | 998 | 999 | 1000 | 1001 | 1002 | 1003 | 1004 | 1005 | 1006 | 1007 | 1008 | 1009 | 1010 | 1011 | 1012 | 1013 | 1014 | 1015 | 1016 | 1017 | 1018 | 1019 | 1020 | 1021 | 1022 | 1023 | 1024 | 1025 | 1026 | 1027 | 1028 | 1029 | 1030 | 1031 | 1032 | 1033 | 1034 | 1035 | 1036 | 1037 | 1038 | 1039 | 1040 | 1041 | 1042 | 1043 | 1044 | 1045 | 1046 | 1047 | 1048 | 1049 | 1050 | 1051 | 1052 | 1053 | 1054 | 1055 | 1056 | 1057 | 1058 | 1059 | 1060 | 1061 | 1062 | 1063 | 1064 | 1065 | 1066 | 1067 | 1068 | 1069 | 1070 | 1071 | 1072 | 1073 | 1074 | 1075 | 1076 | 1077 | 1078 | 1079 | 1080 | 1081 | 1082 | 1083 | 1084 | 1085 | 1086 | 1087 | 1088 | 1089 | 1090 | 1091 | 1092 | 1093 | 1094 | 1095 | 1096 | 1097 | 1098 | 1099 | 1100 | 1101 | 1102 | 1103 | 1104 | 1105 | 1106 | 1107 | 1108 | 1109 | 1110 | 1111 | 1112 | 1113 | 1114 | 1115 | 1116 | 1117 | 1118 | 1119 | 1120 | 1121 | 1122 | 1123 | 1124 | 1125 | 1126 | 1127 | 1128 | 1129 | 1130 | 1131 | 1132 | 1133 | 1134 | 1135 | 1136 | 1137 | 1138 | 1139 | 1140 | 1141 | 1142 | 1143 | 1144 | 1145 | 1146 | 1147 | 1148 | 1149 | 1150 | 1151 | 1152 | 1153 | 1154 | 1155 | 1156 | 1157 | 1158 | 1159 | 1160 | 1161 | 1162 | 1163 | 1164 | 1165 | 1166 | 1167 | 1168 | 1169 | 1170 | 1171 | 1172 | 1173 | 1174 | 1175 | 1176 | 1177 | 1178 | 1179 | 1180 | 1181 | 1182 | 1183 | 1184 | 1185 | 1186 | 1187 | 1188 | 1189 | 1190 | 1191 | 1192 | 1193 | 1194 | 1195 | 1196 | 1197 | 1198 | 1199 | 1200 | 1201 | 1202 | 1203 | 1204 | 1205 | 1206 | 1207 | 1208 | 1209 | 1210 | 1211 | 1212 | 1213 | 1214 | 1215 | 1216 | 1217 | 1218 | 1219 | 1220 | 1221 | 1222 | 1223 | 1224 | 1225 | 1226 | 1227 | 1228 | 1229 | 1230 | 1231 | 1232 | 1233 | 1234 | 1235 | 1236 | 1237 | 1238 | 1239 | 1240 | 1241 | 1242 | 1243 | 1244 | 1245 | 1246 | 1247 | 1248 | 1249 | 1250 | 1251 | 1252 | 1253 | 1254 | 1255 | 1256 | 1257 | 1258 | 1259 | 1260 | 1261 | 1262 | 1263 | 1264 | 1265 | 1266 | 1267 | 1268 | 1269 | 1270 |<th
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |



RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW.

(88) Date of publication of the international search report:
12 April 2001

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:
1 November 2001

(15) Information about Correction:
see PCT Gazette No. 44/2001 of 1 November 2001, Section
II

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

5

CONTINUING APPLICATION DATA

This patent application claims the benefit of U.S. provisional patent application No. 60/123,148, filed March 5, 1999, which is incorporated by reference herein.

10

GOVERNMENT FUNDING

The present invention was made with government support under Grant No. DE 09761, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

15

BACKGROUND OF THE INVENTION

Porphyromonas gingivalis (formerly *Bacteroides gingivalis*) is an obligately anaerobic bacterium which is implicated in periodontal disease. *P. gingivalis* produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors. A number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by *P. gingivalis* proteases. Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.

Progressive periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration. Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site. Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a. The complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases. The human plasma convertases

5 cleave the α -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e. C3a and C5a). The anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability. The larger products from C3 and C5 cleavage (i.e. C3b and C5b) participate in functions including complement cascade activation, opsonization, and lytic complex formation.

10 Recent studies have indicated that this periodontopathogen produces at least seven different enzymes belonging to the cysteine and serine catalytic classes of peptidases, among which three cysteine proteinases (gingipains) are predominant (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458). The gingipains are the best characterized group of *P. gingivalis* enzymes as their structure, function, enzymatic properties and pathological significance are known. From *in vitro* studies it is apparent that two gingipains 15 R (also referred to generally as "Arg-gingipains" and more specifically as RgpA and RgpB), enzymes specific for cleavage at Arg-Xaa peptide bonds, have a significant potential to contribute to the development and/or maintenance of a pathological inflammatory state in infected periodontal pockets through: (i) activation of the kallikrein-kinin cascade, (ii) the release of neutrophil 20 chemotactic activity from native and oxidized C5 of the complement pathway, and (iii) activation of factor X. In addition, gingipain K (also referred to as "Lys-gingipain"), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis. Finally, the presence of a hemagglutinin/adhesion domain in the 25 non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of *P. gingivalis* to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.

30 In comparison to the gingipains, relatively little is known about other cysteine proteinases produced by *P. gingivalis*. Two genes, referred to as *tpr* and *prtT* have been cloned and sequenced and although they encode a putative papain-like and streptopain-like cysteine proteinases, respectively, neither has been purified and characterized.

The presence of serine proteinase activity in cultures of *P. gingivalis* has been known for several years; however, only limited information is available about such enzymes. Indeed, a serine endopeptidase has been isolated from culture media, although it was only superficially characterized (Hinode D., et al., 5 (1993) *Infect. Immun.* **59**, 3060-3068). On the other hand, an enzyme referred to as glycylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested 10 that, in collaboration with collagenase, glycylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) *J. Dent. Res.* **64**, 106-111). In addition to this potential pathological function, glycylprolyl peptidase may also play a vital role in providing *P. gingivalis* with dipeptides which can be transported inside the cell and serve as a source of carbon, 15 nitrogen, and energy for this asaccharolytic organism. Recently, a gene encoding glycylprolyl peptidase in *P. gingivalis* has been cloned and sequenced, and it is now apparent that this enzyme is homologous to dipeptidyl-peptidase IV (DPP-IV) from other organisms (Kiyama, M., et al. (1998) **1396**, 39-46). The nucleotide sequence of the genome of this bacterium is currently being 20 determined by The Institute for Genomic Research, and is available at www.tigr.org.

SUMMARY OF THE INVENTION

The present invention is directed to an isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Alternatively, the isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof is isolated from *P. gingivalis*. Typically, amidolytic activity is determined with a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The peptide cleaved by the isolated prolyl tripeptidyl-peptidase can include the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID

NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, or SEQ ID NO:37. The amino acid sequence of the isolated prolyl tripeptidyl-peptidase can include the amino acid sequence GXSXXG (SEQ ID NO:39), the 5 amino acid sequence GXSXGG (SEQ ID NO:40), or the amino acid sequence of SEQ ID NO:30.

Another aspect of the invention is an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 10 amino acids. Typically, the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The invention is also directed to an isolated polypeptide comprising an 15 amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

An alternative aspect of the invention is an isolated nucleic acid fragment 20 encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no 25 greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The nucleic acid fragment can have a nucleotide sequence comprising SEQ ID NO:38. A complement of the nucleic acid fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least 30 about 20 nucleotides of the complement hybridize.

Another aspect of the invention is an isolated nucleic acid fragment 35 encoding a polypeptide that includes an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

The invention is also directed at a method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, including identifying a molecule that inhibits the

amidolytic activity of the prolyl-tripeptidyl peptidase. The inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

An aspect of the invention is a method of reducing growth of a bacterium. This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof. The method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase. The method can be used to protect an animal from a periodontal disease caused by *P. gingivalis* including administering to the animal the inhibitor. The disease can be selected from the group consisting of gingivitis and periodontitis. The inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.

Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The immunogenic composition can include an adjuvant.

The invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.

Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ ID NO:44, or SEQ ID NO:45.

Definitions

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the 5 definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.

“Peptidase,” “proteinase,” and “protease” all refer to enzymes that 10 catalyze the hydrolysis of peptide bonds in a polypeptide. A “peptide bond” or “amide bond” is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid. “Peptidase inhibitor,” “proteinase inhibitor,” “protease inhibitor,” and “inhibitor” all refer to molecules 15 that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.

As used herein, the term “isolated” means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized. Preferably, the polypeptide or nucleic acid fragment is purified, i.e., essentially 20 free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.

“Amidolytic activity” refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide. The term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide. 25 “Prolyl-tripeptidyl peptidase” and “PTP” refer to a polypeptide having a particular “amidolytic activity”. A “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula NH₂-Xaa-Xaa-Pro-Yaa-(Xaa)_n (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or 30 modified amino acid except proline, and the α -amino of the amino terminal residue is not blocked. A “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide. The term “natural amino acid” refers to the 20 amino acids typically produced by a cell. The term “modified amino acid”

refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A “target polypeptide” is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.

5 An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.

10 “Nucleic acid fragment” as used herein refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA. A nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques. A nucleic acid molecule may be 15 equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.

20 “Percentage amino acid identity” refers to a comparison of the amino acids of two polypeptides as described herein.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the *P. gingivalis* cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles). (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.

30 Fig. 2. SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme. *Lane a*, molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa; α -lactalbumin, 14

kDa); *lane b*, acetone precipitate from Triton X-100 extract of *P. gingivalis*, *lane c*: hydroxyapatite column eluate; *lane d*, Phenyl-Sepharose column eluate; *lane e*, MonoQ column eluate; *lane f*, purified PTP-A from MonoP column wash; *lane g*, autoradiograph of 3 H-DFP labeled enzyme exposed for 96 h to X-ray film. All 5 samples were reduced and boiled prior to PAGE analysis.

Fig. 3. Multiple sequence alignment of *P. gingivalis* PTP-A (PTP-A) and its bacterial and eukaryotic homologues. Pg-DPP, DPP from *P. gingivalis* (Kiyama, M., et al., (1998) *Bioch. Bioph. Acta* **1396**, 39-46) containing an 10 amino-terminal sequence corrected according to the *P. gingivalis* W83 genome data available from The Institute of Genomic Research at www.tigr.org); Fm-DPP, DPP from *Flavobacterium meningosepticum*; Hs-DPP, human DPP IV; and Mm-FAP, mouse fibroblast activation protein. Peptide sequences obtained 15 from PTP-A analysis described herein are indicated with arrows (note that the sequence of the peptide 81-97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal α -helix is double-underlined. Homologous regions (i.e., regions of identical amino acids and/or 20 conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background.

Fig. 4. Comparison of *P. gingivalis* PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3). Sequences of *P. gingivalis* PTP-A, DPP, DPP-H1, DPP-H2, and DPP-H3 were obtained from 25 conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished *P. gingivalis* genome database: gnl | TIGR | *P. gingivalis* contig 126 (positions 13 228 – 15 426), contig 87 (positions 6 424 – 4 399), contig 65 (positions 161 – 1 786), contig 101 (positions 30 8 895 – 6 845), and contig 9 (positions 4 216 – 2 162), respectively. Residues predicted as catalytic triads are marked with asterisks. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted.

Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

5 **Fig. 5. Influence of Pefabloc-serine proteinase inhibitor on *P. gingivalis* growth.**

10 **Fig. 6. Comparison of *P. gingivalis* PTP-A and DPP to sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3).** Sequences of *P. gingivalis* PTP-A (126PP), DPP (87PP), DPP-H1 (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

15

Fig. 7. Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ ID NO:30) of PTP-A.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the 25 alpha-carboxyl group end of the proline.

When the prolyl peptidase is a prolyl tripeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or 30 modified amino acid except proline, and the α -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro-Yaa peptide bond. Preferably, isolated polypeptides do not cleave a target peptide having a blocked α -amino of the amino terminal residue.

Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond. In increasing order of preference, isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 amino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 5 amino acids or at least 3,000 Da. Preferably, the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.

When the prolyl peptidase is a prolyl dipeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide 10 of the general formula $\text{NH}_2\text{-Xaa-Zaa-Yaa-(Xaa)}_n$ (SEQ ID NO:12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the α -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Zaa-Yaa peptide bond. Preferably, isolated 15 polypeptides does not cleave a target peptide having a blocked α -amino of the amino terminal residue. Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond.

Due to their cyclic aliphatic character proline residues bestow unique 20 conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the amino-termini of many biologically active peptides, may protect them against proteolytic degradation by peptidases with general specificity. A specialized group of proteolytic enzymes, typically referred 25 to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide. The peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline. The bacterial prolyl peptidases can cleave a polypeptide to liberate a 30 tripeptide or a dipeptide. Prolyl peptidases that do not cleave a target peptide if the α -amino of the amino terminal residue is blocked can be referred to as exopeptidases. The *in vivo* activity of these specialized proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other

biologically active peptides. In addition, hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re-utilization of amino acids by living organisms, including bacteria. However, prolyl peptidases from bacterial pathogens, if released into the host environment, may 5 interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.

The external (i.e., cell surface) localization and uncontrolled activity of bacterial peptidases, including prolyl peptidases, likely contributes significantly to run-away inflammation in the human host and the pathological degradation of 10 connective tissue during periodontitis. For instance, working in concert bacterial prolyl peptidases (e.g., prolyl tripeptidyl peptidases and DPP IV) have the ability to completely degrade collagen fragments locally generated by endogenous or bacterial collagenases. Because type I collagen is the major component of 15 periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation. Thus, there is a need in the art to characterize bacterial peptidases to facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

The polypeptides of the present invention, preferably prolyl peptidases, can 20 be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation. Antibodies to prolyl peptidases can also be used to identify and/or 25 isolate additional prolyl peptidases. Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.

An example of a prolyl-tripeptidyl peptidase is prolyl-tripeptidyl peptidase A (SEQ ID NO:30) (also referred to as PTP-A) from *P. gingivalis*. Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass 30 peptidase may be due to the proteolytic cleavage of the peptidase from the surface of *P. gingivalis*. PTP-A is a new member of clan SC, family S9 of serine peptidases. Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which

plays a pivotal role peptidase activity. The members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine. Members of the clan SC are also characterized by a tertiary structure including $\beta/\alpha/\beta$ units, and an α/β hydrolase fold. In addition to the 5 catalytic triad order, the amino acid sequence GXSXXG (SEQ ID NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family. Family S9 has the consensus sequence GXSXGG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies 10 peptidases to this family. For instance, peptidases of this family generally have two domains, an amino-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad. Some members of the S9 family have only the catalytic domain.

15 The S9 family is diverged and divided in three subfamilies: S9A, cytosolic oligopeptidases from archaea and eukaryotes; S9B, eukaryotic acylaminoacylpeptidases; and S9C, dipeptidyl peptidase IV from bacteria and eukaryotes. The catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ ID NO:30 and include the remaining carboxy-terminal 20 amino acids (see, e.g., Fulop, et al., (1998) *Cell* 94, 161-170). Despite structural similarities to peptidases from the S9 family, the tripeptidyl-peptidase activity of PTP-A is unusual for this family of enzymes, and no other known similar activity has so far been attributed to any other member of the S9 family. In fact, all strict tripeptidyl-peptidases belong only to the subtilisin family (S8) and S33 family of 25 serine peptidases; however, they neither share a structural relationship with PTP-A nor have activity limited to cleavage after proline residues. In particular, there are no other known prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Iodoacetamide is a compound that is 30 traditionally a peptidase inhibitor. Typically, the activity of a prolyl tripeptidyl peptidase is increased about two-fold. Furthermore, unlike oligopeptidases, the prolyl tripeptidyl-peptidases of the present invention can cleave target peptidases having as few as 4 amino acids but also target peptides having at least 30 amino

acids or a molecular weight of at least 3,000 Da. In these respects, the *P. gingivalis* tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

5 Examples of putative prolyl-dipeptidyl peptidases are DPP-H1 (SEQ ID NO:43), DPP-H2 (SEQ ID NO:44), and DPP-H3 (SEQ ID NO:45). These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6). Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4). DPP IV has been
10 characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized. DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24. DPP IV has been purified in two forms. One of the forms is a full length gene translation product containing a blocked amino-terminal residue. The second form had the amino-terminal amino acid
15 sequence HSYRAAVYDYDVRRNLVKPLSEHVG (SEQ ID NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39-46), indicating that it was proteolytically truncated on the amino-terminus.

In *P. gingivalis*, PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane
20 anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N-terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure. Nevertheless,
25 membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media. The cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the
30 bacterium entirely dependant on an external peptide supply. In this regard, PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl-peptidases may inhibit the *in vivo* growth of organisms, including *P. gingivalis*.

For instance, treatment of *P. gingivalis* cultures in lagphase (i.e., the period after inoculation of a culture and before the organism begins to divide) and early logarithmic growth with the inhibitors PEFABLOCK and 3,4-dichloroisocoumarin inhibits growth of *P. gingivalis*.

5 Preferably, a polypeptide of the invention, preferably a prolyl peptidase, contains the amino acid sequence GXSXXG (SEQ ID NO:39), most preferably, GXSXGG (SEQ ID NO:40), where G is glycine, X is any amino acid, and S is the active site serine. The active site serine can be identified by, for instance, labeling with diisopropylfluorophosphate as described herein. Preferably, the catalytic 10 domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID 15 NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).

The invention further includes a polypeptide, preferably a prolyl tripeptidyl-peptidase, that shares a significant level of primary structure with SEQ ID NO:30. 20 The two amino acid sequences (i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO:30) are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted 25 in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the 30 number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in SEQ ID NO:30, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100. Preferably, a prolyl tripeptidyl peptidase has

greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30. Preferably, amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ ID NO:30 are used. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

5 In general, the amidolytic activity of the polypeptides of the invention, preferably prolyl peptidases, can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer. Preferably, the lower ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1:100, even more preferably at least about 1:1,000, most preferably at least about 1:10,000. Preferably, the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1:1,000,000 and most preferably no greater than about 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay. Preferably, the buffer is about 200 mM HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES. Preferably, the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5. Preferably, the temperature of the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours. Preferably, the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1:100 to no greater than 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours. In general, the time of the assay can vary 10 depending on the substrate and enzyme:substrate ratio. Typically, target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase. Preferably, the assay is 15 allowed to continue until at least 1 % of the target peptide is hydrolyzed.

20 Prolyl-tripeptidyl peptidases of the present invention preferably are inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2-aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfluorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and 25 diisopropylfluorophosphate, and most preferably diisopropylfluorophosphate. The

peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin, α_1 -proteinase inhibitor, α_1 -antichymotrypsin and α_2 -macroglobulin, most preferably. Significantly and unexpectedly, the amidolytic activity of a prolyl-tripeptidyl peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Preferably, the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.

The polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID NO:30. An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro-Yaa peptide bond present in a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25). Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro-Yaa peptide bond. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free NH_2 .

Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will

hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond. An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain. Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side 5 chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond.

10 Prolyl peptidases can be obtained by several methods. Isolation of a prolyl-tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art. Alternatively, cells can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface. The following are 15 nonlimiting examples of suitable protein purification procedures: fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration 20 using, for example, Sephadex G-75. Preferably, isolation of a prolyl-tripeptidyl peptidase from *P. gingivalis* is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.

25 Prolyl peptidases can also be isolated from organisms other than *P. gingivalis*. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region. A “coding region” is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a coding region are generally determined by a translation start codon 30 at its 5' end and a translation stop codon at its 3' end. “Regulatory region” refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked. Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation

stop sites, and terminators. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved

5 under conditions compatible with the regulatory region. Alternatively, other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein. A prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art.

10 Alternatively, the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.

The expression of a prolyl-tripeptidyl peptidase by an organism other than *P. gingivalis* can be detected using specific substrates of the general formula NH₂-

15 Xaa-Xaa-Pro-LG or NH₂-Xaa-Xaa-Pro-Yaa (SEQ ID NO:41), where LG is a leaving group. The leaving group can be a chromogenic or fluorogenic group known to the art. The expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free leaving group, each of which can be assayed using techniques known to those of

20 skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.

As described in the Examples, the amino acid sequence of the amino-terminal end of a PTP-A fragment was used to identify the nucleotide sequence of the PTP coding region. The nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished *P. gingivalis* W83 genome. However, even though the nucleotides that encode the *P. gingivalis* PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated. The data obtained from the database only contained

25 the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame. Moreover, there is little data known to the art regarding regulatory regions required for either the transcription or the translation of a nucleotide sequence in *P. gingivalis*.

Thus, a person of ordinary skill, having the nucleotide sequence of the genomic clone, would not be able to predict that the open reading frame encoding PTP-A was transcribed or translated. Moreover, even if there was a suggestion that the open reading frame was both transcribed and translated, there is no suggestion 5 that the polypeptide encoded by the open reading frame would have the novel activity of PTP-A.

Accordingly, the present invention is directed to a nucleic acid fragment 10 encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof. The nucleic acid fragment can have a nucleotide sequence as shown in SEQ ID NO:38. Alternatively, nucleic acid fragments of the invention include those whose complement hybridize to SEQ 15 ID NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38. Preferably, at least about 20 nucleotides of the complement hybridize with SEQ ID NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.

Alternatively, the nucleic acid fragment can have a nucleotide sequence 20 encoding a polypeptide having the amino acid sequence shown in SEQ ID NO:30. An example of the class of nucleotide sequences encoding such a polypeptide is SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.

The identification of similar coding regions in other organisms can be 25 accomplished by screening individual wild-type microorganisms for the presence of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.

Standard hybridizing conditions are a modification of the conditions used 30 by Church et al. ((1984) *Proc. Natl. Acad. Sci. USA* **81**, 1991): 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C. Preferably, a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the

nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.

“Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment. Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'-
10 ATGC and 5'-GCAT are complementary. The term complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment. For instance the third nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT
15 will not base pair, but these two nucleic acid fragments are complementary as defined herein. Typically two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.

Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase.
20 For instance, a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38. Preferably a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length. Particularly preferred probes are

TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTACGGAGGAC

25 CT (SEQ ID NO:36,

GTGGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTT
(SEQ ID NO:37, and SEQ ID NO:38. Methods of detectably labeling a probe are well known to the art.

30 The nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro-Yaa

peptide bond on a target polypeptide of the general formula NH₂-Xaa-Xaa-Pro-Yaa-(Xaa)_n (SEQ ID NO:25). Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).

5 Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody. Preferably the antibody is directed to PTP-A. The production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.

10 The use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ ID NO:38. The coding region can then be isolated and ligated into a vector as described below. Two nucleic acid sequences are "similar" if the two nucleic acid sequences can be aligned so that the 15 number of identical amino acids along the lengths of their sequences are optimized. Preferably, two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.

20 As mentioned above, a nucleic acid fragment of the invention can be inserted in a vector. Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual.*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the 25 nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid.

30 Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK233-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which

numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacetyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used 25 terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

The nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth 30 medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein. Alternatively, antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45. An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal. Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal.

Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein. Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal. An example of a fragments of a prolylpeptidase is a catalytic domain. Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

Accordingly, an aspect of the invention is an immunogenic composition comprising an isolated prolyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, preferably a prolyl tripeptidyl-peptidase. The prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the Pro-Yaa peptide bond present in a target polypeptide with the general formula NH₂-Xaa-Xaa-Pro-Yaa-(Xaa)_n (SEQ ID NO:25), wherein the amidolytic activity is measured at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:100 to no greater than about 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

The immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other

5 ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

10 The immunogenic composition can be used in a method for protecting an animal from a disease caused by *P. gingivalis*. This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification. The diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include lose of tooth attachment and periodontal pocket formation.

15 Alternatively and preferably, periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase. An inhibitor of a prolyl peptidase, preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier. For instance, inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well 20 known to the art (see, e.g., Kornman, K., (1993) *J. Periodontol.* 64, 782-791). Preferably, an inhibitor is applied subgingivally or by controlled release delivery.

25 The prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria *in vitro* or *in vivo*. Preferably, the bacteria is a periodontal pathogen, i.e., a bacterial pathogen that causes periodontal disease, more preferably the bacteria is *P. gingivalis*. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply. The action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the *in vivo* growth of organisms, 30 including *P. gingivalis*. The method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl-tripeptidyl peptidase) and the amount of free amino acids that result from further cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl

peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased. The amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.

5 Preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor. Preferably, an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase,

10 by blocking the active site of the polypeptide. The polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.

The present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active modification thereof, preferably a prolyl-tripeptidyl peptidase. The method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule. The amidolytic activity can be measured by cleavage of the Pro-Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein. One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected that some modified amino acids will cause the target peptide to act as an inhibitor.

EXAMPLES

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

Example 1Materials

Diisopropylfluorophosphate (DFP), leupeptin and 3,4-dichloroisocoumarin, were purchased from Calbiochem (La Jolla, CA). Antipain, iodoacetamide, 5 substance P, bradykinin and bradykinin related peptides, were obtained from Sigma. Other peptides used in this study were synthesized at the Molecular Genetic Instrumental Facility (University of Georgia, Athens, GA) using Fmoc protocol with an advanced ChemTech MPS350 automated synthesizer. H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA 10 (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked amino-terminal group) were obtained from Bachem (King of Prussia, PA). Prolinal was kindly provided by Dr. James Powers (Georgia Institute 15 of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).

15

Methods

Source and Cultivation of Bacteria— *P. gingivalis* HG66 was obtained from Dr. Roland Arnold (University of North Carolina, Chapel Hill), while the strains W50 (ATCC 53978) and ATCC 33277 were obtained from the ATCC. All 20 cells were grown as described previously (Chen, Z., et al., (1992) *J. Biol. Chem.* 267, 18896-18901).

Enzyme Activity Assays— Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (1mM) in 0.2 M HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The 25 concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA). In inhibition studies, the enzyme was first preincubated with inhibitor for 15 min at 37°C, substrate added, and residual activity recorded after 5 minutes to 30 minutes. 30 H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.

Protein Determination—Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.

Localization of Tripeptidyl-Peptidase Activity—Cultures of *P. gingivalis* HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake). Unbroken cells and large debris were removed by centrifugation (10,000 x g, 30 minutes) and the opalescent supernatant subjected to ultracentrifugation (150,000 x g, 120 minutes), yielding a pellet containing bacterial membranes and a supernatant which was considered as membrane-free cell extract. All fractions, as well as the full culture, culture medium, and full culture after sonication, were assayed for amidolytic activity against H-Ala-Phe-Pro-pNA.

Enzyme Purification—All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram of cells wet weight). Triton X-100 (10% volume/volume in H₂O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes). Proteins in the supernatant were precipitated with cold acetone (-20°C) added to a final concentration of 60% and collected by centrifugation. The pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide. The dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml/hour. After equilibration, the column was washed until the A₂₈₀ fell to zero. Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H-Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively. The activity against the latter

substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate. The column was washed with two volumes of equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. 5 Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml/minute, following which bound proteins were eluted with a gradient of 0- 300 mM NaCl. 10 The active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis-Tris buffer, using a pH gradient developed with 50 ml of 10x diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0.

15 *Electrophoretic Techniques*— The SDS-PAGE system of Schagger and von Jagow (Schagger, H., and von Jagow, G. (1987) *Anal. Biochem.* 166, 368-379), was used to monitor enzyme purification and estimate the enzyme molecular mass. For amino-terminal sequence analysis, proteins resolved in SDS-PAGE were electroblotted to polyvinylidene difluoride membranes using 10 mM CAPS, pH 11, 20 10% methanol (Matsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038). The membrane was washed thoroughly with water and stained with Coomassie Blue G250. The blot was air dried, and protein bands cut out and subjected to NH₂-terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.

25 *Enzyme Fragmentation*—The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes. Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458) from *P. gingivalis* was then added to make an enzyme:substrate molar ratio of 1:100. The reaction mixture was 30 made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a μBondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a

gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.

For determination of the active site serine residue and to confirm that the purified enzyme was a serine peptidase, 100 µg of purified PTP-A was first 5 incubated with 170 µCi of [1,3-³H]DFP (Amersham, Arlington Heights, IL) for 30 minutes at 25°C in 20 mM HEPES, pH 7.5. The reaction was quenched by addition of cold DFP to a final concentration of 10 mM and the radiolabelled material analyzed by SDS-PAGE, followed by autoradiographic analysis. The gel was dehydrated, soaked in PPO solution for 2 hours, dried, and the DFP-binding 10 proteins detected by fluorography after an exposure time of 96 hours on X-ray film (XAR; Kodak, Rochester, NY). The bulk of radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse-phase HPLC as described above. Radioactivity in each peptide fraction was measured using a β liquid scintillation counter, and the labeled peptide, as well as 15 other selected peptides were subjected to sequence analysis.

Identification of the PTP-A Gene— The database containing the unfinished *P. gingivalis* W83 genome, available from The Institute for Genomic Research, was searched for the presence of nucleotide sequences corresponding to the NH₂-terminal and the internal PTP-A amino acid sequences using the TBLASTN 20 algorithm, BLAST version 2.0.8, and the default values for all parameters (Altschul, S.F., et al., (1997) *Nucleic Acid Res.* 25, 3389-3402). An identified clone gnl | TIGR | *P. gingivalis*_126 was retrieved from The Institute for Genomic Research data base (<http://www.tigr.org>). The position of the PTP-A gene was localized using the NCBI open reading frame (ORF) finder (available from the 25 National Center for Biotechnology Information, at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>). The amino acid sequence, obtained by conceptual translation of the entire ORF, was further used for homology screening by use of the NCBI BLAST search tool.

Enzyme Specificity— Peptides were incubated with 1 µg PTP-A at an 30 enzyme:substrate molar ratio of 1:100 for 3 hours or 24 hours in 50 µl of 200 mM HEPES, pH 7.5, at 37°C, and the reaction stopped by acidification with trifluoroacetic acid. The samples were then subjected to reverse-phase high

pressure liquid chromatography using a μ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA) and an acetonitrile gradient (0-80 % in 0.075% trifluoroacetic acid in 50 min). Each peak, detected at 220 nm, was collected, lyophilized, re-dissolved in 50% (volume/volume) methanol, 0.1% acetic acid and subjected to analysis by mass spectrometry.

5 *Mass Spectrometry*—A Finnigan MAT 95S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C., et al., (1997) *J. Biol. Chem.* **272**, 5747-5751). Peptides were identified by fitting of the obtained 10 spectra to specific sequences using an Internet application program MsFit available at <http://falcon.ludwig.ucl.ac.uk/msfit.html>.

Example 2

Enzyme Localization, Purification and Initial Characterization

15 Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of *P. gingivalis* HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated 20 enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form. Subsequent acetone precipitation of proteins in the Triton X-100 fraction successfully separated the activity from pigment which remained in solution. The redissolved protein fraction, after dialysis, was applied 25 to hydroxyapatite (100 ml) equilibrated with 20 mM potassium phosphate buffer pH 7.0. The elution was carried out with 20 mM potassium phosphate buffer pH 7.0, using a phosphate gradient from 20 mM to 300 mM at flow rate 20 ml/h. At this step substantial separation of the PTP-A activity from both the DPP IV and bulk protein was achieved (Fig. 1a). Further purification performed by subsequent 30 chromatography steps including Phenyl-Sepharose (Fig. 1b), MonoQ (Fig. 1c) and MonoP columns (Fig. 1d), resulted in the isolation of purified enzyme.

Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h. The column was

washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied. The PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by 5 ultrafiltration. The concentrated PTP-A containing fractions were applied to a MonoQ column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl. The concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP 10 column equilibrated with the same buffer. A pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.

Significantly, the chromatography step on the MonoP column yielded the A₂₈₀ profile much sharper than the activity peak. Although this imperfect overlap of protein and activity may suggest that the protein component does not represent 15 the active enzyme, the rest of data argues with such a contention. This apparent contradiction may be likely explained by the enzyme inhibition by the reaction product of H-Ala-Phe-Pro-pNA hydrolysis but this possibility has not been explored. The yield of protein and activity recovery in a typical purification procedure is summarized in Table 1.

Table 1. Purification of the PTP- A from *P. gingivalis*

Step	Volume (ml)	Protein (mg)	Total activity*	Specific activity (units/mg)	Purification fold	Yield (%)
Triton X-100 extract						
5 after centrifugation	200	1200	757 673	642	1	100
Acetone precipitate	50	600	537 622	896	1.4	71
Hydroxyapatite chromatography	50	22	400 039	18 183	28	53
Phenyl-Sepharose						
MonoQ	48 3	10 1.5	312 505 244 828	31 250 163 218	48 254	41 32
MonoP	4	0.7	188 400	269 142	420	25

* Based on the enzymatic activity using H-Ala-Phe-Pro-pNA where one unit = mOD/min/1ml

SDS-PAGE analysis of the purified enzyme revealed the presence of two protein bands with apparent molecular masses of 81.8 and 75.8 kDa, respectively (Fig. 2, lane f). Autoradiography of the enzyme sample radiolabeled with [1,3-³H]DFP (Fig. 2, lane g) clearly indicated that the bands represented either two distinct serine peptidases or different molecular mass forms of the same enzyme. In an attempt to distinguish between these two options, the electrophoretically resolved proteins were subjected to amino terminal sequence analysis. Unfortunately, it was found that the 81.8 kDa form of PTP-A had a blocked N-terminus. In contrast, the sequence NH₂-SAQTRFSAADLNALMP (SEQ ID NO:23) was found at the N-terminus of the lower molecular mass form of the enzyme. This result led us to the possibility that the 75.8 kDa form of PTP-A was derived from the 81.8 kDa form through proteolytic cleavage of a 6 kDa amino-terminal peptide. To confirm this hypothesis and, in addition, to localize the active site residue within *P. gingivalis* PTP-A, the mixture containing both radiolabeled enzymes was proteolytically fragmented and peptides resolved by reverse-phase HPLC. This procedure yielded only one major radioactive peptide peak, and the purified peptide was found to have a single amino acid sequence: IGVHGX_XGGFMTTNL (SEQ ID NO:24), where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP. These data convincingly indicate that the two protein bands of purified PTP-A represents different forms of the same enzyme. The portion of the purified PTP-A having a truncated N-terminus may be due to cleavage by Lys-specific peptidase and is likely to be an artifact which occurred during the purification procedure. Nevertheless, the proteolytic shedding of membrane bound PTP-A also occurs during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.

Example 3

pH Optimum, Stability and Inhibition Profile

Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases

(Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase. Surprisingly, however, 3,4-dichloroisocumarin was only a poor inhibitor, and PMSF, leupeptin, antipain and prolinal had no effect at all. Interestingly, 5 preincubation of PTP-A with iodoacetamide, but not with N-ethylmaleimide, stimulated enzyme amidolytic activity about two-fold. Human plasma inhibitors, such as α_1 -proteinase inhibitor, α_1 -antichymotrypsin and α_2 -macroglobulin did not affect the enzyme activity, nor were they cleaved by PTP-A.

10 The effect of inhibitors on amidolytic activity of DPP IV was also determined using the same conditions as those used for PTP-A, but using H-Gly-Pro-pNA as a substrate.

Table 2. Effect of inhibitors on the amidolytic activity of PTP-A and DPP IV.
 Results are for a 15-min incubation at 37 C in 0.2 HEPES pH 7.6,
 with 1 mM H-Ala-Phe-Pro-pNA as substrate.

	Inhibitor	Concentration	Residual activity of PTP-A, %	Residual activity of DPP IV, %
5	Diisopropyl fluorophosphate	10 mM	0	0
		10 mM	96	20
10	Phenylmethanesulfonyl fluoride	1mg/ml	20	15
		10mg/ml	0	0
15	PEFABLOC SC	1 mM	56	100
	3,4-dichloroisocoumarin	5mM	200	100
20	Iodoacetamide	5 mM	100	100
	N-Ethylmaleimide	1 mM	98	100
25	1,10-orthophenanthroline	5 mM	93	100
		0.1 mM	100	100
30	EDTA	0.1 mM	100	100
	Leupeptin	0.1 mM	100	20
35	Antipain	10 mM	100	0
	Prolinal	10 mM	100	30
	Val-Pro	10 mM	100	1
	Ala-Pro			
	Ala-Gly-Pro			

Example 4
Substrate Specificity

Among several chromogenic substrates tested, including H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, H-Pro-pNA, only H-Ala-Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl-peptidase activity. To further confirm this specificity several synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A. Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved (Table 3), with the significant exception of peptides with adjacent proline residues (peptides 3, 4 and 16). In addition, a free α -amino group was absolutely required for cleavage after the third proline residue as exemplified by resistance to enzymatic hydrolysis of peptide 9, which differs from the peptide 8 only in acylation of the α -amino group of the N-terminal valine residue. Except for these two limitations, the peptide bond -Pro- \downarrow -Yaa- was cleaved at the same rate in all peptides with the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the amino acids and the length of the peptide. In all cases the reaction was completed within 3 hours and prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus. In addition, these data indicate that the preparation of PTP-A was free of any contamination with either aminopeptidase, dipeptidyl peptidase, or endopeptidase activities.

The cleavage specificity of DPP IV was also determined using the same conditions as those used for PTP-A. The results (Table 3) demonstrate that DPP IV does not cleave between two proline residues.

Table 3. Cleavage specificity of PTP-A and DPP IV on synthetic peptides.

Substrate	Cleavage site	SEQ ID NO:
Peptide 1	H-Arg-Pro-Pro- ¹ -Gly-Phe-Ser-Pro-Phe-Arg	1
Peptide 2	H-Arg-Pro-Pro- ¹ -Gly-Phe	2
Peptide 3	H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	3
Peptide 4	H-Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	4
Peptide 5	H-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg	5
Peptide 6	H-Arg-Pro- ¹ -Lys-Pro- ¹ -Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂	6
Peptide 7	H-Val-Pro-Pro- ¹ -Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Ala-Pro-His-Arg-Gln	7
Peptide 8	H-Val-Pro-Pro- ¹ -Gly-Glu-Asp-Ser-Lys	8
Peptide 9	Ac-Val-Pro-Pro-Gly-Glu-Asp-Ser-Lys	9
Peptide 10	H-Val-Glu-Pro- ¹ -Ile-Pro-Tyr	10
Peptide 11	H-Arg-Gly-Pro- ¹ -Phe-Pro-Ile	11
Peptide 12	H-Ala-Arg-Pro- ¹ -Ala-D-Lys-amide	
Peptide 13	H-Pro-Asn-Pro- ¹ -Asn-Gly-Gly-Asn-Phe-Ile	13
Peptide 14	H-Arg-His-Pro- ¹ -Lys-Tyr-Lys-Thr-Glu-Leu	14
Peptide 15	H-Gly-Val-Pro- ¹ -Iys-Thr-His-Leu-Glu-Leu	15
Peptide 16	H-Lys-Gly-Pro-Pro-Ala-Ala-Leu-Thr-Leu	16
Peptide 17	H-Gln-Lys-Gln-Met-Ser-Asp-Arg-Glu-Asn-Asp-Met-Ser-Pro-Ser-Asn-Val-Val-Pro-His-Val-Pro-Pro-Thr-Thr-Glu-Asn-Lys-Pro-Lys-Val-Gln	17
Peptide 18	H-Phe-Leu-Arg-Glu-Pro-Val-Ile-Phe-Leu	18
Peptide 19	H-Gly-Ile-Arg-Pro-Tyr-Glu-Ile-Leu-Ala	19
Peptide 20	H-Leu-Pro- ¹ -Asp-Leu-Asp-Ser-Ser-Leu-Ala-Ser-Ile-Gln-Glu-Leu-Ser-Pro-Gln-Glu-Pro-Pro-Arg-Pro-Pro-Glu-Ala	20
Peptide 21	H-Cys-Leu-Ser-Ser-Gly-Thr-Leu-Pro-Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser	21
Peptide 22	H-Lys-Ile-Ala-Gly-Tyr-His-Leu-Glu-Leu	22
Peptide 23	H-Ser-Pro- ¹ -Tyr-Ser-Ser-Asp-Thr-Thr	46
Peptide 24	H-Ala-Pro- ¹ -Val-Arg-Ser-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys	47

¹ indicates cleavage site mediated by PTP-A¹ indicates cleavage site mediated by DPP IV

The lack of cleavage after internal proline residues in the synthetic peptides corresponds well with the absence of any proteolytic activity on several protein substrates including IgA, IgG, albumin, azocasein, carboxymethylated 5 rybonuclease and gelatin. However, the size of substrate, which is a limiting factor in the activity of oligopeptidases (Walter, R., et al., (1980) *Mol. Cell. Biochem.* 30, 111-126), is not restricting in the case of PTP-A, because the enzyme is able to cleave a tripeptide (NH₂-Xaa-Xaa-Pro) from the N-terminus of both human cystatin C and interleukin 6.

10

Example 5

PTP-A Sequence Analysis

Partial PTP-A amino acid sequence data allowed us to identify the *P. gingivalis* genomic clone gnl | TIGR | *P. gingivalis*_126 in the Unfinished 15 Microbial Genomes data base, TIGR. An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB 20 were present in the protein primary structure inferred from the nucleotide sequence of the ORF. The 732 amino acid polypeptide with a calculated mass of 82,266 Da was encoded in this ORF. The homology search performed using the NCBI TBLASTN tool against GenBank+EMBL+DDBJ+PDB databases and subsequent 25 multiple sequence alignments using the ClustalW Multiple Sequence Alignment tool (Fig. 3) indicated that PTP-A is a new member of the prolyl oligopeptidase (S9) family of serine peptidases (Rawlings, N.D., et al., (1991) *Biochem. J.* 279, 907-908).

25

The sequence GXSXGG (SEQ ID NO:40) is a signature feature for the S9 family of serine peptidases. Within this large and diverse S9 family of evolutionary and functionally related enzymes both from prokaryotes and eukaryotes, PTP-A was most closely related to bacterial dipeptidyl peptidase IV (DPP IV) from *Flavobacterium meningosepticum*, *Xantomonas maltophilus*, and *P. gingivalis*, 30 sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively. Remarkably, the COOH-terminal region of the PTP-A molecule (residues 502 - 732) shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3). This part of the molecule contains the amino acid

residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima,T., et al., (1995) *Arch. Biochem. Biophys.* **320**, 123-128) it is apparent that Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP-A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP. In addition, the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic α -helix responsible for membrane anchoring of this enzyme.

In *P. gingivalis* PTP-A, as well as in DPP IV, all activities are cell surface associated, and it is conceivable that the enzymes are membrane anchored through putative signal sequences which are not cleaved but remain as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. The cell surface localization of di- and tripeptidyl-peptidases suggests a putative physiological function in providing nutrients for growing bacterial cells. Here, the inability of asaccharolytic *P. gingivalis* to utilize free amino acids (Dashper, S.G., et al., *J. Dent Res.* **77**, 1133 (Abstract) (1988)) makes the bacterium entirely dependant on an external peptide supply. In this regard, DPP-IV and PTP-A activities are probably very important, if not indispensable, for bacterial growth.

This suggestion is strongly corroborated by the fact that the *P. gingivalis* genome contains three additional genes encoding peptidases homologous with DPP-IV and PTP-A and one related to aminopeptidase B. The peptidases homologous with DPP-IV and PTP-A are referred to as homologs H1 (SEQ ID NO:43), H2 (SEQ ID NO:44), and H3 (SEQ ID NO:45) (Fig. 6). If expressed, each gene product would probably have enzymatic activity because each has a well preserved catalytic triad (Fig. 4). In addition, all of these genes encode a putative signal peptide which may act in providing membrane-anchorage motifs.

Example 6**Influence of Proteinase Inhibitor on *P. gingivalis* Growth**

To evaluate whether *P. gingivalis* growth was influenced by the presence of a peptidase inhibitor, *P. gingivalis* in logphase growth was diluted 1:5 into liquid media and incubated at 37°C. The cell density was monitored by measuring the optical density at 600 nm (OD₆₀₀). When the optical density began to increase, Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml. The control culture received no Pefabloc. The cultures receiving Pefabloc exhibited decreased growth (Figure 5). The peptidase inhibitor had to be added before the culture reached an OD₆₀₀ of about 0.3 for the peptidase inhibitor to have an effect on growth.

The complete disclosures of all patents, patent applications, publications, and nucleic acid and protein database entries, including for example GenBank accession numbers and EMBL accession numbers, that are cited herein are hereby incorporated by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

20

Sequence Listing Free Text

SEQ ID NOS:1-11: Synthetic peptides

SEQ ID NO:12: Target peptide

SEQ ID NOS:13-22: Synthetic peptides

25 SEQ ID NO:23: Amino-terminus of the lower molecular mass form of PTP-A.

SEQ ID NO:24: Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.

30 SEQ ID NO:25: Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.

SEQ ID NO:26: Mouse fibroblast activation protein

	SEQ ID NO:27:	Human DPP IV
	SEQ ID NO:28:	DPP from <i>Flavobacterium meningosepticum</i>
	SEQ ID NO:29:	DPP from <i>P. gingivalis</i>
	SEQ ID NO:30:	<i>P. gingivalis</i> PTP-A
5	SEQ ID NO:31:	Portion of PTP-A
	SEQ ID NO:32:	Portion of DPP from <i>P. gingivalis</i>
	SEQ ID NO:33:	Portion of H1 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:34:	Portion of H2 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:35:	Portion of H3 homolog of <i>P. gingivalis</i> DPP
10	SEQ ID NOs:36-37:	Probes
	SEQ ID NO:38:	Nucleotide sequence of coding region encoding PTP-A.
	SEQ ID NO:39:	Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSXXG.
	SEQ ID NO:40:	Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSXGG.
15	SEQ ID NO:41:	A specific substrate for a prolyl-tripeptidyl peptidase, where Xaa represents a natural or modified amino acid residue, and Yaa represents a natural or modified amino acid residue except proline.
20	SEQ ID NO:42:	DPP from <i>P. gingivalis</i>
	SEQ ID NO:43:	H1 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:44:	H2 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:45:	H3 homolog of <i>P. gingivalis</i> DPP
	SEQ ID NO:46:	Synthetic peptides
25	SEQ ID NO:47:	Synthetic peptides
	SEQ ID NO:48:	Amino terminal sequence of DPP IV

What is claimed is:

1. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
2. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours, and wherein the prolyl tripeptidyl-peptidase is isolated from *P. gingivalis*.
3. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the peptide cleaved by the isolated prolyl tripeptidyl-peptidase comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, and SEQ ID NO:37.
4. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSXXG (SEQ ID NO:39).
5. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSXGG (SEQ ID NO:40).
6. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises SEQ ID NO:30.

7. An isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
8. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
9. An isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
10. The nucleic acid fragment of claim 9 wherein the nucleic acid fragment has a nucleotide sequence comprising SEQ ID NO:38.
11. The nucleic acid fragment of claim 9 wherein a complement of the nucleic acid fragment hybridizes to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
12. An isolated nucleic acid fragment encoding a polypeptide wherein the polypeptide comprises an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
13. A method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, comprising identifying a molecule that inhibits the amidolytic activity of the prolyl-

tripeptidyl peptidase by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

14. A method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
15. A method for protecting an animal from a periodontal disease caused by *P. gingivalis* comprising administering to the animal the inhibitor of claim 14 wherein the disease is selected from the group consisting of gingivitis and periodontitis.
16. The method of claim 15 wherein the inhibitor is administered by a method selected from the group consisting of subgingival application and controlled release delivery.
17. A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl dipeptidyl-peptidase with an inhibitor of the prolyl dipeptidyl-peptidase.
18. An immunogenic composition comprising an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
19. The immunogenic composition of claim 18 further comprising an adjuvant.

20. A composition comprising an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
21. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:43.
22. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:44.
23. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:45.

1/19




Fig. 1a




Fig. 1b

2/19




Fig. 1c




Fig. 1d

3/19




Fig. 2

Fig. 3a

Fig. 3b

Fig. 3c

Fig. 3

SEQ ID NO:

2 6	Mn-FAP	1	MKTWLKATVGMTTAAATLWICIVLRLPSR-WYKPEGNTK-RALTLLKDILNGTFSYKTYF
2 7	Hs-DPP	1	MKTPMWRVILCLIGAAATVTTTIVTPVWVILNGTDDATAADSR-KTYTILDYLKNTYRLKLYS
2 8	Fm-DPP	1	---MKKKITFSLISTAVVAFHGLSAQEITLDKIVSQFRAK-GISGIAISND---
2 9	Pg-DPP	1	---MKRPVITLIGIVVWCAAGTGNKPKVDRKETSCMFYARSAGSCITRSMPD---
3 0	PTP-A	1	---MKKKITFQQLFLSVCAITALPCSAQSPETSGKEETLEQLMPCGKEFYN--FYPEYVV
			↑
5 9	Mn-FAP	59	PNWIESEQYTHQS-FDDNTMFEYNTETRE--SYTIIISNSIMKSVN--ATDYYJTSPPDQRFVY
	Hs-DPP	60	LRWISDHEPYK--QENNLLVNAEYGN--SSVFILENSTFDEFGHSINDYSISSPDGQFTI
	Fm-DPP	48	---CENYATTI--EPTGIAKSYKTSQ--KEKNIIVDGSFQGYT---FSNDESK--II
	Pg-DPP	51	---CEHYTEMNRERTAIITRYNYASEKAVDTFSVERARECPFKQIONYEVSTIGHHLL
		56	GLQWMDNMFIE---GDDLVENKANEKSAQITRFSAAADLNALMPEGCKFQTTDAFPSFR
			↑
114	Mn-FAP	114	ESDYSKMRYSYTAHYTYDONGEFVRYGYELPRPIQYIOWSPVQGSKTAYVYONNITYK
	Hs-DPP	116	FEYNYVKQMRHSYTAHSYDIYDLINKRQLTTEERIPNNTQWITSPYGHKLYVWNTDLYVK
	Fm-DPP	92	LOKSSQSIYRHSELGEKEVDRDLKSRTWVSNANWIE-PKFSPGSKVAFIADNNLFYQ
	Pg-DPP	106	FTDMESTYRHSYRAVYDVYDVRNRLVKPUSHEVCKVMIPTFSPPD3RMVAFVRDNNTFJK
		113	TIDAGRGLVLFQEGGLVGEFMLAKVYIIFDNEETASDPSPVGDRVAVRNNTFIA
			↑
174	Mn-FAP	174	QRP--GPPFQITYTGERNRTFNGTIPDWYEEEMILATKYLWSPD3KFLAMVFFNDSDI
	Hs-DPP	176	IEP--NLPSYRITWICKEDIYNGTIPDWYEEEFVAYSALWMSPNGTELAYAQFNDTEV
	Fm-DPP	151	DLN--TGKRIITDGGKKNEILINGLCDPWYEEEFCHADYYQWN-KAGDALVYFREDERKV
	Pg-DPP	166	KFD--FPEVQVMDGOINSIINGATDWYEEFPGVTNLMSWS-ADNAFLAFYRSPDESAY
		173	RGGKLGEGMSRAIAYTIDGTEFLVYQAMHQERGKLEKGTWMS-BK3SCSCLAFYRMDQSMV
			↑
232	Mn-FAP	232	PITIAYSYGCGD--QYHRTINIPYPKAGAKNPVVMVFLIVDRTYPHNYG--PMEMVPPEMI
	Hs-DPP	234	PLIEYSFYSDESLOQPKTVRMPYPKAGAVNPTMKEFVNTDSLSSVNTATSQIQTAPASM
	Fm-DPP	208	PEINIPIXYON--LYPKIIMTYKYPKAGEENSAYTLYQOISGCKSAQ---LNFGSSERY
	Pg-DPP	223	PEYRMPMVPDK--LYHEDYTYKYPKAGEKONSTVSIILYVNAADRNIKS--VS1PIDADG
		232	KPTPIVDYHP---LEAESKPKIYFMAGTPSHHVTvCITYHLLAIGKTVY--LQIGEPEKEK

Fig. 3a

Mm-FAP	287	ASSDYYFSMLTWSSPERVOTQWIKRQTVNVS	M	CD	FREDWHAECPKQEQH	FEESRT
Hs-DPP	294	LGDDHILCDVTWATERISLOWLARRIONYSW	M	CD	DESSGRWNCLVAROHL	EMSTIGW
Fm-DPP	262	YIPOLFOIN	N	CD	YDESSGRWNCLVAROHL	EMSTIGW
Pg-DPP	277	YIPRIAFID	N	CD	YDESSGRWNCLVAROHL	EMSTIGW
	285	FLRNLSNSP	N	CD	YDESSGRWNCLVAROHL	EMSTIGW
Mm-FAP	347	AGGFFFVSTPAFSODATSYKIFSDKDGYKH	T	CD	TKDTVENAICIT	TSCKWEATY
Hs-DPP	354	MGRFRBPSEPHFLDGNFSFYKILISNEECYR	H	CD	TKDTVENAICIT	TSCKWEATY
Fm-DPP	311	ETDNEITMEELDDNS	N	CD	TKDTVENAICIT	TSCKWEATY
Pg-DPP	326	WPSDWIQTKEETRGCG	N	CD	TKDTVENAICIT	TSCKWEATY
	335	YPLHP-LTELPGSNNQFIWQSSR	N	CD	TKDTVENAICIT	TSCKWEATY
Mm-FAP	407	SIFYSSNFEFGYPGRN	T	CD	TKDTVENAICIT	TSCKWEATY
Hs-DPP	414	YLYYISNEYKGMPPGRN	T	CD	TKDTVENAICIT	TSCKWEATY
Fm-DPP	368	---TKEWVQIONTEKGSINKV	N	CD	TKDTVENAICIT	TSCKWEATY
Pg-DPP	384	---GTVFQOSAEFSPIRR	N	CD	TKDTVENAICIT	TSCKWEATY
	393	---GIRLYFESTEASPLER	N	CD	TKDTVENAICIT	TSCKWEATY
Mm-FAP	467	Y-GPGCPTISTIHDGRTDOE	T	CD	TKDTVENAICIT	TSCKWEATY
Hs-DPP	473	S-GPGCPLYTLHSSVNDKG	R	CD	TKDTVENAICIT	TSCKWEATY
Fm-DPP	421	S-TARKEPTKYLKDANGD	V	CD	TKDTVENAICIT	TSCKWEATY
Pg-DPP	435	SAAATPAVVSFRSKAKELR	I	CD	TKDTVENAICIT	TSCKWEATY
	446	Q-SETMPRKVTVTNIG-KGSHTILEAKNPDIGYAMPE	I	CD	TKDTVENAICIT	TSCKWEATY
Mm-FAP	525	PPQFDRSKYPLIIVYGGPC	S	CD	TKDTVENAICIT	TSCKWEATY
Hs-DPP	531	PPHFDKSKYPLIIVYGGPC	S	CD	TKDTVENAICIT	TSCKWEATY
Fm-DPP	480	PKNFDRKAKYPLIIVYGGPC	S	CD	TKDTVENAICIT	TSCKWEATY
Pg-DPP	495	FIDFDPSRHYPLIIVYGGPC	S	CD	TKDTVENAICIT	TSCKWEATY
	502	ELHEDHAKKYPVLYVYGGPC	H	CD	TKDTVENAICIT	TSCKWEATY

Fig. 3b

Mm-FAP	582	DEKEFELAIVKRLGVIEVEDQITAVRKFIEMGFIDEERIAITMGMSYGGVSSITALASGIGUF	582	DEKEFELAIVKRLGVIEVEDQITAVRKFIEMGFIDEERIAITMGMSYGGVSSITALASGIGUF
Hs-DPP	588	DKTMMHAIIANRRLGTFEVEDQTEKAROFSKMGFVDNKRKIAITMGMSYGGVTSMTGSGVFT	588	DKTMMHAIIANRRLGTFEVEDQTEKAROFSKMGFVDNKRKIAITMGMSYGGVTSMTGSGVFT
Fm-DPP	539	TKYKKVTKYKNLKGKYEILEDQITIAKMGNOQSYNDKSRIGIEMGMSYGGVMASTLMTKGADVF	539	TKYKKVTKYKNLKGKYEILEDQITIAKMGNOQSYNDKSRIGIEMGMSYGGVMASTLMTKGADVF
Pg-DPP	551	SEMRKCTYMOLGVEESDDQIAATAQGQPPVYDAAIRGIGWNSYGGVTTMSLCRGNEDF	551	SEMRKCTYMOLGVEESDDQIAATAQGQPPVYDAAIRGIGWNSYGGVTTMSLCRGNEDF
	561	AAFEQVTHRLQTEMDOMGCVDFLKQSOWDADRIGMHGMSYGGFMINLMLIHGDVF		AAFEQVTHRLQTEMDOMGCVDFLKQSOWDADRIGMHGMSYGGFMINLMLIHGDVF
		*	*	
Mm-FAP	642	KOGIAVAPSSWEYMASIYSEREMGLPTEPKDDNLEHYYKNSTVMPARAELYFRNVDVLLIHGTA	642	KOGIAVAPSSWEYMASIYSEREMGLPTEPKDDNLEHYYKNSTVMPARAELYFRNVDVLLIHGTA
Hs-DPP	648	KOGIAVAPSSWEYMASIYSEREMGLPTEPKDDNLEHYYKNSTVMPARAELYFRNVDVLLIHGTA	648	KOGIAVAPSSWEYMASIYSEREMGLPTEPKDDNLEHYYKNSTVMPARAELYFRNVDVLLIHGTA
Fm-DPP	599	KMGLIAVAPVTSRWEYIYESVTERMGLPTPEDNLHYRNSITVMSRAENFKOVEVLLIHGTA	599	KMGLIAVAPVTSRWEYIYESVTERMGLPTPEDNLHYRNSITVMSRAENFKOVEVLLIHGTA
Pg-DPP	611	KAGIAVAPVADWRFYDPSVTERMRTKNEA--SCGXKMSAAIDVASOLOQG-NLIVVSSASA	611	KAGIAVAPVADWRFYDPSVTERMRTKNEA--SCGXKMSAAIDVASOLOQG-NLIVVSSASA
	621	KMGLIAVAPVTSRWEYIYESVTERMGLPTPEDNLHYRNSITVMSRAENFKOVEVLLIHGTA		KMGLIAVAPVTSRWEYIYESVTERMGLPTPEDNLHYRNSITVMSRAENFKOVEVLLIHGTA
		*	*	
Mm-FAP	702	DDNVHFFONSAQIAKALVNAQWDFPQAMMYSPOONHGfissersonlyTHMTHFLKOCFSLSD	702	DDNVHFFONSAQIAKALVNAQWDFPQAMMYSPOONHGfissersonlyTHMTHFLKOCFSLSD
Hs-DPP	708	DDNVHFFGSAQISKALVDPGVDFQAMMYSPOONHGfissersonlyTHMTHFLKOCFSLSD	708	DDNVHFFGSAQISKALVDPGVDFQAMMYSPOONHGfissersonlyTHMTHFLKOCFSLSD
Fm-DPP	656	DDNVHFFONSMEEFSEA LIONKKQEDFMAPPKNHSITLIGGNTRQLYEVKNTINYTLEN	656	DDNVHFFONSMEEFSEA LIONKKQEDFMAPPKNHSITLIGGNTRQLYEVKNTINYTLEN
Pg-DPP	668	DDNVHFFONTMLEFTEALM0A1IEPDMATYMDKKNHSITLIGGNTRQLYEVKNTINYTLEN	668	DDNVHFFONTMLEFTEALM0A1IEPDMATYMDKKNHSITLIGGNTRQLYEVKNTINYTLEN
	678	DDNVHFFONTMLEFTEALM0A1IEPDMATYMDKKNHSITLIGGNTRQLYEVKNTINYTLEN		DDNVHFFONTMLEFTEALM0A1IEPDMATYMDKKNHSITLIGGNTRQLYEVKNTINYTLEN

Fig. 3c

	SEQ ID NO.:
PTP-A	556 VDADTRIGMHEGWSYGGFMV . . . RIMLTHGAIIDPPVIVWQHSLFLDPAKVARTYPDYYMYP SHEHNVAGFED-R 717 31
DPP	499 VDADTRIGMHEGWSYGGFMV . . . NELIVSGADDNMHLQNTMLFTEDAIQANIPFDMAIYMOKNHSIYGGNTR 661 32
DPP-H1	350 VDPPDRITATYGASHGCCYAT . . . PIFWVQGANDPRVNINEPQIVTAAARCGFEVHYMKYNECHGFHREENS 524 33
DPP-H2	640 VNGKKVKGQEGASGYGGFMV . . . PILLHGSVMDNNVPTAESVNLYNPAKIKILGREVEFIEFTBQDFTEFERR 810 34
DPP-H3	495 VLGDRITCAVGASGYGGFSV . . . PIMMNGELDFRILASQVMAAFDAAQLRCVPSSEMLIMPDENHWMVLOQNA 667 35

Fig. 4

9/19


Influence of Pefablock-serine proteinase inhibitor on *P. gingivalis* growth.

Fig. 5

10/19

Fig. 6a

Fig. 6b

Fig. 6c

Fig. 6d

Fig. 6

SEQ ID NO:

30	126PP	1	M[R][F]QQ[F]-----[S]VCALTVALPCSAQS[PETSGKE]FTLEQI[PGCKEF]-----YNF[YPE]YV
42	87PP	1	-----[P]DGE[H]Y-----[T]EMNRERT
43	65PP	1	-----[D]KCC-----[N]ENYH[FA]
44	101PP	1	[Y]R[Q]SLMLI[LSAAT]SSIEAQTIQQMIKAGGPW[PVRAAF]KTD[TVGMNGSK]NPADLLR[QAY
45	9PP	1	[M]N[Q]KTFSMMAAS-----[I]IGSAAMTPSAGTNTGEHLTPEL[E]MTLSR[Q]SEMA[LS]-----[P]DGKTA[VY]

126PP	55	V[G]QWMGD[V]YVF-----[I]EGDDL[V]NKANG-----[K]SAQ[TT]F[SA]ADL[N]ALMPEGCKF[Q]
87PP	16	A[Q]I[R]Y-----[Y]AS-----[G]KAVDTL[F]SVER-----[A]RECPE[K]QI[Q]-----[V]E
65PP	14	S[N]D[G]-----[S]-----[N]TRDLT[F]PD[G]V[K]-----[A]SILNM[K]KEQ[K]-----[Y]M
101PP	61	[D]ATDKDLR[N]MSAD[K]DGR[IA]GR[K]AGS[KA]ER[SE]MAVY[S]F[AL]TAEH[F]AKADIE[V]FGQGRMSLW
9PP	57	AVSF[P]-----[D]V[K]-----[N]KATRE[F]TVNLD-----[G]SGRKQITD[ES]N-----[E]YAPAW

126PP	104	T[D]AFPSFRTLDAGRC-----[L]VLF[Q]GGT[V]GFD[ML]ARKV[Y]T-----[F]DTNEETASLD[ES]P-----
87PP	50	V[S]ST[G]-----[L]LFT[D]MES-----[I]YRHSYRAAVYD[D]V[ER]N[V]K[P]-----[S]EHV[G]KVM[MI]P[F]SP-----
65PP	46	[T]ISMNK-----[N]PQ-----[T]FEPEYKLN[V]GELTQLYEN-----[K]DAANP[Q]GYB[ED]K-----
101PP	121	[D]DKOIGT[AD]SPNSK[G]DTT[L]RF[SA]S[LS]V[P]CTH[L]IKS[Q]L[E]GDTTATDVRVVL[K]F[K]TA
9PP	98	[M]D[G]K[R]-----[I]AFMS[Q]EG-----[S]MQLWMNNA[D]T[ER]Q[LS]N-----[I]EGC[IT]G[R]F[F]SP-----

126PP	157	-V-----[C]DR[V]Y[V]RNHN-[Y]TARG-----[G]KLGE[G]MSRAIA[V]-----[D]GT[ET]L[V]GQA-----
87PP	103	[D]-----[C]RMV[F]VRDMN-[I]F[K]-----[K]FDFDTE-----[V]QV[TD]GQ[IN]SULNGATD
65PP	90	-D-----[C]F[RG]Y[S]-----[L]VNGIESEL[V]YKD-----[L]VNGIESEL[V]YKD-----
101PP	181	R[D]SALYPNYT[G]K[ER]ISLKHMM[G]TFISGGSLSP[G]TGYVLT[S]YR[V]SRDNKPAV[T]Y[N]QLRD
9PP	144	-D-----[E]KQV[IT]K[D]-----[I]KFGKRT[KD]IY[P]DLDK

Fig. 6a

12/19

126PP	201	VHQREFGTEKG--TFS	SPKGSCLA	YRM-	QS-MVKPTPH	IVDYH-	--P
87PP	144	WVYEEFGV	TNL--MSW	SADNAFLA	AFVRS-	DES-AVPEYR	MPMYED--R
65PP	112	LARGEFR	ELKKR--THW	DDTFGV	YENYA-	SKN-KDEAYV	LTNLD--S
101PP	241	ARGNILLN	NEKEALC	GMMPHEDM	MVIRKEGN	AKRLVAFD	PMGKGEKTLVSNLPE
9PP	170	ATGR	IITDLMYK--H	DEWVET	TPHPFI-	AN-ATDGM	ITIGKD--E
126PP	243	EAE	S	PLYYP	MAGT--PSHH	TVG	YHLA--TG-KTVY
87PP	188	YPEDY	T	KYK	PAGE--KINSTV	SLH	YVNA--DR-NTKSV
65PP	153	DK-T	TRIVYD	KQON--K	TDAD	GDYIPR	UAF
101PP	301	SP	ARYM	LYKQEK	PGKGDPLF	FRH	YDVSGLHLS-RN-
9PP	210	ME-GER	YEA	PKW--S	DDRQSDW	NRDRS	QYVYGP
					YLN	AEV	FGYST
126PP	296	NIT	VAE--VNRA	QNECKV	NAIDAE	TGR	FRVRLT
87PP	241	DEL	AVT--LNRL	QNDFKM	YVHPIPKS	LVPLK	DKFVET
65PP	188	-R--	Y	Y	Y	Y	DKFVET
101PP	361	TY	TDI	APDSK	RA	TRP	FRATIM
9PP	247	-M	Y	Y	Y	Y	Y
126PP	346	GSN	NOFH	WOSR	RDG	GNH	YD
87PP	292	GG	--F	YVSE	KDGFA	TY	DNKGV
65PP	224	GKE	FSV	Y	Y	Y	YDD
101PP	421	GKH--LIV	MGS-ADAF	GNT	NLKSGV	TPNSYD	DKOFF
9PP	287	GKS--IAW	ISMER	DGYES--	DK	NPVSAG	FDLS

126PP	389	-FPKG[TIR]YFESTEASPLTERHFTC	TPKGTRD[LTP-ESGMHRTO]SPD-GSA[TDIF
87PP	333	-VPASGT-VEYQOSAFESPTSBAYA	DAKGRKTK-LSL-NVCGTNDALFSGN-YAYYNTY
65PP	235	-DE- -1	-KFI- -LXD-L
101PP	478	RFDPRKNN-XYTFRAENG-SRKOLYR	QDFTKLEISQIQTGEDVYQWFGVAA[DNGAVWYSGQ
9PP	332	QMAPDSKGH[YLACKEA- -ETNLLMEI	ITKGRNIRQITQGQHDYAFDSVRND- -VMI[AKR
126PP	446	QSPTM[PRKVMV]TNIGKQ[ESHTL]EAK[NPDTCYAM]PEI[TRG	- - - - - TMAAD[GOTP]Lyyk[IT
87PP	388	SSAATPAVSVFRSK[AKELRTL]ED[VALRER]KAYFYNPKEFIT	TIKTO[SG- - - - - LELNAA[IV
65PP	269	- - - - - MPOLK- - - - - EED- - - - -	- - - - - KFKSRDG-LTI[HGF]IT
101PP	536	SANNADRLYR[DGTGKLVWD]ISAEKLANIDFTPARMDW-	- - - - - YTAPDG-TVVEC[MY
9PP	387	HSFE[PPD]YRVN[KA]EAOAVTAEKVLIDP[TP]ICEKR- - -	- - - - - GNML[ITWV
126PP	501	MPLHFDPAK[KYPM]LVY[KGCC	PHAO[MTKTRSSVGGDIY]M[AGKGYAVFTVPSRC[SAN
87PP	447	KFIDEDESRH[PVLMVQ]S	PN[SOVLD--RYSF]D-MEHYL[ASKEYM]VACVDRG[RG]A
65PP	299	LPKAALLEGK[KV]P[IVNP]HGG--P	- - - - - SWGENP[ETQ]IFASRGYATLQVNFR[SGC
101PP	589	EPQFDESK[KYPM]LVY[KGCC	- - - - - MIAAQGIVMVYT[PSCTG
9PP	443	LP[PNFDK]NKKY[P]LVY[KGCC	- - - - - QNTVS-OFWSE[RLM]AEQGYV[IAPNR]C[VPS
126PP	559	RGA[AEQVIHRL]GOTEM[ADOMC]CSD-FLK[SQSMVDP	DRIGV[HEGMSYGGEM]T[MT]LTHG
87PP	502	RGE[EWRKCTY]MQLGFESDDQ[AAAT-ATG]OLP[VDA	VARIGIWM[MSYGGIT]LMSL[CRGN
65PP	353	YCKEFLRAGFKQ[GRKAMDDVE]VR-VA[LSQGWVDE]D	DR[TAIYGA]SH[GGY]A[LMG]LVM[KTP
101PP	643	YCQEYAARHVN[AW]DRTADE[IGA]KEFIR[HSF]VNGKKV[CE	GASYGGFM[QY]TOTKT-
9PP	498	E[GOKWNEQISGDYGGON]WRYUTAVD-EMK[KEPYVDE]DRIGAV	GASYGGFSVVM[AGE]HD

Fig. 6c

126PP	618	DVFKVEVAGGCPVIA--	D	AN--RYEIMYCFERYFDA--PQENPEGYD-AANILK
87PP	561	GTRKAGIAVADPA--	D	WR--FYDSMVFPERMRT--PKENASGKIK-MSSALD
65PP	412	DLYACCGDYGVSNITYTFFDSFPEYIK--	D	PFKEMVKEIIMYDLDNPEFAAAIAKE-VSBSFFQ
101PP	702	DTEAAAVSHAGISSIS--N	D	---
9PP	557	KREAAFTAAHAGIFNLEMQYATTEEMMFA-NWDI	D	GDPPWERDN--VVAQRQIYA-TSEHKF
126PP	662	RAGDIKGRIATLICGAIDPVIVWQHSTLFLD	D	ACVKARTYPDYYVYPSHEHNVMcED-FVH
87PP	605	IASQOLQNLIVSISADDNVLQNLQNL	D	MAIMDKNHSYGGNTTERHD
65PP	469	D-KIINKPLFVVQGANDPRVNINESDQIVT	D	ALRAGEFVPMVKYNECHGFHREENSME
101PP	755	AD-KIHTPLLILHCSMDTNVPTAESVLYNAKIL	D	QDHFVIEPEERIRW
9PP	612	Q-NWDTIHLMIHGELDFRILASQAMAAFDAAOLRG	D	EVFIEETQDHFVIEPEERIRW
126PP	721	YETITrrYETDHD--	D	GPSEMILYMPDENHWVLOQNALLF
87PP	665	YTRKAKFLFDNL--	D	
65PP	528	YRAMILGFFFAKHLKK--	D	
101PP	814	TNSICAWEFARMQDDPTWNWELYPVNLL	D	
9PP	671	HRIFFGWLDFMLKK--	D	

Fig. 6d

15/19




Fig. 7

16/19

P. gingivalis W 83 PTP sequence

SEQ ID NO: 38 13228 atgaagaagacaatcttccaacaactattctgtctgtttgtcc
 SEQ ID NO: 30 M K K T I F Q Q L F L S V C A
 13273 cttacagtggccttgccttgcggctcagtctcctgaaacgagt
 L T V A L P C S A Q S P E T S
 13318 ggtaaggagttactctttagcaactgatgcccggaggaaaagag
 G K E F T L E Q L M P G G K E
 13363 ttttataactttacccgaatacgtggcgggttgcataatggatg
 F Y N F Y P E Y V V G L Q W M
 13408 ggagacaattatgtcttatacgagggtgatgatgtttat
 G D N Y V F I E G D D L V F N
 13453 aaggcgaatggcaaatcggtcagacgaccagatttctgctgcc
 K A N G K S A Q T T R F S A A
 13498 gatctcaatgcactcatgccggaggatgaaattcagacgact
 D L N A L M P E G C K F Q T T
 13543 gatgcttccttcattccgcacactcgatgccggacgggactg
 D A F P S F R T L D A G R G L
 13588 gtcgttctatccaaaggaggattagtcggattcgatatgctt
 V V L F T Q G G L V G F D M L
 13633 gctcgaaaggtaacttatcttcgataccaaatgaggagacggct
 A R K V T Y L F D T N E E T A
 13678 tctttggatttctcctgtggagaccgtgtgcctatgtcaga
 S L D F S P V G D R V A Y V R
 13723 aaccataacccatcattgctgtggaggtaattgggagaaggt
 N H N L Y I A R G G K L G E G
 13768 atgtcacgagctatcgctgtgactatcgatggaactgagactctc
 M S R A I A V T I D G T E T L
 13813 gtatatggccaggccgtacaccacgtgaattcggtatcgaaaaaa
 V Y G Q A V H Q R E F G I E K
 13858 ggtacattctggctccaaaaggagctgccttgcttctatcga
 G T F W S P K G S C L A F Y R
 13903 atggatcagagtatggtaaggcctacccgatagtggattatcat
 M D Q S M V K P T P I V D Y H
 13948 ccgctcgaagccgagtcacaccgttacgggtggatctatcatctggccaca
 P L E A E S K P L Y Y P M A G
 13993 actccgtcacaccacgttacgggtggatctatcatctggccaca
 T P S H H V T V G I Y H L A T
 14038 ggtaaaggcgttatctacaaacgggtgaacccaaggaaaaattt
 G K T V Y L Q T G E P K E K F
 14083 ctgacgaatttggatccggacgaaaatatcttgcata
 L T N L S W S P D E N I L Y V
 14128 gctgaggtgaatcgtgtcaaaacgaatgtaaggtaatgcctat
 A E V N R A Q N E C K V N A Y
 14173 gacgctgagaccggtagattcgccgtacgcgtttttgttgcacc
 D A E T G R F V R T L F V E T
 14218 gataaacattatgttagagccgttacatccctgacattcctccg
 D K H Y V E P L H P L T F L P

Fig. 7a

17/19

14263 ggaagtaacaatcagttcattggcagagccgtcgacggatgg
 G S N N Q F I W Q S R R D G W
 14308 aaccatcttatctgtatgatactacaggtcgatccgtcag
 N H L Y L Y D T T G R L I R Q
 14353 gtgacaaaaggggagtgggaggttacaaactttcaggcttcgat
 V T K G E W E V T N F A G F D
 14398 cccaagggAACACCGCTCTATTCGAAAGTACCGAAGCCAGCCCT
 P K G T R L Y F E S T E A S P
 14443 ctcgaacGCCATTACTGTATTGATACTAAAGGAGGAAAGACA
 L E R H F Y C I D I K G G K T
 14488 aaagatctgactCCGGAGTCGGAAATGCACCGCACTCAGCTATCT
 K D L T P E S G M H R T Q L S
 14533 CCTGATGGTTCTGCCATAATCGATATTTCACTGTC
 P D G S A I I D I F Q S P T V
 14578 CCGCGTAAGGTTACAGTGACAAATATCGGCAAAGGGTCTCACACA
 P R K V T V T N I G K G S H T
 14623 CTCTTGGAGGCTAAGAACCCCGATAACGGGCTATGCCATGCCGGAG
 L L E A K N P D T G Y A M P E
 14668 ATCAGAACGGGTACCATCATGGCGGCCGATGGGAGACACCTT
 I R T G T I M A A D G Q T P L
 14713 TATTACAAGCTCACGATGCCGTTCATTCGATCCGGCAAAGAAA
 Y Y K L T M P L H F D P A K K
 14758 TATCCTGTATTGTCTATGTTACGGAGGACCTCATGCCAACTC
 Y P V I V Y V Y G G P H A Q L
 14803 GTAAACCAAGACATGGCGCAAGCTCTGCGGTGGATGGATATCTAT
 V T K T W R S S V G G W D I Y
 14848 ATGGCACAGAAAGGCTATGCCGTCTTACGGTGGATAGTCGCGGA
 M A Q K G Y A V F T V D S R G
 14893 TCTGCCAATAGAGGGCTGTTCGAGCAGGTTATTCTACGTCGT
 S A N R G A A F E Q V I H R R
 14938 TTGGGGCAGACCGAGATGGCCGATCAGATGTGCGGTGTGGATTTC
 L G Q T E M A D Q M C G V D F
 14983 CTCAAGAGCCAATCATGGTGGATGCCGATAGAAATAGGAGTACAT
 L K S Q S W V D A D R I G V H
 15028 GGCTGGAGCTATGGTGGCTTATGACTACGAATCTGATGCTTACG
 G W S Y G G F M T T N L M L T
 15073 CACGGCGATGTCTCAAAGTCGGAGTAGCCGGCGGGCCTGTCATA
 H G D V F K V G V A G G P V I
 15118 GACTGGAATCGATATGAGATTATGTCGGTGAGCGTTATTCTGAT
 D W N R Y E I M Y G E R Y F D
 15163 GCGCCACAGGAAATCCGAAAGGATACGATGCTGCCAACCTGCTC
 A P Q E N P E G Y D A A N L L
 15208 AAACGAGCCGGTGTGAAAGGACGACTTATGCTGATTCTATGGA
 K R A G D L K G R L M L I H G
 15253 GCGATCGATCCGGTCGTGGATGGCAGCATTCACTCCTTCCCT

Fig. 7b

18/19

A I D P V V V W Q H S L L F L
15298 gatgcttgcgtgaaggcacgcacctatcctgactattacgtctat
D A C V K A R T Y P D Y Y V Y
15343 ccgagccacgaacataatgtgatggggccggacagagtacattg
P S H E H N V M G P D R V H L
15388 tatgaaacaataacccgttatttcacagatcacttatga 15426
Y E T I T R Y F T D H L *

Fig. 7c

Fig. 7d

INTERNATIONAL SEARCH REPORT

Inte nal Application No
PCT/US 00/05551

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N15/57 C12N9/48 A61K39/02		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12N A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIYAMA, M. ET AL.: "Sequence analysis of the <i>Porphyromonas gingivalis</i> dipeptidyl peptidase IV gene" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1396, no. 1, 4 March 1998 (1998-03-04), pages 39-46, XP000925951 cited in the application the whole document	7
A	---	1-6, 8-16, 18-20 -/-
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 5 October 2000		Date of mailing of the international search report 10.01.01
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel: (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016		Authorized officer Fuchs, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/05551

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Derwent Publications Ltd., London, GB; Class B04, AN 1990-053917 XP002149298 & JP 02 005880 A (SUNSTAR KK), 10 January 1990 (1990-01-10) abstract	7
A		1-6, 8-16, 18-20
P,X	BANBULA, A. ET AL.: "Prolyl Tripeptidyl Peptidase from <i>Porphyromonas gingivalis</i> " JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 14, April 1999 (1999-04), pages 9246-9252, XP002149297 the whole document	1-16, 18-20
A	---- KABASHIMA, T. ET AL.: "Cloning, Sequencing, and Expression of the Dipeptidyl Peptidase IV Gene from <i>Flavobacterium meningosepticum</i> in <i>Escherichia coli</i> " ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 320, no. 1, 20 June 1995 (1995-06-20), pages 123-128, XP000925965 the whole document	1-16, 18-20
A	---- KURAMITSU, H.K.: "Proteases of <i>Porphyromonas gingivalis</i> : what don't they do?" ORAL MICROBIOLOGY AND IMMUNOLOGY, vol. 13, no. 5, October 1998 (1998-10), pages 263-270, XP000925947 abstract page 267, column 2, line 34 -page 268, column 1, line 58	1-16, 18-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/05551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 15 and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16 AND 18-20 COMPLETELY

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-16 and 18-20 completely

An isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof being isolated from *Porphyromonas gingivalis*; an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; an isolated nucleic acid fragment encoding a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, an isolated nucleic acid fragment encoding a polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; a method of identifying an inhibitor of a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; a method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; an immunogenic composition comprising an isolated prolyl tripeptidyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids; a composition comprising an inhibitor of an isolated prolyl tripeptidyl peptidase;

2. Claim : 17 partially and 21 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 43;

3. Claim : 17 partially and 22 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 44;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

4. Claim : 17 partially and 23 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 45.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/05551

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 2005880	A 10-01-1990	NONE	

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52147 A3

(51) International Patent Classification⁷: C12N 15/57, 9/48, A61K 39/02

(21) International Application Number: PCT/US00/05551

(22) International Filing Date: 3 March 2000 (03.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/123,148 5 March 1999 (05.03.1999) US

(71) Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; 632 Boyd Graduate Studies, Athens, GA 30602-7411 (US).

(71) Applicants and
(72) Inventors: TRAVIS, James [US/US]; 825 Riverbend Parkway, Athens, GA 30605 (US). POTEMPA, Jan [US/US]; Apt. #102, 170 Barrington Drive, Athens, GA 30605 (US). BANBULA, Agnieszka [US/US]; Apt. #E13, 280 Picadilly Square, Athens, GA 30605 (US).

(74) Agent: MUETING, Ann, M.; Mueting, Raasch, Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,

[Continued on next page]

(54) Title: BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE



a

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159</td
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----------



RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW.

(88) Date of publication of the international search report:
12 April 2001

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:
1 November 2001

(15) Information about Correction:
see PCT Gazette No. 44/2001 of 1 November 2001, Section
II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— with international search report

BACTERIAL PROLYL PEPTIDASES AND METHODS OF USE

5

CONTINUING APPLICATION DATA

This patent application claims the benefit of U.S. provisional patent application No. 60/123,148, filed March 5, 1999, which is incorporated by reference herein.

10

GOVERNMENT FUNDING

The present invention was made with government support under Grant No. DE 09761, awarded by the National Institutes of Health. The Government may have certain rights in this invention.

15

BACKGROUND OF THE INVENTION

Porphyromonas gingivalis (formerly *Bacteroides gingivalis*) is an obligately anaerobic bacterium which is implicated in periodontal disease. *P. gingivalis* produces several distinct proteolytic enzymes, many of which are recognized as important virulence factors. A number of physiologically significant proteins, including collagen, fibronectin, immunoglobulins, complement factors C3, C4, C5, and B, lysozyme, iron-binding proteins, plasma proteinase inhibitors, fibrin and fibrinogen, and factors of the plasma coagulation cascade system, are hydrolyzed by *P. gingivalis* proteases. Broad proteolytic activity plays a role in the evasion of host defense mechanisms and the destruction of gingival connective tissue in progressive periodontitis.

Progressive periodontitis is characterized by acute tissue degradation promoted by collagen digestion and a vigorous inflammatory response characterized by excessive neutrophil infiltration. Gingival crevicular fluid accumulates in periodontitis as periodontal tissue erosion progresses at the foci of the infection, and numerous plasma proteins are exposed to proteinases expressed by the bacteria at the injury site. Neutrophils are recruited to the gingiva, in part, by the humoral chemotactic factor C5a. The complement components C3 and C5 are activated by complex plasma proteases with "trypsin-like" specificities called convertases. The human plasma convertases

5 cleave the α -chains of C3 and C5 at a specific site generating biologically active factors known as anaphylatoxins (i.e. C3a and C5a). The anaphylatoxins are potent proinflammatory factors exhibiting chemotactic and/or spasmogenic activities as well as promoting increased vascular permeability. The larger products from C3 and C5 cleavage (i.e. C3b and C5b) participate in functions including complement cascade activation, opsonization, and lytic complex formation.

10 Recent studies have indicated that this periodontopathogen produces at least seven different enzymes belonging to the cysteine and serine catalytic classes of peptidases, among which three cysteine proteinases (gingipains) are predominant (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458). The gingipains are the best characterized group of *P. gingivalis* enzymes as their structure, function, enzymatic properties and pathological significance are known. From *in vitro* studies it is apparent that two gingipains 15 R (also referred to generally as "Arg-gingipains" and more specifically as RgpA and RgpB), enzymes specific for cleavage at Arg-Xaa peptide bonds, have a significant potential to contribute to the development and/or maintenance of a pathological inflammatory state in infected periodontal pockets through: (i) activation of the kallikrein-kinin cascade, (ii) the release of neutrophil 20 chemotactic activity from native and oxidized C5 of the complement pathway, and (iii) activation of factor X. In addition, gingipain K (also referred to as "Lys-gingipain"), an enzyme which cleaves Lys-Xaa peptide bonds, degrades fibrinogen. This may add to a bleeding on probing tendency associated with periodontitis. Finally, the presence of a hemagglutinin/adhesion domain in the 25 non covalent multiprotein complexes of RgpA and gingipain K suggests participation of these enzymes in the binding of *P. gingivalis* to extracellular matrix proteins which may facilitate tissue invasion by this pathogen.

30 In comparison to the gingipains, relatively little is known about other cysteine proteinases produced by *P. gingivalis*. Two genes, referred to as *tpr* and *prtT* have been cloned and sequenced and although they encode a putative papain-like and streptopain-like cysteine proteinases, respectively, neither has been purified and characterized.

The presence of serine proteinase activity in cultures of *P. gingivalis* has been known for several years; however, only limited information is available about such enzymes. Indeed, a serine endopeptidase has been isolated from culture media, although it was only superficially characterized (Hinode D., et al., 5 (1993) *Infect. Immun.* **59**, 3060-3068). On the other hand, an enzyme referred to as glycylylprolyl peptidase (DPP IV) was found to be associated with bacterial surfaces and two molecular mass forms of this peptidase have been described. This enzyme has also been shown to possess the ability to hydrolyze partially degraded type I collagen, releasing the Gly-Pro dipeptide, and it was suggested 10 that, in collaboration with collagenase, glycylylprolyl peptidase may contribute to the destruction of the periodontal ligament (Abiko, Y., et al. (1985) *J.Dent. Res.* **64**, 106-111). In addition to this potential pathological function, glycylylprolyl peptidase may also play a vital role in providing *P. gingivalis* with dipeptides which can be transported inside the cell and serve as a source of carbon, 15 nitrogen, and energy for this asaccharolytic organism. Recently, a gene encoding glycylylprolyl peptidase in *P. gingivalis* has been cloned and sequenced, and it is now apparent that this enzyme is homologous to dipeptidyl-peptidase IV (DPP-IV) from other organisms (Kiyama, M., et al. (1998) 1396, 39-46). The nucleotide sequence of the genome of this bacterium is currently being 20 determined by The Institute for Genomic Research, and is available at www.tigr.org.

SUMMARY OF THE INVENTION

The present invention is directed to an isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids. Alternatively, the isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof is isolated from *P. gingivalis*. Typically, amidolytic activity is determined with a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The peptide cleaved by the isolated prolyl tripeptidyl-peptidase can include the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID 25 30

5 NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-
Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, or
SEQ ID NO:37. The amino acid sequence of the isolated prolyl tripeptidyl-
peptidase can include the amino acid sequence GXSXXG (SEQ ID NO:39), the
amino acid sequence GXSXGG (SEQ ID NO:40), or the amino acid sequence of
SEQ ID NO:30.

10 Another aspect of the invention is an isolated polypeptide, active analog,
active fragment, or active modification thereof having amidolytic activity for
cleavage of a peptide bond present in a target polypeptide having at least 4
amino acids. Typically, the polypeptide:target polypeptide ratio of at least about
1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH
7.5 at 37°C for at least about 3 hours.

15 The invention is also directed to an isolated polypeptide comprising an
amino acid sequence having a percentage amino acid identity of greater than 35
% with SEQ ID NO:30.

20 An alternative aspect of the invention is an isolated nucleic acid fragment
encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active
modification thereof, having amidolytic activity for cleavage of a peptide bond
present in a target polypeptide having at least 4 amino acids. Typically, the
prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no
greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C
for at least about 3 hours. The nucleic acid fragment can have a nucleotide
sequence comprising SEQ ID NO:38. A complement of the nucleic acid
fragment can hybridize to SEQ ID NO:38 under hybridization conditions of 0.5
25 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by
three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least
about 20 nucleotides of the complement hybridize.

30 Another aspect of the invention is an isolated nucleic acid fragment
encoding a polypeptide that includes an amino acid sequence having a
percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

The invention is also directed at a method of identifying an inhibitor of a
prolyl-tripeptidyl peptidase, active analog, active fragment, or active
modification thereof, including identifying a molecule that inhibits the

amidolytic activity of the prolyl-tripeptidyl peptidase. The inhibitor is identified by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

An aspect of the invention is a method of reducing growth of a bacterium. This method includes inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, or a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof. The method includes contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase. The method can be used to protect an animal from a periodontal disease caused by *P. gingivalis* including administering to the animal the inhibitor. The disease can be selected from the group consisting of gingivitis and periodontitis. The inhibitor can be administered by a method selected from the group consisting of subgingival application and controlled release delivery.

Another aspect of the invention is an immunogenic composition including an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids. Typically, the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours. The immunogenic composition can include an adjuvant.

The invention is also directed to a composition including an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.

Additional aspects of the invention include a dipeptidyl peptidase having an amino acid sequence including SEQ ID NO:43, SEQ ID NO:44, or SEQ ID NO:45.

Definitions

“Polypeptide” as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of amino acids. Thus, for example, the terms peptide, oligopeptide, protein, and enzyme are included within the 5 definition of polypeptide. This term also includes post-expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. A polypeptide can be produced by an organism, or produced using recombinant techniques, or chemically or enzymatically synthesized.

“Peptidase,” “proteinase,” and “protease” all refer to enzymes that 10 catalyze the hydrolysis of peptide bonds in a polypeptide. A “peptide bond” or “amide bond” is a covalent bond between the alpha-amino group of one amino acid and the alpha-carboxyl group of another amino acid. “Peptidase inhibitor,” “proteinase inhibitor,” “protease inhibitor,” and “inhibitor” all refer to molecules 15 that inhibit a peptidase that catalyzes the hydrolysis of peptide bonds in a polypeptide.

As used herein, the term “isolated” means that a polypeptide or a nucleic acid fragment has been either removed from its natural environment, produced using recombinant techniques, or chemically or enzymatically synthesized.

Preferably, the polypeptide or nucleic acid fragment is purified, i.e., essentially 20 free from any other polypeptides or nucleic acid fragments and associated cellular products or other impurities.

“Amidolytic activity” refers to the ability of a polypeptide to catalyze the hydrolysis of at least one peptide bond in a polypeptide. The term “cleavage” can also be used to refer to the hydrolysis of a peptide bond in a polypeptide.

“Prolyl-tripeptidyl peptidase” and “PTP” refer to a polypeptide having a 25 particular “amidolytic activity”. A “prolyl-tripeptidyl peptidase” is able to hydrolyze the peptide bond between the proline and the Yaa residues in a target polypeptide with the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or 30 modified amino acid except proline, and the α -amino of the amino terminal residue is not blocked. A “prolyl tripeptidyl-peptidase” does not have to cleave all members of the target peptide. The term “natural amino acid” refers to the 20 amino acids typically produced by a cell. The term “modified amino acid”

refers to, for instance, acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

A "target polypeptide" is a polypeptide that is the potential substrate of the amidolytic activity of a prolyl tripeptidyl-peptidase.

5 An active analog, active fragment, or active modification of a polypeptide of the invention is one that has amidolytic activity by hydrolysis of a peptide bond present in the target polypeptide as described herein. Active analogs, fragments, and modifications are described in greater detail herein.

10 "Nucleic acid fragment" as used herein refers to a linear polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides, and includes both double- and single-stranded DNA and RNA. A nucleic acid fragment may include both coding and non-coding regions that can be obtained directly from a natural source (e.g., a microorganism), or can be prepared with the aid of recombinant or synthetic techniques. A nucleic acid molecule may be 15 equivalent to this nucleic acid fragment or it can include this fragment in addition to one or more other nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression of cloning vector.

20 "Percentage amino acid identity" refers to a comparison of the amino acids of two polypeptides as described herein.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. Purification of the prolyl tripeptidyl peptidase from the acetone precipitate of the *P. gingivalis* cell extracts. Absorbance at 280 nm (open triangles), amidolytic activity against H-Ala-Phe-Pro-pNA (closed diamonds), and H-Gly-Pro-pNA (closed circles). (a) Separation of PTP-A on hydroxyapatite. (b) Separation of PTP-A on Phenyl-Sepharose HP. (c) Separation of PTP-A on MonoQ FPLC. (d) Chromatofocusing of PTP-A on Mono-P.

30 Fig. 2. SDS -PAGE of fractions from purification of PTP-A and the autoradiography of the purified enzyme. Lane a, molecular mass markers (phosphorylase B, 97 kDa; bovine serum albumin, 68 kDa; ovalbumin, 43 kDa; carbonic anhydrase, 30 kDa; soybean trypsin inhibitor, 20 kDa; α -lactalbumin, 14

kDa); *lane b*, acetone precipitate from Triton X-100 extract of *P. gingivalis*, *lane c*: hydroxyapatite column eluate; *lane d*, Phenyl-Sepharose column eluate; *lane e*, MonoQ column eluate; *lane f*, purified PTP-A from MonoP column wash; *lane g*, autoradiograph of 3 H-DFP labeled enzyme exposed for 96 h to X-ray film. All 5 samples were reduced and boiled prior to PAGE analysis.

Fig. 3. Multiple sequence alignment of *P. gingivalis* PTP-A (PTP-A) and its bacterial and eukaryotic homologues. Pg-DPP, DPP from *P. gingivalis* (Kiyama, M., et al., (1998) *Bioch. Bioph. Acta* **1396**, 39-46) containing an 10 amino-terminal sequence corrected according to the *P. gingivalis* W83 genome data available from The Institute of Genomic Research at www.tigr.org); Fm-DPP, DPP from *Flavobacterium meningosepticum*; Hs-DPP, human DPP IV; and Mm-FAP, mouse fibroblast activation protein. Peptide sequences obtained 15 from PTP-A analysis described herein are indicated with arrows (note that the sequence of the peptide 81-97 corresponds to the N-terminus of the lower molecular weight form of PTP-A); catalytic triad is marked with asterisks; and the proposed PTP-A membrane-anchoring N-terminal α -helix is double-underlined. Homologous regions (i.e., regions of identical amino acids and/or 20 conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background.

Fig. 4. Comparison of *P. gingivalis* PTP-A and DPP active site domains to corresponding sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3). Sequences of *P. gingivalis* PTP-A, DPP, DPP-H1, DPP-H2, and DPP-H3 were obtained from 25 conceptual translation of the following open reading frames retrieved from The Institute for Genomic Research (TIGR) unfinished *P. gingivalis* genome database: gnl | TIGR | *P. gingivalis* contig 126 (positions 13 228 – 15 426), contig 87 (positions 6 424 – 4 399), contig 65 (positions 161 – 1 786), contig 101 (positions 30 8 895 – 6 845), and contig 9 (positions 4 216 – 2 162), respectively. Residues predicted as catalytic triads are marked with asterisks. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted.

Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.

5 **Fig. 5. Influence of Pefabloc-serine proteinase inhibitor on *P. gingivalis* growth.**

10 **Fig. 6. Comparison of *P. gingivalis* PTP-A and DPP to sequences of three putative homologues identified within the *P. gingivalis* genome (DPP-H1, DPP-H2 and DPP-H3). Sequences of *P. gingivalis* PTP-A (126PP), DPP (87PP), DPP-H1 (65PP), DPP-H2 (101PP), and DPP-H3 (9PP) were obtained as described in Fig. 4. Homologous regions (i.e., regions of identical amino acids and/or conservative substitutions) are highlighted. Identical regions are shown as white letters on a black background. Similar regions (i.e., conservative substitutions) are shown as white letters on a grey background.**

15 **Fig. 7. Nucleotide sequence (SEQ ID NO:38) and amino acid sequence (SEQ ID NO:30) of PTP-A.**

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention provides isolated polypeptides, preferably isolated prolyl peptidases, more preferably prolyl dipeptidyl-peptidases and prolyl tripeptidyl-peptidases, most preferably prolyl-tripeptidyl peptidases, that have amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide, where the bond is between a proline and an amino acid residue attached to the 25 alpha-carboxyl group end of the proline.

When the prolyl peptidase is a prolyl tripeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), wherein Xaa is a natural or modified amino acid, Yaa is a natural or 30 modified amino acid except proline, and the α -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Pro-Yaa peptide bond. Preferably, isolated polypeptides do not cleave a target peptide having a blocked α -amino of the amino terminal residue.

Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond. In increasing order of preference, isolated polypeptides can cleave a target peptide that is at least 4 amino acids or at least 300 Da, at least 10 amino acids or at least 750 Da, at least 20 amino acids or at least 1,500 Da, or at least 30 5 amino acids or at least 3,000 Da. Preferably, the prolyl-tripeptidyl peptidases cleave peptides 1, 2, 7, 8, and 10-15 shown in Table 3, human cystatin C, and interleukin 6.

When the prolyl peptidase is a prolyl dipeptidyl-peptidase, the peptidase has amidolytic activity by hydrolysis of a peptide bond present in a target polypeptide 10 of the general formula $\text{NH}_2\text{-Xaa-Zaa-Yaa-(Xaa)}_n$ (SEQ ID NO:12), wherein Xaa is a natural or modified amino acid, Zaa is a proline or alanine, Yaa is a natural or modified amino acid except proline or hydroxyproline, and the α -amino of the amino terminal residue is not blocked, wherein the peptide bond of the target polypeptide that is hydrolyzed is the Zaa-Yaa peptide bond. Preferably, isolated 15 polypeptides does not cleave a target peptide having a blocked α -amino of the amino terminal residue. Preferably, the only peptide bond of the target peptide that is hydrolyzed is the Pro-Yaa bond.

Due to their cyclic aliphatic character proline residues bestow unique 20 conformational constraints on polypeptide chain structures, significantly affecting the susceptibility of proximal peptide bonds to proteolytic cleavage. Those proline residues, which often appear near the amino-termini of many biologically active 25 peptides, may protect them against proteolytic degradation by peptidases with general specificity. A specialized group of proteolytic enzymes, typically referred to as prolyl peptidases, has evolved to cleave (i.e., hydrolyze) a peptide bond adjacent to a proline residue in a polypeptide. The peptide bond adjacent to a proline residue can be referred to as a prolyl-X bond, where prolyl is the proline residue, and X is an amino acid residue attached to the alpha-carboxyl group end of the proline. The bacterial prolyl peptidases can cleave a polypeptide to liberate a 30 tripeptide or a dipeptide. Prolyl peptidases that do not cleave a target peptide if the α -amino of the amino terminal residue is blocked can be referred to as exopeptidases. The *in vivo* activity of these specialized proteolytic enzymes may have important physiological significance, because it may lead to inactivation of many biologically active peptides and/or transformation of the activity of other

biologically active peptides. In addition, hydrolysis of prolyl-X bonds in conjunction with general catabolic pathways should allow the complete re-utilization of amino acids by living organisms, including bacteria. However, prolyl peptidases from bacterial pathogens, if released into the host environment, may 5 interfere with the physiological functions of biologically active polypeptides and, therefore, contribute to the pathogenicity of infectious disease.

The external (i.e., cell surface) localization and uncontrolled activity of bacterial peptidases, including prolyl peptidases, likely contributes significantly to run-away inflammation in the human host and the pathological degradation of 10 connective tissue during periodontitis. For instance, working in concert bacterial prolyl peptidases (e.g., prolyl tripeptidyl peptidases and DPP IV) have the ability to completely degrade collagen fragments locally generated by endogenous or bacterial collagenases. Because type I collagen is the major component of 15 periodontal ligament, its enhanced degradation by bacterial prolyl peptidases may contribute to loss of tooth attachment and periodontal pocket formation. Thus, there is a need in the art to characterize bacterial peptidases to facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

The polypeptides of the present invention, preferably prolyl peptidases, can 20 be used as a source of antibodies for inhibiting the peptidase activity and thereby possibly reducing periodontitis, loss of tooth attachment and periodontal pocket formation. Antibodies to prolyl peptidases can also be used to identify and/or 25 isolate additional prolyl peptidases. Knowledge of prolyl peptidases can also be used to make inhibitors of prolyl peptidases and to make immunogenic compositions that could be used to elicit the production of antibodies to prolyl peptidases and thereby possibly reduce gingivitis, periodontitis, loss of tooth attachment, and/or periodontal pocket formation.

An example of a prolyl-tripeptidyl peptidase is prolyl-tripeptidyl peptidase 30 A (SEQ ID NO:30) (also referred to as PTP-A) from *P. gingivalis*. Purified PTP-A has apparent molecular masses of 81.8 and 75.8 kDa. The lower molecular mass peptidase may be due to the proteolytic cleavage of the peptidase from the surface of *P. gingivalis*. PTP-A is a new member of clan SC, family S9 of serine peptidases. Clans of serine peptidases are grouped on the basis of the order of certain amino acids in the polypeptide that make up the "catalytic triad" which

plays a pivotal role peptidase activity. The members of the clan SC are characterized by the catalytic triad in the polypeptide in the order of serine, aspartic acid, and histidine. Members of the clan SC are also characterized by a tertiary structure including $\beta/\alpha/\beta$ units, and an α/β hydrolase fold. In addition to the 5 catalytic triad order, the amino acid sequence GXSXXG (SEQ ID NO:39), where X is any amino acid and S is the active site serine, is a signature of all members of the clan SC with some distinguishing features specific for each family. Family S9 has the consensus sequence GXSXGG (SEQ ID NO:40). Besides this consensus sequence, there is a general similarity of primary structures which classifies 10 peptidases to this family. For instance, peptidases of this family generally have two domains, an amino-terminal domain that contains a membrane binding domain, and a carboxy-terminal domain, also referred to as the catalytic domain. The catalytic domain contains the residues of the catalytic triad. Some members of the S9 family have only the catalytic domain.

15 The S9 family is diverged and divided in three subfamilies: S9A, cytosolic oligopeptidases from archae and eukaryotes; S9B, eukaryotic acylaminoacylpeptidases; and S9C, dipeptidyl peptidase IV from bacteria and eukaryotes. The catalytic domain of peptidases from family S9 typically begin at about residue 400 of SEQ ID NO:30 and include the remaining carboxy-terminal 20 amino acids (see, e.g., Fulop, et al., (1998) *Cell* **94**, 161-170). Despite structural similarities to peptidases from the S9 family, the tripeptidyl-peptidase activity of PTP-A is unusual for this family of enzymes, and no other known similar activity has so far been attributed to any other member of the S9 family. In fact, all strict 25 tripeptidyl-peptidases belong only to the subtilisin family (S8) and S33 family of serine peptidases; however, they neither share a structural relationship with PTP-A nor have activity limited to cleavage after proline residues. In particular, there are no other known prolyl tripeptidyl peptidases with an activity that is increased by iodoacetamide relative to the same prolyl tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Iodoacetamide is a compound that is 30 traditionally a peptidase inhibitor. Typically, the activity of a prolyl tripeptidyl peptidase is increased about two-fold. Furthermore, unlike oligopeptidases, the prolyl tripeptidyl-peptidases of the present invention can cleave target peptidases having as few as 4 amino acids but also target peptides having at least 30 amino

acids or a molecular weight of at least 3,000 Da. In these respects, the *P. gingivalis* tripeptidyl peptidase is a unique enzyme, and the isolation and characterization of this novel bacterial prolyl peptidase will facilitate the development of therapies to inhibit the activity of the bacterial peptidases.

5 Examples of putative prolyl-dipeptidyl peptidases are DPP-H1 (SEQ ID NO:43), DPP-H2 (SEQ ID NO:44), and DPP-H3 (SEQ ID NO:45). These peptidases have a significant percentage amino acid similarity with DPP IV and PTP-A (see Fig. 6). Each dipeptidyl peptidase is expected to have enzymatic activity, as each has a well preserved catalytic triad (Fig. 4). DPP IV has been
10 characterized and the gene encoding the peptidase has been cloned, however the substrate specificity has not been well characterized. DPP IV has been found to cleave SEQ ID NOs:6, 20, 23, and 24. DPP IV has been purified in two forms. One of the forms is a full length gene translation product containing a blocked
15 amino-terminal residue. The second form had the amino-terminal amino acid sequence HSYRAAVYDYDVRRNLVKPLSEHVG (SEQ ID NO:48), which corresponds to residues 116-140 of DPP IV (Kiyama, M., et al. (1998) 1396, 39-46), indicating that it was proteolytically truncated on the amino-terminus.

In *P. gingivalis*, PTP-A and DPP IV activity is cell surface associated. While not intending to be limiting, it is conceivable that the enzyme is membrane
20 anchored through a putative signal sequence which is not cleaved but remains as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. However, a significant portion of the purified PTP-A has a truncated N-terminus, apparently due to cleavage by Lys-specific peptidase and likely to be an artifact which has occurred during the purification procedure. Nevertheless,
25 membrane bound PTP-A and DPP IV is proteolytically cleaved and shed during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media. The cell surface localization of PTP-A supports a putative physiological function in providing nutrients for growing bacterial cells. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the
30 bacterium entirely dependant on an external peptide supply. In this regard, PTP-A and DPP IV activities are probably very important, if not indispensable, for bacterial growth, and inhibition of prolyl tripeptidyl-peptidases and dipeptidyl-peptidases may inhibit the *in vivo* growth of organisms, including *P. gingivalis*.

For instance, treatment of *P. gingivalis* cultures in lagphase (i.e., the period after inoculation of a culture and before the organism begins to divide) and early logarithmic growth with the inhibitors PEFABLOCK and 3,4-dichloroisocoumarin inhibits growth of *P. gingivalis*.

5 Preferably, a polypeptide of the invention, preferably a prolyl peptidase, contains the amino acid sequence GXSXXG (SEQ ID NO:39), most preferably, GXSXGG (SEQ ID NO:40), where G is glycine, X is any amino acid, and S is the active site serine. The active site serine can be identified by, for instance, labeling with diisopropylfluorophosphate as described herein. Preferably, the catalytic 10 domain of the prolyl tripeptidyl-peptidases of the invention begins at about residue 400 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6), more preferably, at about residue 502 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID 15 NOs:43-45 (see Fig. 6), most preferably, at about residue 556 of SEQ ID NO:30 and includes the remaining carboxy-terminal amino acids and the corresponding amino acids of SEQ ID NOs:43-45 (see Fig. 6).

The invention further includes a polypeptide, preferably a prolyl tripeptidyl-peptidase, that shares a significant level of primary structure with SEQ ID NO:30. 20 The two amino acid sequences (i.e., the amino acid sequence of the polypeptide and the sequence SEQ ID NO:30) are aligned such that the residues that make up the catalytic triad, i.e., the serine, aspartic acid, and the histidine, are in register, then further aligned to maximize the number of amino acids that they have in common along the lengths of their sequences; gaps in either or both sequences are permitted 25 in making the alignment in order to place the residues of the catalytic triad in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the 30 number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in SEQ ID NO:30, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100. Preferably, a prolyl tripeptidyl peptidase has

greater than 35 % identity, more preferably at least about 40 % identity, most preferably at least about 45 % identity with SEQ ID NO:30. Preferably, amino acids 154-732 of SEQ ID NO:30 are used, more preferably amino acids 400-732 of SEQ ID NO:30 are used. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.

In general, the amidolytic activity of the polypeptides of the invention, preferably prolyl peptidases, can be measured by assay of the cleavage of a target polypeptide in the presence of prolyl peptidase and a buffer. Preferably, the lower ratio of prolyl tripeptidyl-peptidase to target polypeptide is at least about 1:1, more preferably at least about 1:100, even more preferably at least about 1:1,000, most preferably at least about 1:10,000. Preferably, the higher ratio of prolyl peptidase to target polypeptide is no greater than about 1:10,000,000, more preferably no greater than about 1:1,000,000 and most preferably no greater than about 1:100,000. Buffers in which a prolyl peptidase is active are suitable for the assay. Preferably, the buffer is about 200 mM HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), more preferably about 50 mM HEPES, most preferably about 20 mM HEPES. Preferably, the pH of the buffer is at least about pH 6.0 and no greater than pH 8.0, more preferably about pH 7.5. Preferably, the temperature of the assay is at about 37°C. The assay can be carried out for at least about 1 minute to no greater than 24 hours. Preferably, the amidolytic activity of the prolyl peptidases are measured at a prolyl peptidase:target polypeptide ratio of at least about 1:100 to no greater than 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at about 37°C for at least about 3 hours. In general, the time of the assay can vary depending on the substrate and enzyme:substrate ratio. Typically, target peptides are stable under these conditions, and typically it is difficult to detect background levels of hydrolysis in the absence of a prolyl peptidase. Preferably, the assay is allowed to continue until at least 1 % of the target peptide is hydrolyzed.

Prolyl-tripeptidyl peptidases of the present invention preferably are inhibited by a compound chosen from the group consisting of PEFABLOCK (4-(2-aminoethyl)-benzenesulfonyl-fluoride hydrochloride), diisopropylfluorophosphate, and 3,4-dichloroisocoumarin, more preferably PEFABLOCK and diisopropylfluorophosphate, and most preferably diisopropylfluorophosphate. The

peptidases of the present invention are preferably not inhibited by a compound chosen from the group consisting of leupeptin, antipain, E-64, pepstatin, α_1 -proteinase inhibitor, α_1 -antichymotrypsin and α_2 -macroglobulin, most preferably. Significantly and unexpectedly, the amidolytic activity of a prolyl-tripeptidyl peptidase of the present invention is increased by iodoacetamide relative to the prolyl-tripeptidyl peptidase in the absence of iodoacetamide under the same conditions. Preferably, the effect of iodoacetamide on amidolytic activity is measured by incubating in 200 mM HEPES, pH 7.6, at least about 0.1 nM of the prolyl tripeptidyl-peptidase with the inhibitor for about 15 minutes, adding about 1 mM of H-Ala-Phe-Pro-pHA, and incubating for at least about 1 minute before assaying for amidolytic activity. Typically, at least about 1 mM to no greater than 100 mM of inhibitor is used.

The polypeptides of the invention include a polypeptide having SEQ ID NO:30, or an active analog, active fragment, or active modification of SEQ ID NO:30. An active analog, active fragment, or active modification of a polypeptide having SEQ ID NO:30 is one that has amidolytic activity by hydrolysis of the Pro-Yaa peptide bond present in a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25). Active analogs of a polypeptide having SEQ ID NO:30 include prolyl-tripeptidyl peptidases having amino acid substitutions that do not eliminate hydrolysis of SEQ ID NO:25 at the Pro-Yaa peptide bond. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free NH_2 .

Active fragments of a prolyl-tripeptidyl peptidase of the invention include prolyl-tripeptidyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will

hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond. An example of a fragment of a prolyl-tripeptidyl peptidase is a catalytic domain. Modified prolyl-tripeptidyl peptidases include prolyl-tripeptidyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acid, including side 5 chain modifications, backbone modifications, and N- and C-terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like. Modified prolyl-tripeptidyl peptidases will hydrolyze SEQ ID NO:25 at the Pro-Yaa peptide bond.

10 Prolyl peptidases can be obtained by several methods. Isolation of a prolyl-tripeptidyl peptidase present on the surface of a cell producing the peptidase typically requires lysis of the cell followed by purification methods that are well known in the art. Alternatively, cells can be treated with a detergent, for instance Triton X-100, to remove the peptidase from the cell surface. The following are 15 nonlimiting examples of suitable protein purification procedures: fractionation on immunoaffinity, ion-exchange, hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5, or MonoP columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on an ion-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration 20 using, for example, Sephadex G-75. Preferably, isolation of a prolyl-tripeptidyl peptidase from *P. gingivalis* is accomplished using a combination of hydroxyapatite, Phenyl-Sepharose HP, MonoQ HR 5/5 and MonoP column chromatography steps as described herein.

25 Prolyl peptidases can also be isolated from organisms other than *P. gingivalis*. Other organisms can express a prolyl-tripeptidyl peptidase that is encoded by a coding region having similarity to the PTP-A coding region. A “coding region” is a linear form of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a coding region are generally determined by a translation start codon 30 at its 5' end and a translation stop codon at its 3' end. “Regulatory region” refers to a nucleic acid fragment that regulates expression of a coding region to which a regulatory region is operably linked. Non limiting examples of regulatory regions include promoters, transcription initiation sites, translation start sites, translation

stop sites, and terminators. "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A regulatory element is "operably linked" to a coding region when it is joined in such a way that expression of the coding region is achieved

5 under conditions compatible with the regulatory region. Alternatively, other organisms can express a prolyl-tripeptidyl peptidase from a recombinant coding region encoding the peptidase. The identification of similar coding regions in other organisms can be accomplished as described herein. A prolyl-tripeptidyl peptidase can be isolated using purification methods that are well known in the art.

10 Alternatively, the peptidase can be chemically synthesized using methods that are well known in the art including, for instance, solid phase synthesis. Examples of, for instance, coding and regulatory regions are described herein.

The expression of a prolyl-tripeptidyl peptidase by an organism other than *P. gingivalis* can be detected using specific substrates of the general formula NH₂-

15 Xaa-Xaa-Pro-LG or NH₂-Xaa-Xaa-Pro-Yaa (SEQ ID NO:41), where LG is a leaving group. The leaving group can be a chromogenic or fluorogenic group known to the art. The expression of a prolyl-tripeptidyl peptidase by an organism and subsequent cleavage of a specific substrate results in a free amino acid or a free leaving group, each of which can be assayed using techniques known to those of

20 skill in the art. Other methods can be based on immunogenic properties of PTP-A, for instance immunoassays and histochemistry, the detection of mRNA, and PCR related methods, all of which are known to one of skill in the art.

As described in the Examples, the amino acid sequence of the amino-terminal end of a PTP-A fragment was used to identify the nucleotide sequence of the PTP coding region. The nucleotide sequence was present in a publically available database containing the nucleotide sequence of the partially finished *P. gingivalis* W83 genome. However, even though the nucleotides that encode the *P. gingivalis* PTP-A were known, there was no indication that the nucleotides were in fact transcribed and translated. The data obtained from the database only contained

25 the nucleotide sequence of a genomic clone; there was no disclosure that the nucleotides did or did not contain an open reading frame. Moreover, there is little data known to the art regarding regulatory regions required for either the transcription or the translation of a nucleotide sequence in *P. gingivalis*.

Thus, a person of ordinary skill, having the nucleotide sequence of the genomic clone, would not be able to predict that the open reading frame encoding PTP-A was transcribed or translated. Moreover, even if there was a suggestion that the open reading frame was both transcribed and translated, there is no suggestion 5 that the polypeptide encoded by the open reading frame would have the novel activity of PTP-A.

Accordingly, the present invention is directed to a nucleic acid fragment 10 encoding a polypeptide, particularly a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof. The nucleic acid fragment can have a nucleotide sequence as shown in SEQ ID NO:38. Alternatively, nucleic acid fragments of the invention include those whose complement hybridize to SEQ 15 ID NO:38 under standard hybridization conditions as described herein. During hybridization the entire nucleotide sequence of the complement can hybridize with SEQ ID NO:38. Preferably, at least about 20 nucleotides of the complement hybridize with SEQ ID NO:38, more preferably at least about 50 nucleotides, most preferably at least about 100 nucleotides.

Alternatively, the nucleic acid fragment can have a nucleotide sequence 20 encoding a polypeptide having the amino acid sequence shown in SEQ ID NO:30. An example of the class of nucleotide sequences encoding such a polypeptide is SEQ ID NO:38. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each member of the class can be readily determined by one skilled in the art by reference to the standard genetic code.

The identification of similar coding regions in other organisms can be 25 accomplished by screening individual wild-type microorganisms for the presence of nucleotide sequences that are similar to the coding region of PTP-A, which is shown in SEQ ID NO:38. Screening methods include, for instance, hybridization of a detectably labeled probe with a nucleic acid fragment.

Standard hybridizing conditions are a modification of the conditions used 30 by Church et al. ((1984) *Proc. Natl. Acad. Sci. USA* **81**, 1991): 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, and three washes, each for 20 minutes in 2x SSC, 0.1 % SDS, at 65°C. Preferably, a probe will hybridize to the nucleotide sequence set forth in SEQ ID NO:38 under standard hybridizing conditions. Generally the probe does not have to be complementary to all the

nucleotides of the nucleic acid fragment as long as there is hybridization under the above-stated conditions.

“Complement” and “complementary” refer to the ability of two single stranded nucleic acid fragments to base pair with each other, where an adenine on one nucleic acid fragment will base pair to a thymine on a second nucleic acid fragment and a cytosine on one nucleic acid fragment will base pair to a guanine on a second nucleic acid fragment. Two nucleic acid fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide sequence in a second nucleic acid fragment. For instance, 5'-
10 ATGC and 5'-GCAT are complementary. The term complement and complementary also encompasses two nucleic acid fragments where one nucleic acid fragment contains at least one nucleotide that will not base pair to at least one nucleotide present on a second nucleic acid fragment. For instance the third
15 nucleotide of each of the two nucleic acid fragments 5'-ATTGC and 5'-GCTAT will not base pair, but these two nucleic acid fragments are complementary as defined herein. Typically two nucleic acid fragments are complementary if they hybridize under the standard conditions referred to herein.

Preferred probes are nucleic acid fragments complementary to a coding region or another nucleotide sequence that encodes a prolyl-tripeptidyl peptidase.
20 For instance, a probe can comprise a consecutive series of nucleotides complementary to a portion of SEQ ID NO:38. Preferably a probe is at least about 18 bases, more preferably at least about 21 bases, and most preferably at least about 24 bases in length. Particularly preferred probes are
TTCGATCCGGCAAAGAAATATCCTGTTATTGTCTATGTTACGGAGGAC
25 CT (SEQ ID NO:36,
GTGGATGCCGATAGAATAGGAGTACATGGCTGGAGCTATGGTGGCTT
(SEQ ID NO:37, and SEQ ID NO:38. Methods of detectably labeling a probe are well known to the art.

30 The nucleic acid fragment that is identified by the probe is further analyzed to determine if it encodes a polypeptide with amidolytic activity of the Pro-Yaa

peptide bond on a target polypeptide of the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Xaa-(Xaa)}_n$ (SEQ ID NO:25). Another method for screening individual microorganisms for the presence of nucleotide sequences that are similar to the coding regions of the present invention is the polymerase chain reaction (PCR).

5 Individual wild-type microorganisms containing nucleic acid fragments encoding a prolyl-tripeptidyl peptidase can also be identified using antibody. Preferably the antibody is directed to PTP-A. The production of antibodies to a particular polypeptide is known to a person of skill in the art, and is further detailed herein.

10 The use of hybridization of a probe to a coding region present in individual wild-type microorganisms can be used as a method to identify a coding region identical or similar to a coding region present in SEQ ID NO:38. The coding region can then be isolated and ligated into a vector as described below. Two nucleic acid sequences are "similar" if the two nucleic acid sequences can be aligned so that the 15 number of identical amino acids along the lengths of their sequences are optimized. Preferably, two nucleotide acid sequences have, in increasing order of preference, preferably at least about 90 %, at least about 92 %, at least about 94%, at least about 96%, most preferably at least about 98% identity.

As mentioned above, a nucleic acid fragment of the invention can be 20 inserted in a vector. Construction of vectors containing a nucleic acid fragment of the invention employs standard ligation techniques known in the art. See, e.g., Sambrook et al, *Molecular Cloning: A Laboratory Manual.*, Cold Spring Harbor Laboratory Press (1989) or Ausubel, R.M., ed. *Current Protocols in Molecular Biology* (1994). A vector can provide for further cloning (amplification of the 25 nucleic acid fragment), i.e., a cloning vector, or for expression of the polypeptide encoded by the coding region, i.e., an expression vector. The term vector includes, but is not limited to, plasmid vectors, viral vectors, cosmid vectors, or artificial chromosome vectors. Typically, a vector is capable of replication in a bacterial host, for instance *E. coli*. Preferably the vector is a plasmid.

30 Selection of a vector depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, vector replication rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK223-2, pTrc99A, and pET-(X) wherein (X) denotes a vector family in which

numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA) and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

An expression vector optionally includes regulatory regions operably linked to the coding region. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3' direction) coding region. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*, *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

An expression vector can optionally include a Shine Dalgarno site (e.g., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is an often used terminator that is incorporated into bacterial expression systems (J. Brosius et al., (1981) *J. Mol. Biol.* 148 107-127).

The nucleic acid fragment used to transform the host cell optionally includes one or more marker sequences, which typically encode a polypeptide that inactivates or otherwise detects or is detected by a compound in the growth medium. For example, the inclusion of a marker sequence can render the transformed cell resistant to an antibiotic, or it can confer compound-specific metabolism on the transformed cell. Examples of a marker sequence are sequences that confer resistance to kanamycin, ampicillin, chloramphenicol, and tetracycline.

Antibodies can be produced to a polypeptide having the sequence of SEQ ID NOs:30, 43, 44 or 45, or a polypeptide having a percentage amino acid identity as described herein. Alternatively, antibodies can be made to an antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having the sequence 5 of SEQ ID NOs:30, 43, 44 or 45. An antigenic analog, antigenic fragment, or antigenic modification of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 is one that generates an immune response in an animal. Antigenic analogs of a polypeptide having SEQ ID NOs:30, 43, 44 or 45 include prolyl peptidases having amino acid substitutions that do not eliminate peptide antigenicity in an animal.

10 Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs, as described herein. Fragments of a prolyl peptidase of the invention include prolyl peptidases containing deletions or additions of one or more contiguous or noncontiguous amino acids such that the resulting polypeptide will generate an immune response in an animal. An example of a 15 fragments of a prolylpeptidase is a catalytic domain. Modified prolyl peptidases include prolyl peptidases that are chemically and enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid 20 moieties, cofactors, and the like.

Accordingly, an aspect of the invention is an immunogenic composition comprising an isolated prolyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, preferably a prolyl tripeptidyl-peptidase. The prolyl tripeptidyl-peptidase preferably has amidolytic activity for cleavage of the 25 Pro-Yaa peptide bond present in a target polypeptide with the general formula NH₂-Xaa-Xaa-Pro-Yaa-(Xaa)_n (SEQ ID NO:25), wherein the amidolytic activity is measured at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:100 to no greater than about 1:1,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.

30 The immunogenic composition can further include excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the immunogenic composition. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other

5 ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the immunogenic composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

10 The immunogenic composition can be used in a method for protecting an animal from a disease caused by *P. gingivalis*. This method includes administering the immunogenic composition and eliciting antibodies to a prolyl peptidase, antigenic analog, antigenic fragment, or antigenic modification. The diseases that can be treated in this manner include periodontal diseases, which includes gingivitis and periodontitis. Clinical hallmarks of periodontitis include lose of tooth attachment and periodontal pocket formation.

15 Alternatively and preferably, periodontal diseases can be treated by the use of inhibitors of a prolyl peptidase. An inhibitor of a prolyl peptidase, preferably a prolyl tripeptidyl-peptidase, can be present in a composition that preferably contains a pharmaceutically acceptable carrier. For instance, inhibitors can be applied systemically, subgingivally (e.g., subgingival irrigation) and/or by controlled release delivery directly into the periodontal pocket using methods well known to the art (see, e.g., Kornman, K., (1993) *J. Periodontol.* **64**, 782-791).
20 Preferably, an inhibitor is applied subgingivally or by controlled release delivery.

25 The prolyl peptidases, active analogs, fragments, and modifications thereof can be used in a method of reducing growth of bacteria *in vitro* or *in vivo*. Preferably, the bacteria is a periodontal pathogen, i.e., a bacterial pathogen that causes periodontal disease, more preferably the bacteria is *P. gingivalis*. The inability of asaccharolytic *P. gingivalis* to utilize free amino acids makes the bacterium entirely dependant on an external peptide supply. The action of the polypeptides of the invention may be required for bacterial growth, and inhibition of the polypeptides of the invention may inhibit the *in vivo* growth of organisms, including *P. gingivalis*. The method includes decreasing the amount of dipeptides and/or tripeptides (e.g., the result of cleavage of SEQ ID NO:25 by a prolyl-tripeptidyl peptidase) and the amount of free amino acids that result from further cleavage of the dipeptides and/or tripeptides present by inhibiting a prolyl

peptidase, active analog, active fragment, or active modification thereof, such that the amount of dipeptides and/or tripeptides generated by the polypeptides is decreased. The amount of dipeptides and/or tripeptides is decreased relative to the amount of dipeptides and/or tripeptides present in the absence of the inhibitor.

5 Preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor, a monoclonal antibody that inhibits the prolyl peptidase, or polyclonal antibodies that inhibit the prolyl peptidase, more preferably, the amount of dipeptides and/or tripeptides generated is decreased by an inhibitor. Preferably, an inhibitor acts to inhibit a polypeptide of the invention, preferably a prolyl peptidase,

10 by blocking the active site of the polypeptide. The polypeptide can be present on the surface of the bacteria or secreted into the environment, preferably the polypeptide is present in the surface of the bacteria.

The present invention is also directed to a method of developing an inhibitor of a prolyl peptidase, active analog, active fragment, or active modification thereof, preferably a prolyl-tripeptidyl peptidase. The method includes identifying a molecule that inhibits the amidolytic activity of the prolyl peptidase. This can be accomplished by, for instance, incubating the prolyl peptidase with a candidate molecule under conditions that promote amidolytic activity of the prolyl peptidase and determining if the amidolytic activity of the prolyl peptidase is decreased relative to the amidolytic activity in the absence of the molecule. The amidolytic activity can be measured by cleavage of the Pro-Yaa peptide bond present in the target polypeptide SEQ ID NO:25 as described herein. One method of developing an inhibitor includes using the target peptide SEQ ID NO:25 and replacing the Xaa residues with modified amino acids. It is expected that some modified amino acids will cause the target peptide to act as an inhibitor.

EXAMPLES

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

Example 1Materials

Diisopropylfluorophosphate (DFP), leupeptin and 3,4-dichloroisocoumarin, were purchased from Calbiochem (La Jolla, CA). Antipain, iodoacetamide, 5 substance P, bradykinin and bradykinin related peptides, were obtained from Sigma. Other peptides used in this study were synthesized at the Molecular Genetic Instrumental Facility (University of Georgia, Athens, GA) using Fmoc protocol with an advanced ChemTech MPS350 automated synthesizer. H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, and H-Pro-pNA 10 (where pNA is p- Nitroanilide; Z is benzyloxycarbonyl; and H is hydrogen and denotes an unblocked amino-terminal group) were obtained from Bachem (King of Prussia, PA). Prolinal was kindly provided by Dr. James Powers (Georgia Institute of Technology, Atlanta) and cystatin C by Dr. Magnus Abrahamson (University of Lund, Sweden).

15

Methods

Source and Cultivation of Bacteria— *P. gingivalis* HG66 was obtained from Dr. Roland Arnold (University of North Carolina, Chapel Hill), while the strains W50 (ATCC 53978) and ATCC 33277 were obtained from the ATCC. All 20 cells were grown as described previously (Chen, Z., et al., (1992) *J. Biol. Chem.* 267, 18896-18901).

Enzyme Activity Assays— Routinely, the tripeptidyl peptidase amidolytic activity was measured with H-Ala-Phe-Pro-pNA (1mM) in 0.2 M HEPES (N-2-hydroxyethylpeperazine,N'-2-ethansulfonic acid), pH 7.5 at 37°C. The 25 concentration of enzyme was 0.1 nM to 1 nM. The assay was performed in a total volume of 0.2 ml on microplates, and the initial turnover rate was recorded at 405 nm using a microplate reader (Spectramax Molecular Devices, Sunnyvale, CA). In inhibition studies, the enzyme was first preincubated with inhibitor for 15 min at 37°C, substrate added, and residual activity recorded after 5 minutes to 30 minutes. 30 H-Gly-Pro-pNA, Z-Ala-Pro-pNA, Z-Gly-Pro-pNA and H-Pro-pNA (1 mM final concentration) were assayed in the same manner.

Protein Determination—Protein concentration was determined using the BCA reagent kit (Sigma, St. Louis, MO), using bovine serum albumin as a standard.

Localization of Tripeptidyl-Peptidase Activity—Cultures of *P. gingivalis* HG66, W50 and ATCC 33277, at different phases of growth, were subjected to the following fractionation procedure. The cells were removed by centrifugation (10,000 x g, 30 minutes), washed twice with 10 mM Tris, 150 mM NaCl, pH 7.4, resuspended in 50 mM Tris, pH 7.6, and disintegrated by ultrasonication in an ice bath at 1500 Hz for 5 cycles (5 minutes sonication/5 minutes brake). Unbroken cells and large debris were removed by centrifugation (10,000 x g, 30 minutes) and the opalescent supernatant subjected to ultracentrifugation (150,000 x g, 120 minutes), yielding a pellet containing bacterial membranes and a supernatant which was considered as membrane-free cell extract. All fractions, as well as the full culture, culture medium, and full culture after sonication, were assayed for amidolytic activity against H-Ala-Phe-Pro-pNA.

Enzyme Purification—All purification steps were performed at 4°C except for FPLC separations, which were carried out at room temperature. Cells were harvested by centrifugation (6,000 x g, 30 minutes), washed with 50 mM potassium phosphate buffer, pH 7.4, and resuspended in the same buffer (150 ml per 50 gram of cells wet weight). Triton X-100 (10% volume/volume in H₂O) was added slowly to the bacterial cell suspension to a final concentration of 0.05%. After 120 minutes of gentle stirring, unbroken cells were removed by centrifugation (28,000 x g, 60 minutes). Proteins in the supernatant were precipitated with cold acetone (-20°C) added to a final concentration of 60% and collected by centrifugation. The pellet was redissolved in 50 mM potassium phosphate buffer, pH 7.0, and extensively dialyzed against 20 mM potassium phosphate, pH 7.0, containing 0.02% sodium azide. The dialyzed fraction was clarified by centrifugation (28,000 x g, 30 min) and applied to a hydroxyapatite column (BioRad, Melville, NY) equilibrated with 20 mM potassium phosphate, pH 7.0, at a flow rate of 20 ml/hour. After equilibration, the column was washed until the A₂₈₀ fell to zero. Bound proteins were eluted with a gradient from 20-300 mM potassium phosphate and fractions (7 ml) analyzed for dipeptidyl- and tripeptidyl-peptidase activity using H-Gly-Pro-pNA and H-Ala-Phe-Pro-pNA, respectively. The activity against the latter

substrate was pooled, saturated with 1 M ammonium sulfate, clarified by centrifugation, and directly loaded onto a Phenyl-Sepharose HP (Pharmacia, Piscataway, NJ) column equilibrated with 50 mM potassium phosphate, pH 7.0, containing 1 M ammonium sulfate. The column was washed with two volumes of equilibration buffer, followed by buffer containing 0.5 M ammonium sulfate, and developed with a descending gradient of ammonium sulfate from 0.5 to 0 M. 5 Active fractions were pooled, extensively dialyzed against 20 mM Tris, pH 7.5, and applied to a MonoQ HR 5/5 FPLC column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer at 1.0 ml/minute, 10 following which bound proteins were eluted with a gradient of 0- 300 mM NaCl. The active fractions were pooled, dialyzed against 25 mM Bis-Tris, pH 6.3, and subjected to chromatofocusing on a MonoP FPLC column equilibrated with Bis-Tris buffer, using a pH gradient developed with 50 ml of 10x diluted Polybuffer 74 (Pharmacia), adjusted to a pH of 4.0.

15 *Electrophoretic Techniques*—The SDS-PAGE system of Schagger and von Jagow (Schagger, H., and von Jagow, G. (1987) *Anal. Biochem.* 166, 368-379), was used to monitor enzyme purification and estimate the enzyme molecular mass. For amino-terminal sequence analysis, proteins resolved in SDS-PAGE were electroblotted to polyvinylidene difluoride membranes using 10 mM CAPS, pH 11, 20 10% methanol (Matsudaira, P. (1987) *J. Biol. Chem.* 262, 10035-10038). The membrane was washed thoroughly with water and stained with Coomasie Blue G250. The blot was air dried, and protein bands cut out and subjected to NH₂-terminal sequence analysis with an Applied Biosystems 491 Protein Sequencer using the program designed by the manufacturers.

25 *Enzyme Fragmentation*—The purified prolyl tripeptidyl peptidase (PTP-A) was partially denatured by incubation in 6 M urea in 0.02 M Tris, pH 7.6, for 60 minutes. Low molecular mass gingipain R (RgpB) (Potempa, J., et al. (1995) *Prospect. Drug Discovery and Design* 2, 445-458) from *P. gingivalis* was then added to make an enzyme:substrate molar ratio of 1:100. The reaction mixture was 30 made in 1 mM cysteine and the sample incubated overnight at 37°C. Generated peptides were separated by reverse-phase HPLC using a μBondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA). Peptides were eluted with 0.1% trifluoroacetic acid and acetonitrile containing 0.08% trifluoroacetic acid, using a

gradient from 0 to 80% acetonitrile over 60 minutes. Peptides were monitored at 220 nm and collected manually.

For determination of the active site serine residue and to confirm that the purified enzyme was a serine peptidase, 100 µg of purified PTP-A was first 5 incubated with 170 µCi of [1,3-³H]DFP (Amersham, Arlington Heights, IL) for 30 minutes at 25°C in 20 mM HEPES, pH 7.5. The reaction was quenched by addition of cold DFP to a final concentration of 10 mM and the radiolabelled material analyzed by SDS-PAGE, followed by autoradiographic analysis. The gel was dehydrated, soaked in PPO solution for 2 hours, dried, and the DFP-binding 10 proteins detected by fluorography after an exposure time of 96 hours on X-ray film (XAR; Kodak, Rochester, NY). The bulk of radiolabelled protein was subjected to proteolytic fragmentation with RgpB and peptides obtained separated by reverse-phase HPLC as described above. Radioactivity in each peptide fraction was measured using a β liquid scintillation counter, and the labeled peptide, as well as 15 other selected peptides were subjected to sequence analysis.

Identification of the PTP-A Gene— The database containing the unfinished *P. gingivalis* W83 genome, available from The Institute for Genomic Research, was searched for the presence of nucleotide sequences corresponding to the NH₂-terminal and the internal PTP-A amino acid sequences using the TBLASTN 20 algorithm, BLAST version 2.0.8, and the default values for all parameters (Altschul, S.F., et al., (1997) *Nucleic Acid Res.* **25**, 3389-3402). An identified clone gnl | TIGR | *P. gingivalis*_126 was retrieved from The Institute for Genomic Research data base (<http://www.tigr.org>). The position of the PTP-A gene was localized using the NCBI open reading frame (ORF) finder (available from the 25 National Center for Biotechnology Information, at <http://www.ncbi.nlm.nih.gov/gorf/gorf.html>). The amino acid sequence, obtained by conceptual translation of the entire ORF, was further used for homology screening by use of the NCBI BLAST search tool.

Enzyme Specificity— Peptides were incubated with 1 µg PTP-A at an 30 enzyme:substrate molar ratio of 1:100 for 3 hours or 24 hours in 50 µl of 200 mM HEPES, pH 7.5, at 37°C, and the reaction stopped by acidification with trifluoroacetic acid. The samples were then subjected to reverse-phase high

pressure liquid chromatography using a μ Bondapak C-18 column (3.9 x 300 mm) (Waters, Millford, MA) and an acetonitrile gradient (0-80 % in 0.075% trifluoroacetic acid in 50 min). Each peak, detected at 220 nm, was collected, lyophilized, re-dissolved in 50% (volume/volume) methanol, 0.1% acetic acid and subjected to analysis by mass spectrometry.

5 *Mass Spectrometry*—A Finnigan MAT 95S, sector mass spectrometer (Finnigan MAT, Bremen, Germany) equipped with an electrospray source (ESI) was used operated essentially as described previously (Stenfors, C., et al., (1997) *J. Biol. Chem.* 272, 5747-5751). Peptides were identified by fitting of the obtained 10 spectra to specific sequences using an Internet application program MsFit available at <http://falcon.ludwig.ucl.ac.uk/msfit.html>.

Example 2

Enzyme Localization, Purification and Initial Characterization

15 Analysis of amidolytic activity against H-Ala-Phe-Pro-pNA in several fractions of *P. gingivalis* HG66, W50 and ATCC 33277 clearly indicated that an enzyme(s) with prolyl tripeptidyl-peptidase activity is localized on the cell surface in all strains tested with less than 5% of the total activity being found in the medium regardless of the growth phase of the bacterial culture. Cell associated 20 enzyme was easily detached from the bacterial surface by treatment with a low concentration (0.05%) of Triton X-100. This procedure released more than 85-90% of activity in a soluble form. Subsequent acetone precipitation of proteins in the Triton X-100 fraction successfully separated the activity from pigment which remained in solution. The redissolved protein fraction, after dialysis, was applied 25 to hydroxyapatite (100 ml) equilibrated with 20 mM potassium phosphate buffer pH 7.0. The elution was carried out with 20 mM potassium phosphate buffer pH 7.0, using a phosphate gradient from 20 mM to 300 mM at flow rate 20 ml/h. At this step substantial separation of the PTP-A activity from both the DPP IV and bulk protein was achieved (Fig. 1a). Further purification performed by subsequent 30 chromatography steps including Phenyl-Sepharose (Fig. 1b), MonoQ (Fig. 1c) and MonoP columns (Fig. 1d), resulted in the isolation of purified enzyme.

Phenyl-Sepharose HP (25 ml) was equilibrated with 50 mM potassium phosphate, 1M ammonium sulfate, pH 7.0, at flow rate 30 ml/h. The column was

washed with two volumes of equilibration buffer and a step gradient of 0.5 M ammonium sulfate was applied, following which a descending gradient of 0.5 to 0 M ammonium sulfate was applied. The PTP-A containing fractions were extensively dialyzed against 20 mM Tris-HCl, pH 7.0, and concentrated by 5 ultrafiltration. The concentrated PTP-A containing fractions were applied to a MonoQ column equilibrated with the same buffer. The column was washed with 5 volumes of equilibration buffer, following which bound protein was eluted with a gradient of 0-300 mM NaCl. The concentrated fraction of PTP-A from the MonoQ column was equilibrated with 25 mM Bis-Tris, pH 6.3, and loaded on a MonoP 10 column equilibrated with the same buffer. A pH gradient was developed using 50 ml of Polybuffer 74, with the pH adjusted to 4.0.

Significantly, the chromatography step on the MonoP column yielded the A_{280} profile much sharper than the activity peak. Although this imperfect overlap of protein and activity may suggest that the protein component does not represent 15 the active enzyme, the rest of data argues with such a contention. This apparent contradiction may be likely explained by the enzyme inhibition by the reaction product of H-Ala-Phe-Pro-pNA hydrolysis but this possibility has not been explored. The yield of protein and activity recovery in a typical purification procedure is summarized in Table 1.

Table 1. Purification of the PTP- A from *P. gingivalis*

Step		Volume (ml)	Protein (mg)	Total activity*	Specific activity (units/mg)	Purification fold	Yield (%)
Triton X-100 extract after centrifugation							
5	Acetone precipitate	200	1200	757 673	642	1	100
	Hydroxyapatite chromatography	50	600	537 622	896	1.4	71
10		50	22	400 039	18 183	28	53
	Phenyl-Sepharose	48	10	312 505	31 250	48	41
	MonoQ	3	1.5	244 828	163 218	254	32
15							
	MonoP	4	0.7	188 400	269 142	420	25

* Based on the enzymatic activity using H-Ala-Phe-Pro-pNA where one unit = mOD/min/1ml

SDS-PAGE analysis of the purified enzyme revealed the presence of two protein bands with apparent molecular masses of 81.8 and 75.8 kDa, respectively (Fig. 2, lane f). Autoradiography of the enzyme sample radiolabeled with [1,3-³H]DFP (Fig. 2, lane g) clearly indicated that the bands represented either two distinct serine peptidases or different molecular mass forms of the same enzyme. In an attempt to distinguish between these two options, the electrophoretically resolved proteins were subjected to amino terminal sequence analysis. Unfortunately, it was found that the 81.8 kDa form of PTP-A had a blocked N-terminus. In contrast, the sequence NH₂-SAQTTRFSAADLNALMP (SEQ ID NO:23) was found at the N-terminus of the lower molecular mass form of the enzyme. This result led us to the possibility that the 75.8 kDa form of PTP-A was derived from the 81.8 kDa form through proteolytic cleavage of a 6 kDa amino-terminal peptide. To confirm this hypothesis and, in addition, to localize the active site residue within *P. gingivalis* PTP-A, the mixture containing both radiolabeled enzymes was proteolytically fragmented and peptides resolved by reverse-phase HPLC. This procedure yielded only one major radioactive peptide peak, and the purified peptide was found to have a single amino acid sequence: IGVHGWXYGGFMTTNL (SEQ ID NO:24), where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP. These data convincingly indicate that the two protein bands of purified PTP-A represents different forms of the same enzyme. The portion of the purified PTP-A having a truncated N-terminus may be due to cleavage by Lys-specific peptidase and is likely to be an artifact which occurred during the purification procedure. Nevertheless, the proteolytic shedding of membrane bound PTP-A also occurs during cultivation of the bacteria, as indicated by variable amount of soluble activities found in cell free culture media.

Example 3

pH Optimum, Stability and Inhibition Profile

Using the amidolytic activity assay with H-Ala-Phe-Pro-pNA it was found that the enzyme has a broad pH optimum from pH 6.0 to 8.0 and in 0.2 M HEPES, pH 7.6 was stable for at least 12 hours at 25°C or 37°C. PTP-A activity was not affected by class specific synthetic inhibitors of cysteine or metalloproteinases

(Table 2). In contrast, preincubation of the enzyme with DFP or PEFABLOCK resulted in total loss of activity, supporting its classification as a serine peptidase. Surprisingly, however, 3,4-dichloroisocumarin was only a poor inhibitor, and PMSF, leupeptin, antipain and prolinal had no effect at all. Interestingly, 5 preincubation of PTP-A with iodoacetamide, but not with N-ethylmaleimide, stimulated enzyme amidolytic activity about two-fold. Human plasma inhibitors, such as α_1 -proteinase inhibitor, α_1 -antichymotrypsin and α_2 -macroglobulin did not affect the enzyme activity, nor were they cleaved by PTP-A.

10 The effect of inhibitors on amidolytic activity of DPP IV was also determined using the same conditions as those used for PTP-A, but using H-Gly-Pro-pNA as a substrate.

Table 2. Effect of inhibitors on the amidolytic activity of PTP-A and DPP IV.
 Results are for a 15-min incubation at 37 C in 0.2 HEPES pH 7.6,
 with 1 mM H-Ala-Phe-Pro-pNA as substrate.

	Inhibitor	Concentration	Residual activity of PTP-A, %	Residual activity of DPP IV, %
5	Diisopropyl fluorophosphate	10 mM	0	0
		10 mM	96	20
10	Phenylmethanesulfonyl fluoride	1mg/ml	20	15
		10mg/ml	0	0
15	PEFABLOC SC	1 mM	56	100
	3,4-dichloroisocoumarin	5mM	200	100
20	Iodoacetamide	5 mM	100	100
	N-Ethylmaleimide	1 mM	98	100
25	1,10-orthophenanthroline	5 mM	93	100
		0.1 mM	100	100
30	EDTA	0.1 mM	100	100
	Leupeptin	0.1 mM	100	20
35	Antipain	10 mM	100	0
	Prolinal	10 mM	100	30
	Val-Pro	10 mM	100	1
	Ala-Pro			
	Ala-Gly-Pro			

Example 4**Substrate Specificity**

Among several chromogenic substrates tested, including H-Ala-Phe-Pro-pNA, H-Gly-Pro-pNA, Z-Gly-Pro-pNA, Z-Ala-Pro-pNA, H-Pro-pNA, only H-Ala-
5 Phe-Pro-pNA was hydrolyzed by PTP-A indicating a prolyl specific tripeptidyl-peptidase activity. To further confirm this specificity several synthetic peptides composed of 5 to 34 amino acid residues and containing at least one proline residue were tested as substrates for PTP-A. Out of 22 peptides tested only those with a proline residue in the third position from the amino terminal end were cleaved
10 (Table 3), with the significant exception of peptides with adjacent proline residues (peptides 3, 4 and 16). In addition, a free α -amino group was absolutely required for cleavage after the third proline residue as exemplified by resistance to enzymatic hydrolysis of peptide 9, which differs from the peptide 8 only in acylation of the α -amino group of the N-terminal valine residue. Except for these
15 two limitations, the peptide bond -Pro- \downarrow -Yaa- was cleaved at the same rate in all peptides with the general formula $\text{NH}_2\text{-Xaa-Xaa-Pro-Yaa-(Xaa)}_n$ (SEQ ID NO:25), where Xaa represents any amino acid residue while Yaa could be any residue except proline, regardless of the chemical nature of the amino acids and the length of the peptide. In all cases the reaction was completed within 3 hours and
20 prolonged incubation for 24 hours did not affect the pattern of cleavage, confirming the absolute requirement for a proline residue at the third position from the unblocked N-terminus. In addition, these data indicate that the preparation of PTP-A was free of any contamination with either aminopeptidase, dipeptidyl peptidase, or endopeptidase activities.
25 The cleavage specificity of DPP IV was also determined using the same conditions as those used for PTP-A. The results (Table 3) demonstrate that DPP IV does not cleave between two proline residues.

Table 3. Cleavage specificity of PTP-A and DPP IV on synthetic peptides.

Substrate	Cleavage site	SEQ ID NO:
Peptide 1	H-Arg-Pro-Pro- \downarrow -Gly-Phe-Ser-Pro-Phe-Arg	1
Peptide 2	H-Arg-Pro-Pro- \downarrow -Gly-Phe	2
Peptide 3	H-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	3
Peptide 4	H-Tyr-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg	4
Peptide 5	H-Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg	5
Peptide 6	H-Arg-Pro- \downarrow -Lys-Pro- \downarrow -Gln-Gln-Phe-Phe-Gly-Leu-Met-NH ₂	6
Peptide 7	H-Val-Pro-Pro- \downarrow -Gly-Glu-Asp-Ser-Lys-Glu-Val-Ala-Ala-Pro-His-Arg-Gln	7
Peptide 8	H-Val-Pro-Pro- \downarrow -Gly-Glu-Asp-Ser-Lys	8
Peptide 9	Ac-Val-Pro-Pro-Gly-Glu-Asp-Ser-Lys	9
Peptide 10	H-Val-Glu-Pro- \downarrow -Ile-Pro-Tyr	10
Peptide 11	H-Arg-Gly-Pro- \downarrow -Ile-Pro-Ile	11
Peptide 12	H-Ala-Arg-Pro- \downarrow -Ala-D-Lys-amide	
Peptide 13	H-Pro-Asn-Pro- \downarrow -Asn-Gln-Gly-Asn-Phe-Ile	13
Peptide 14	H-Arg-His-Pro- \downarrow -Lys-Tyr-Lys-Thr-Glu-Leu	14
Peptide 15	H-Gly-Val-Pro- \downarrow -Lys-Thr-His-Leu-Glu-Leu	15
Peptide 16	H-Lys-Gly-Pro-Pro-Ala-Ala-Leu-Thr-Leu	16
Peptide 17	H-Gln-Lys-Gln-Met-Ser-Asp-Pro-Ser-Asn-Asn-Val-Val-Pro-His-Val-Pro-Pro-Thr-Thr-Glu-Asn-Lys-Pro-Lys-Val-Gln	17
Peptide 18	H-Phe-Leu-Arg-Glu-Pro-Val-Ile-Phe-Leu	18
Peptide 19	H-Gly-Ile-Arg-Pro-Tyr-Glu-Ile-Leu-Ala	19
Peptide 20	H-Leu-Pro- \downarrow -Asp-Ser-Ser-Leu-Ala-Ser-Ile-Gln-Glu-Leu-Ser-Pro-Gln-Glu-Pro-Pro-Pro-Glu-Ala	20
Peptide 21	H-Cys-Leu-Ser-Ser-Gly-Thr-Leu-Pro-Gly-Pro-Gly-Asn-Asp-Ala-Ser-Arg-Glu-Leu-Glu-Ser	21
Peptide 22	H-Lys-Ile-Ala-Gly-Tyr-His-Leu-Glu-Leu	22
Peptide 23	H-Ser-Pro- \downarrow -Tyr-Ser-Ser-Asp-Thr-Thr	46
Peptide 24	H-Ala-Pro- \downarrow -Val-Arg-Ser-Leu-Asn-Cys-Thr-Leu-Arg-Asp-Ser-Gln-Gln-Lys	47

 \downarrow indicates cleavage site mediated by PTP-A \uparrow indicates cleavage site mediated by DPP IV

The lack of cleavage after internal proline residues in the synthetic peptides corresponds well with the absence of any proteolytic activity on several protein substrates including IgA, IgG, albumin, azocasein, carboxymethylated 5 rybonuclease and gelatin. However, the size of substrate, which is a limiting factor in the activity of oligopeptidases (Walter, R., et al., (1980) *Mol. Cell. Biochem.* 30, 111-126), is not restricting in the case of PTP-A, because the enzyme is able to cleave a tripeptide (NH₂-Xaa-Xaa-Pro) from the N-terminus of both human cystatin C and interleukin 6.

10

Example 5

PTP-A Sequence Analysis

Partial PTP-A amino acid sequence data allowed us to identify the *P. gingivalis* genomic clone gnl | TIGR | *P. gingivalis*_126 in the Unfinished 15 Microbial Genomes data base, TIGR. An ORF corresponding to the PTP-A amino acid sequence was found as indicated by the fact that all sequences of the PTP-A derived peptides obtained by the enzyme polypeptide fragmentation with RgpB 20 were present in the protein primary structure inferred from the nucleotide sequence of the ORF. The 732 amino acid polypeptide with a calculated mass of 82,266 Da was encoded in this ORF. The homology search performed using the NCBI TBLASTN tool against GenBank+EMBL+DDBJ+PDB databases and subsequent 25 multiple sequence alignments using the ClustalW Multiple Sequence Alignment tool (Fig. 3) indicated that PTP-A is a new member of the prolyl oligopeptidase (S9) family of serine peptidases (Rawlings, N.D., et al., (1991) *Biochem. J.* 279, 907-908).

25

The sequence GXSXGG (SEQ ID NO:40) is a signature feature for the S9 family of serine peptidases. Within this large and diverse S9 family of evolutionary and functionally related enzymes both from prokaryotes and eukaryotes, PTP-A was most closely related to bacterial dipeptidyl peptidase IV (DPP IV) from *Flavobacterium meningosepticum*, *Xantomonas maltophilus*, and *P. gingivalis*, 30 sharing 31.6%, 30.4%, and 28.5% amino acid sequence identity, respectively. Remarkably, the COOH-terminal region of the PTP-A molecule (residues 502 - 732) shows a significant similarity to the eukaryotic prolyl oligopeptidases with 34% and 33% identity to human DPP IV and mouse fibroblast activation protein (FAP), respectively (Fig. 3). This part of the molecule contains the amino acid

residues which encompass the catalytic triad in all characterized prolyl oligopeptidases, and from the multiple alignments with DPP IV of confirmed active site residues (Kabashima, T., et al., (1995) *Arch. Biochem. Biophys.* **320**, 123-128) it is apparent that Ser-603, Asp-678 and His-710 represent the catalytic triad of PTP-A (Fig. 3). Such an inference is further supported by the direct labeling of Ser-603 by DFP. In addition, the computer assisted search for sequential motifs characteristic for transmembrane domains revealed the presence of such a putative region within the N-terminal sequences of PTP-A, with residues 5 to 25 most likely folded into a hydrophobic α -helix responsible for membrane anchoring of this enzyme.

In *P. gingivalis* PTP-A, as well as in DPP IV, all activities are cell surface associated, and it is conceivable that the enzymes are membrane anchored through putative signal sequences which are not cleaved but remain as a membrane spanning domain similar to other members of the prolyl oligopeptidase family. The cell surface localization of di- and tripeptidyl-peptidases suggests a putative physiological function in providing nutrients for growing bacterial cells. Here, the inability of asaccharolytic *P. gingivalis* to utilize free amino acids (Dashper, S.G., et al., *J. Dent Res.* **77**, 1133 (Abstract) (1988)) makes the bacterium entirely dependant on an external peptide supply. In this regard, DPP-IV and PTP-A activities are probably very important, if not indispensable, for bacterial growth.

This suggestion is strongly corroborated by the fact that the *P. gingivalis* genome contains three additional genes encoding peptidases homologous with DPP-IV and PTP-A and one related to aminopeptidase B. The peptidases homologous with DPP-IV and PTP-A are referred to as homologs H1 (SEQ ID NO:43), H2 (SEQ ID NO:44), and H3 (SEQ ID NO:45) (Fig. 6). If expressed, each gene product would probably have enzymatic activity because each has a well preserved catalytic triad (Fig. 4). In addition, all of these genes encode a putative signal peptide which may act in providing membrane-anchorage motifs.

Example 6**Influence of Proteinase Inhibitor on *P. gingivalis* Growth**

To evaluate whether *P. gingivalis* growth was influenced by the presence of a peptidase inhibitor, *P. gingivalis* in logphase growth was diluted 1:5 into liquid media and incubated at 37°C. The cell density was monitored by measuring the optical density at 600 nm (OD₆₀₀). When the optical density began to increase, Pefabloc was added at 0.5 mg/ml or at 2.0 mg/ml. The control culture received no Pefabloc. The cultures receiving Pefabloc exhibited decreased growth (Figure 5). The peptidase inhibitor had to be added before the culture reached an OD₆₀₀ of about 0.3 for the peptidase inhibitor to have an effect on growth.

The complete disclosures of all patents, patent applications, publications, and nucleic acid and protein database entries, including for example GenBank accession numbers and EMBL accession numbers, that are cited herein are hereby incorporated by reference as if individually incorporated. Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention, and it should be understood that this invention is not to be unduly limited to the illustrative embodiments set forth herein.

20

Sequence Listing Free Text

SEQ ID NOS:1-11: Synthetic peptides

SEQ ID NO:12: Target peptide

SEQ ID NOS:13-22: Synthetic peptides

25 SEQ ID NO:23: Amino-terminus of the lower molecular mass form of PTP-A.

SEQ ID NO:24: Amino acid sequence present in PTP-A, where X apparently represents the active-site serine residue covalently and irreversibly modified by DFP.

30 SEQ ID NO:25: Target peptide, where Xaa represents a natural or modified amino acid residue, Yaa represents a natural or modified amino acid residue except proline, and N is equal to or greater than 1.

SEQ ID NO:26: Mouse fibroblast activation protein

SEQ ID NO:27: Human DPP IV

SEQ ID NO:28: DPP from *Flavobacterium meningosepticum*

SEQ ID NO:29: DPP from *P. gingivalis*

SEQ ID NO:30: *P. gingivalis* PTP-A

5 SEQ ID NO:31: Portion of PTP-A

SEQ ID NO:32: Portion of DPP from *P. gingivalis*

SEQ ID NO:33: Portion of H1 homolog of *P. gingivalis* DPP

SEQ ID NO:34: Portion of H2 homolog of *P. gingivalis* DPP

SEQ ID NO:35: Portion of H3 homolog of *P. gingivalis* DPP

10 SEQ ID NOs:36-37: Probes

SEQ ID NO:38: Nucleotide sequence of coding region encoding PTP-A.

SEQ ID NO:39: Consensus sequence for clan SC where X is any amino acid and S is the active site serine GXSXXG.

SEQ ID NO:40: Consensus sequence for family S9 where X is any amino acid and S is the active site serine GXSXGG.

15 SEQ ID NO:41: A specific substrate for a prolyl-tripeptidyl peptidase, where Xaa represents a natural or modified amino acid residue, and Yaa represents a natural or modified amino acid residue except proline.

20 SEQ ID NO:42: DPP from *P. gingivalis*

SEQ ID NO:43: H1 homolog of *P. gingivalis* DPP

SEQ ID NO:44: H2 homolog of *P. gingivalis* DPP

SEQ ID NO:45: H3 homolog of *P. gingivalis* DPP

SEQ ID NO:46: Synthetic peptides

25 SEQ ID NO:47: Synthetic peptides

SEQ ID NO:48: Amino terminal sequence of DPP IV

What is claimed is:

1. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
2. An isolated prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof having amidolytic activity at a prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours, and wherein the prolyl tripeptidyl-peptidase is isolated from *P. gingivalis*.
3. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the peptide cleaved by the isolated prolyl tripeptidyl-peptidase comprises the sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:11, H-Ala-Arg-Pro-Ala-D-Lys-amide, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:25, and SEQ ID NO:37.
4. The isolated prolyl tripeptidyl-peptidase of claim 2 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSXXG (SEQ ID NO:39).
5. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises the amino acid sequence GXSXGG (SEQ ID NO:40).
6. The isolated prolyl tripeptidyl-peptidase of claim 4 wherein the amino acid sequence of the isolated prolyl tripeptidyl-peptidase comprises SEQ ID NO:30.

7. An isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the polypeptide:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
8. An isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
9. An isolated nucleic acid fragment encoding a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio of at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
10. The nucleic acid fragment of claim 9 wherein the nucleic acid fragment has a nucleotide sequence comprising SEQ ID NO:38.
11. The nucleic acid fragment of claim 9 wherein a complement of the nucleic acid fragment hybridizes to SEQ ID NO:38 under hybridization conditions of 0.5 M phosphate buffer, pH 7.2, 7 % SDS, 10 mM EDTA, at 68°C, followed by three for 20 minutes washes in 2x SSC, and 0.1 % SDS, at 65°C, wherein at least about 20 nucleotides of the complement hybridize.
12. An isolated nucleic acid fragment encoding a polypeptide wherein the polypeptide comprises an amino acid sequence having a percentage amino acid identity of greater than 35 % with SEQ ID NO:30.
13. A method of identifying an inhibitor of a prolyl-tripeptidyl peptidase, active analog, active fragment, or active modification thereof, comprising identifying a molecule that inhibits the amidolytic activity of the prolyl-

tripeptidyl peptidase by incubating the prolyl-tripeptidyl peptidase with the molecule under conditions that promote amidolytic activity of the prolyl-tripeptidyl peptidase and determining if the amidolytic activity of the prolyl-tripeptidyl peptidase is inhibited relative to the amidolytic activity in the absence of molecule.

14. A method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl tripeptidyl-peptidase with an inhibitor of the prolyl tripeptidyl-peptidase.
15. A method for protecting an animal from a periodontal disease caused by *P. gingivalis* comprising administering to the animal the inhibitor of claim 14 wherein the disease is selected from the group consisting of gingivitis and periodontitis.
16. The method of claim 15 wherein the inhibitor is administered by a method selected from the group consisting of subgingival application and controlled release delivery.
17. A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl-peptidase, active analog, active fragment, or active modification thereof, by contacting the prolyl dipeptidyl-peptidase with an inhibitor of the prolyl dipeptidyl-peptidase.
18. An immunogenic composition comprising an isolated prolyl tripeptidyl-peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl-peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids, wherein the prolyl tripeptidyl-peptidase:target polypeptide ratio is at least about 1:1 to no greater than about 1:10,000,000 in about 200 mM HEPES, about pH 7.5 at 37°C for at least about 3 hours.
19. The immunogenic composition of claim 18 further comprising an adjuvant.

20. A composition comprising an inhibitor of an isolated prolyl tripeptidyl-peptidase and a pharmaceutically acceptable carrier.
21. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:43.
22. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:44.
23. A dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO:45.

1/19




Fig. 1a




Fig. 1b

2/19




Fig. 1c




Fig. 1d

3/19




Fig. 2

Fig. 3a

Fig. 3b

Fig. 3c

Fig. 3

Fig. 3a

6/19

Fig. 3b

7/19

Mm-FAP	582	DKELIHAIVYKTKGYVEVEDQITAVRKFIENGFIDEERIAIWGMWSYGGVSSSLATASCTICL
Hs-DPP	588	DKIMHAIVNRLGIFDVEDQITEPKQFDSKQFVDNKEITIWGMWSYGGVTSWVLCSESGVF
Fm-DPP	539	TKYKKVTVKXNLGKXEVEDDQITPAKMGNOSYVDPKSRIGIIGWSYGGVMASTLAVTKGADVF
Pg-DPP	551	EWRKCTYVQMLGVFESDQITATAIGQIPYVDAARIGIIGWSYGGVHTLMSLCRGENETF
	561	AALFQVTHRLGOTEMADOMCQVDFLKSSQSWDADRIGVHGMWSYGGFMTINLMIHGDVF
	*	↔
Mm-FAP	642	KOGIAVAPSSMEYVASYTISEREMGLERPKDDNLHRYKINSTVMAEYFERNVVDYLILIHGTA
Hs-DPP	648	KOGIAVAPSSRMEYVESVTERVYMLGTRPEDNLHRYKINSTVMSRAENFKPVEYLILIHGTA
Fm-DPP	599	KOGIAVAPVNUFRYDSVTERETLQTPOENK--D3YD1NSPTTYAKLKG-KPILLIHGTA
Pg-DPP	611	KOGIAVAPVADWRFYDSVTEREMRTPKENAA-SGYKISSAEDPVASQDQS-NLIVVCSA
	621	KVVAECEPVIDMNRVETMYGERYFDADQENP--E3YDAANLLKRAAGDKKG-RIMLIHGTI
	*	↔
Mm-FAP	702	DDNVHFQNSAQIAKALVNAQVDFQAMMYSDDONEGISSERSONFLYTHMTHFLKQCFSLSD
Hs-DPP	708	DDNVHFQNSAQIAKALVDPGVDFQAMMNTDQCHIASSTAHQDITYTHMSHEIKQCFSLP-
Fm-DPP	656	DDNVHFQNSMDFSEALIONKKOFDFMAYFDKHNSTIGGNTIREQVYKQVNTYIEN---
Pg-DPP	668	DDNVHFQNTMIFERALMVOANIPEDMAYMOKNHSITVCCNTRYHLYTRKAKELFDNL---
	678	DPMYVWQHSLIIFDACYKARTYFDYVYIPSHENVMGPD-RWHLYETIIRYFTIDHL---
	*	↔

Fig. 3C

8/19

		SEQ ID NO.:	
PTP-A	556	YDADRTICW H GSYGGEM T	...RIMLTHCA IP PEPVW W W H FLDA C VKARTY P D Y V F SHEH N M G D -R
DPP	499	VD A DR I IG W GSYGG T	717 31 661 32
DPP-H1	350	VDPDR I ATY G AS H GG Y AT	PLFVVO G AND R VNINESDQIVTA I R A G F E V E V IMVKYNE G GFHRE E NS
DPP-H2	640	VNGK K V C FG G AS S YGG M	524 33 810 34
DPP-H3	495	VDGDR I GA G AS G YGG S V	PLM H GELD F RLASQ A MAAF D AQ L RG V PS E ML I X P DENH W VLQ Q NA 667 35
			*

Fig. 4

9/19


Influence of Pefablock-serine proteinase inhibitor on *P. gingivalis* growth.

Fig. 5

Fig. 6a

Fig. 6b

Fig. 6c

Fig. 6d

Fig. 6

SEQ ID NO:

3 0	126PP	1	[F]FQOF[F] - - - SVALTVALPCSAQSPE[SGKE]F[TEQL]MPGCKE[- - - YNFYP[EYV
4 2	87PP	1	[PDGEHY] - - - T[EMNERT
4 3	65PP	1	[DKCC] - - - NENYH[FA
4 4	101PP	1	[KTDTVGMMGSKY]NPADLLR[OAY
4 5	9PP	1	[TIGSAAMTPSAGTNTEHLTPEL]MTLSR[SEMALS - - - PDGKTAVY

126PP	55	V[G]QWMGDNVF - - - IEGDDL[F]ENKANG - - - KSAQTT[FS]AADDLNALMPEGCKFQ
87PP	16	ATTRY - - - NYAS - - - GKA[VDTL]FSVER - - - ARECP[E]KQIO - - - VE
65PP	14	SN[DG] - - - S - - - NTRDLT[F]EDGVN - - - ASILNMK[KEQK] - - - YM
101PP	61	DATDKDLR[N]SADKDGR[IA]GRKAGSKAER[SE]MAVYSE[ALTAEH]FAKA[DIEVFGQGRMSLW
9PP	57	AVSFP - - - DVK[T] - - - NKATRE[FTVNLD] - - - GSGRKQITDTE[SN] - - - EYAPAW

126PP	104	T[G]AFPSFRTLDAGR[G] - - - L[V]VLFTQGGL[G]FDMLARKVY[T] - - - FTNEETASLD[SF] - -
87PP	50	VSSTG[G]HLLFTDMES - - - IYRHSYRAAVYD[D]VTRN[LYKP] - - - SEHVEK[V]MIP[FS]E[SE] - -
65PP	46	TISMK[N] - - - NNPO - - - FEPYKIN[V]TC[EL]POLYEN - - - KDAANPIQ[GYEE]DK - -
101PP	121	UDDKOIG[ADSPNSK]GDTLRFSA[SLV]P[G]TLLIKS[LE]GDTTATDVRVVLK[E]KTA
9PP	98	MAP[GKR] - - - AFMSNEG[G] - - - SMQLWYNA[D]TERRQ[SN] - - - IEG3G[ITGFL]FSP - -

126PP	157	-V- - - C - - - RYAV[NHN-LY]TARG - - - GKLGE[GMSRAIAV]T[G]RETLY[G]QA - -
87PP	103	-D- - - C - - - RMA[AFV]DNN-IFIK - - - KFDFT[E] - - - VOM[NDG]OINSILNGATD
65PP	90	-D- - - C - - - ELRGYSR - - - LVNG[IESE]LYKDK - - - L[NG]KPAV[LYNQLRD
101PP	181	RDSALYPNYT[G]KERM[SLKHM]SCTFISGGSLSP[PTGKV]VLT[SYR]MSRDNKPAV[LYNQLRD
9PP	144	-D- - - E-KQV[LE]IKD - - - IKG[GKRTKD]MPDLDK

Fig. 6a

12/19

126PP	201	-VHQREFG[TEKG--TFS[SPKGSC[AFYRM-	-DQS-MVKPTFIVDYH--P
87PP	144	WVYEEFFGVTNL--MSWADNAFLATVRS-	DES-AVPEYRMPMYED--K
65PP	112	-LATGEFRLKK--THWDDTFCVIAFNYA-	SKN-KDEAYVLINLD--S
101PP	241	ARGNILLNLTNEKEALGMPHEDM[MTVIRKEGNNAKRLVAFDPMGKGEKTLVSNLPEQFRM	
9PP	170	ATCRIITDLMYK--HMDDEWETI[PHFPI-	AN-ATDGMITIGKD--E
126PP	243	EAES[PLVY[PAGT--PSHHVTVG[YLHIA--TG-KTVY[OTGEP[REKFUTNL[SPDDE	
87PP	188	YPEDDTVY[KPAGF--KNSTVSILHLYNVA--DR-NTKSVS[ERIDADOYIPRI[ATDNA	
65PP	153	DK-TRIVLYD[KON--K--LIRELFANE--DY-DVSGLHL[RS-RK--	
101PP	301	SPD[ARYM[FYQKEKGPKD[PLFIRH[DPDDDRQSDWDRDSQVYLLNAESG[VYGP[TFGSTY	
9PP	210	ME-GEPYEAF[MPW--S-GIEFDSSWP--DG-QNIAVASR[NKG--	
126PP	296	NITVAE--VNRAQNECKV[NA[DAETGRFVRVTFVETDkIVYEP--LH-P--[I[F]P-	
87PP	241	DELA[VMT--LNRLQNDFKM--YVYHPSLVPKLIIQDMNKRYVDSDWIQT--[KEFT-	
65PP	188	-R--[N-YEIDLM[ME--YEGEKSUVVVFMSATYKELI[LME--KEFK--	
101PP	361	TY[DIAPDSKRA[ALIGTLSTDWTRRPFR[ATIMEYNM[EGKA[DTLIRDPSIDA[QY[TPD	
9PP	247	-MA[LS--TN--SIIY[ENLASQ[THN[EGM[GYDTPK--FSEPD	
126PP	346	GSNNOF[IMWSR-RDGWNH[xf[--YDITGR[LIROV[KGWEWV[NFA--C	
87PP	292	GGC--FAVYSE-KDGFAY[Y[--YDNKGVM[RRITISGNWDV[LY--C	
65PP	224	CRE-FSVV[D--YDD	
101PP	421	CRH--LIVMGS-ADAFGN[GNLKSGVTPNSYDKQFF[EDLS[TRKATA[DNFNPVSAG	
9PP	287	GKS--IAWISMERDGYES--DLKRLFVADLA[CKRTH[NPTE[DYNVDMI	

Fig. 6b

126PP	389	-EPKGTTRIYFESTEASPIERHFCIDIKCCKTDP	TP-ESGMHRTOESPD	GSAIDIF
87PP	333	-VFDASGIVFYQSAEESPIRERAYA	SL-NVGTMNDALFSGN	-YAYYINTY
65PP	235	-DE--I	-KFT-	-LIVD-L
101PP	478	RFDRKNN-YYIFRAENG-SRKQFIREBLLKITLEISQFOTGEDVQWQFGVAADNGAWYSGQ	TK	
9PP	332	QMAPDSKCGYELACKEA--ETNLLWELLKTKGKIBQI	10GQHDYADFSVRND	-VMIIAKR
126PP	446	QSPTYPERKVIVMTNIGK3SHTLFEAKNPDTGYAMPEITRTG	--TMAADGOTP	YXKTR
87PP	388	SSAATPAVSVFRSKAKELRTLEDNVALRERKAYRNPKEFTT	TKTOS-LELNAIV	
65PP	269	--MPOKL--	MAEMPI--	-KFKSRDG-LTIHGFIT
101PP	536	SPANNADRLYRUDGTRGKLVWDSSAEKLANIDFTPARDW	--ED-	--YTAPDG-TVVEQMY
9PP	387	HISFEFPPDLYRVNTRKQAAQAVTAEKVLDRTRPITPCERR	--WMRHTD	--GNMINTWV
126PP	501	MFLHEDPAKKYPMIVYVYGG	PAHOVTKTWRSVGGDIYMAOQSYAVFTYDSRGSAN	
87PP	447	KPIDEEDPSRHYPMIVYQYSP	PNSQVLD--RYSEPD-WEHYLASKCYVWACVYDGRGTA	
65PP	299	LEKAALEGKKVPLIVNPHG	P--QGIRD--SWGENPETQFASRCYATLQVNFRLSGG	
101PP	589	LEPPQFDPSKYYPMIVYVYGGTSPINRTLEG	--HYSLA--MVAQGYVVTNPSCHITG	
9PP	443	LEPNFEDKNNKKYPAIYMCQGG	--QNTVS-QFMSFRWNRLMNEQGYVIVIAPNREGVPC	
126PP	559	RGAAFEQVIHRRLGOTEMADOMCIVD	FLKSOSWDAIRIGVHGSYGGFMTTNMLTHG	
87PP	502	RGEEMRKCTYMOGLGVEFSDQIAAT-ALGOLPYVDAARIGI	IGIWMGSYGGYVILMSLICRGN	
65PP	353	YCKEFLRAGHKOLGRKAMDDVEDGVR-YAISQGWVPPDRIAIYGASHGGYALIMGLVXKTP		
101PP	643	YCQEYAARHVNAMDRTADEHIGATKEEIRTHSFVNCKKVKVGC	GASYGGFMHOYLOQKTT-	
9PP	498	FCQKNEQISGDYCCQNPYD-EMKKEPEWVLEDRIGAVGASYGGFSVYMLAQPCHD		

Fig. 6c

126PP	618	DVF[KV]EV[VA]CCGPVI-----	D-----	AN-----	RYEIMYGYC[DRY]FDA-----	POENPEGYD-----	AANLLK
87PP	561	GTE[KAG]TA[VAP]VA-----	D-----	WR-----	FYDSVYJ[TER]MRT-----	PKENASGYK-----	MSSALD
65PP	412	DLYACSVYGVSNITYTFD[SFPEY]MK-----	D-----	FYKEMVKE[SI]WYDLDNPEFAAIAKE-----	VSPFFQ		
101PP	702	D[IF]AAAVSH[AG]ISSIS-----	N-----	YMGSGY[AG]GYS-----	STVASTDSYEMNNPDLYAGHSPLFR		
9PP	557	KREFAAFTIAH[AG]FNL[EM]QYATTEEMFA-----	WMDIGGPFWEKDN-----	VVAQRTYA-----	TSPEHKF		
126PP	662	RAGD[IKGR]MLIHGA-----	PPV-----	CVKARTYPDY-----	WYPSHEH-----	TMCPD-----	RVH[
87PP	605	VASQ[QNL]IIVSABDNVHLQINMLFTE-----	-----	MAIYMDKNHS-----	STYGGNTRYH[
65PP	469	ID-KIINKPLFVVOGANDPRVNTINESDQIVTA[RA]RCF-----	-----	GYNEGH-----	CFHREENSME[
101PP	755	AD-KI[HTP]LILHCSVDTNMPTAESVONLYNALKILGREVEFIE-----	-----	TEQDHFILEEPRIRW			
9PP	612	VO-NWDTP[MI]GELDFRILASQAMA[FD]AQLRGVPSSEM-----	-----	LIYPDENHWLQ[ONAL]F			
126PP	721	YETIT[TRY]ETD[DF]-----	-----				
87PP	665	YTRKA[KF]LFDNL-----	-----				
65PP	528	YRAM[LGFF]AKHILKK-----	-----				
101PP	814	TNS[IC]AWFARM[QDDPT]WWNELYPPVNL	-----				
9PP	671	HRT[FF]GWI[DRM]LKK-----	-----				

Fig. 6d

15/19

Fig. 7a

Fig. 7b

Fig. 7c

Fig. 7d

Fig. 7

16/19

P. gingivalis W 83 PTP sequence

SEQ ID NO: 38 13228 atgaagaagacaatctccaacaactattctgtctgtttgtcc
 SEQ ID NO: 30 M K K T I F Q Q L F L S V C A
 13273 cttacagtggccttgccttgcggctcagtctcctgaaacgagt
 L T V A L P C S A Q S P E T S
 13318 ggttaaggagtttactctttagcaactgatgcccggaggaaaagag
 G K E F T L E Q L M P G G K E
 13363 ttttataacttttaccccaatacgtggcgggttgcataatggatg
 F Y N F Y P E Y V V G L Q W M
 13408 ggagacaattatgtcttatacgagggtgatgatggattttaat
 G D N Y V F I E G D D L V F N
 13453 aaggcgaatggcaaatcggtcagacgaccagatggatgtcgc
 K A N G K S A Q T T R F S A A
 13498 gatctcaatgcactcatgccggaggatgcaaatttcagacgact
 D L N A L M P E G C K F Q T T
 13543 gatgcttcccttcattccgcacactcgatgccggacgggactg
 D A F P S F R T L D A G R G L
 13588 gtcgttctatattacccaaggaggattatcggttcgatatgctt
 V V L F T Q G G L V G F D M L
 13633 gctcggaaagggtgacttatcttcgataccatgaggagacggct
 A R K V T Y L F D T N E E T A
 13678 tctttggattttctccgtggagaccgtgttcctatgtcaga
 S L D F S P V G D R V A Y V R
 13723 aaccataacctttacattgctgtggaggtaattggagaaggt
 N H N L Y I A R G G K L G E G
 13768 atgtcacgagctatcgctgtgactatcgatggaaactgagactctc
 M S R A I A V T I D G T E T L
 13813 gtatatggccaggccgtacaccacgtgaaattcggtatcgaaaaaa
 V Y G Q A V H Q R E F G I E K
 13858 ggtacattctggtctccaaaaggagctgccttgcattatcga
 G T F W S P K G S C L A F Y R
 13903 atggatcagagtatggtgaaggctaccccgatagtggattatcat
 M D Q S M V K P T P I V D Y H
 13948 ccgctcgaagccgagtcacaccacgttacgggtggatctatcatctggccaca
 P L E A E S K P L Y Y P M A G
 13993 actccgtcacaccacgttacgggtggatctatcatctggccaca
 T P S H H V T V G I Y H L A T
 14038 ggttaaggaccgttatctacaaacgggtgaacccaaggaaaaattt
 G K T V Y L Q T G E P K E K F
 14083 ctgacgaatttggatgtggagtcggacaaaatatcttgcata
 L T N L S W S P D E N I L Y V
 14128 gctgaggtgaatcgatgtcaaaaacgaatgtaaatgcctat
 A E V N R A Q N E C K V N A Y
 14173 gacgctgagaccggtagattcgatgtccgtacgctttgttgcacc
 D A E T G R F V R T L F V E T
 14218 gataaacattatgttagagccgtacatcccgtacattcctccg
 D K H Y V E P L H P L T F L P

Fig. 7a

17/19

14263 ggaagtaacaatcagttcatggcagagccgtcgacggatgg
 G S N N Q F I W Q S R R D G W
 14308 aaccatctctatctgtatgatactacaggtcgatccgtcag
 N H L Y L Y D T T G R L I R Q
 14353 gtgacaaaaggggagtgggaggttacaaacttgcaggcttcgat
 V T K G E W E V T N F A G F D
 14398 cccaagggaacacggctctattcgaaagtaccgaagccagccct
 P K G T R L Y F E S T E A S P
 14443 ctcgaacgccattttactgtattgatatcaaaggagaaagaca
 L E R H F Y C I D I K G G K T
 14488 aaagatctgactccggagtcggaatgcaccgactcagctatct
 K D L T P E S G M H R T Q L S
 14533 cctgatgggtctgcataatcgatattttcagtcacactgtc
 P D G S A I I D I F Q S P T V
 14578 ccgcgttaagggttacagtgacaaatatcggcaaagggtctcacaca
 P R K V T V T N I G K G S H T
 14623 ctcttgaggctaaagaaccccgatacggctatgccatgccggag
 L L E A K N P D T G Y A M P E
 14668 atcagaacgggtaccatcatggcgccatggcagacacaccttt
 I R T G T I M A A D G Q T P L
 14713 tattacaagctcacgatgccgcttcatcgatccggcaaagaaa
 Y Y K L T M P L H F D P A K K
 14758 tatccgttattgtctatgttacggaggacatgcggcaactc
 Y P V I V Y Y G G P H A Q L
 14803 gtaaccaagacatggcgcaagctctgtcggtggatggatctat
 V T K T W R S S V G G W D I Y
 14848 atggcacagaaaggctatgccgtcttacggtgatagtcgcca
 M A Q K G Y A V F T V D S R G
 14893 tctgccaatagaggggctgtttcgagcaggattattcatcgctg
 S A N R G A A F E Q V I H R R
 14938 ttggggcagaccgagatggccatcgatgtcggtgtggatttc
 L G Q T E M A D Q M C G V D F
 14983 ctcaagagccaatcatgggtggatgccatagaataggagtacat
 L K S Q S W V D A D R I G V H
 15028 ggctggagctatgggtggctttagactacgaatctgatgcttacg
 G W S Y G G F M T T N L M L T
 15073 cacggcgatgtcttcaaagtccgttagccggcggctgtcata
 H G D V F K V G V A G G P V I
 15118 gactggaatcgatgatgagattatgtacggtgagcgttattcgat
 D W N R Y E I M Y G E R Y F D
 15163 gcccacaggaaaatcccgaaggatacgatgtccaaacctgctc
 A P Q E N P E G Y D A A N L L
 15208 aaacgagccgggtgatctgaaaggacgacttatgtattcatgga
 K R A G D L K G R L M L I H G
 15253 gcgatcgatccgggtcgatggcagcattcactcctttcctt

Fig. 7b

18/19

A I D P V V V W Q H S L L F L
15298 gatgcttcgtgaaggcacgcacctatcctgactattacgtctat
D A C V K A R T Y P D Y Y V Y
15343 ccgagccacgaacataatgtgatggggccggacagagtacattg
P S H E H N V M G P D R V H L
15388 tatgaaaacaataacccgttatttcacagatcacttatga 15426
Y E T I T R Y F T D H L *

Fig. 7c

Fig. 7d

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/05551A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/57 C12N9/48 A61K39/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIYAMA, M. ET AL.: "Sequence analysis of the <i>Porphyromonas gingivalis</i> dipeptidyl peptidase IV gene" BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1396, no. 1, 4 March 1998 (1998-03-04), pages 39-46, XP000925951 cited in the application the whole document	7
A	---	1-6, 8-16, 18-20 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- "&" document member of the same patent family

Date of the actual completion of the international search

5 October 2000

Date of mailing of the international search report

10.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/05551

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Derwent Publications Ltd., London, GB; Class B04, AN 1990-053917 XP002149298 & JP 02 005880 A (SUNSTAR KK), 10 January 1990 (1990-01-10) abstract	7
A	---	1-6, 8-16, 18-20
P,X	BANBULA, A. ET AL.: "Prolyl Tripeptidyl Peptidase from <i>Porphyromonas gingivalis</i> " JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 14, April 1999 (1999-04), pages 9246-9252, XP002149297 the whole document	1-16, 18-20
A	KABASHIMA, T. ET AL.: "Cloning, Sequencing, and Expression of the Dipeptidyl Peptidase IV Gene from <i>Flavobacterium meningosepticum</i> in <i>Escherichia coli</i> " ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 320, no. 1, 20 June 1995 (1995-06-20), pages 123-128, XP000925965 the whole document	1-16, 18-20
A	---	1-16, 18-20
	KURAMITSU, H.K.: "Proteases of <i>Porphyromonas gingivalis</i> : what don't they do?" ORAL MICROBIOLOGY AND IMMUNOLOGY, vol. 13, no. 5, October 1998 (1998-10), pages 263-270, XP000925947 abstract page 267, column 2, line 34 -page 268, column 1, line 58	1-16, 18-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/05551

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 15 and 16 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16 AND 18-20 COMPLETELY

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-16 and 18-20 completely

An isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof being isolated from *Porphyromonas gingivalis*; an isolated polypeptide, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids; an isolated polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; an isolated nucleic acid fragment encoding a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof having amidolytic activity for cleavage of a peptide bond present in a target polypeptide having at least 4 amino acids, an isolated nucleic acid fragment encoding a polypeptide comprising an amino acid sequence having a percentage amino acid identity of greater than 35% with SEQ ID NO: 30; a method of identifying an inhibitor of a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; a method of reducing growth of a bacterium comprising inhibiting a prolyl tripeptidyl peptidase, active analog, active fragment, or active modification thereof; an immunogenic composition comprising an isolated prolyl tripeptidyl peptidase, or an antigenic analog, antigenic fragment, or antigenic modification thereof, the prolyl tripeptidyl peptidase having amidolytic activity for cleavage of a peptide bond present in a target peptide having at least 4 amino acids; a composition comprising an inhibitor of an isolated prolyl tripeptidyl peptidase;

2. Claim : 17 partially and 21 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 43;

3. Claim : 17 partially and 22 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 44;

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

4. Claim : 17 partially and 23 completely

A method of reducing growth of a bacterium comprising inhibiting a prolyl dipeptidyl peptidase, active analog, active fragment, or active modification thereof; a dipeptidyl peptidase having an amino acid sequence comprising SEQ ID NO: 45.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/05551

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 2005880	A 10-01-1990	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.